{
  "tests": [
    {
      "query": "\"What is the termination date of the Marketing Affiliate Agreement between Birch First Global Investments Inc. and Mount Knowledge Holdings Inc.?\"",
      "snippets": [
        {
          "file_path": "cuad/CybergyHoldingsInc_20140520_10-Q_EX-10.27_8605784_EX-10.27_Affiliate Agreement.txt",
          "span": [
            1414,
            1784
          ],
          "answer": "This agreement shall begin upon the date of its execution by MA and acceptance in writing by Company and shall remain in effect until the end of the current calendar year and shall be automatically renewed for successive one (1) year periods unless otherwise terminated according to the cancellation or termination provisions contained in paragraph 18 of this Agreement."
        }
      ]
    },
    {
      "query": "\"What is the renewal term for the Marketing Affiliate Agreement between Birch First Global Investments Inc. and Mount Knowledge Holdings Inc.?\"",
      "snippets": [
        {
          "file_path": "cuad/CybergyHoldingsInc_20140520_10-Q_EX-10.27_8605784_EX-10.27_Affiliate Agreement.txt",
          "span": [
            1414,
            1784
          ],
          "answer": "This agreement shall begin upon the date of its execution by MA and acceptance in writing by Company and shall remain in effect until the end of the current calendar year and shall be automatically renewed for successive one (1) year periods unless otherwise terminated according to the cancellation or termination provisions contained in paragraph 18 of this Agreement."
        }
      ]
    },
    {
      "query": "\"What is the notice period required to terminate the Marketing Affiliate Agreement between Birch First Global Investments Inc and Mount Knowledge Holdings Inc.?\"",
      "snippets": [
        {
          "file_path": "cuad/CybergyHoldingsInc_20140520_10-Q_EX-10.27_8605784_EX-10.27_Affiliate Agreement.txt",
          "span": [
            22066,
            22221
          ],
          "answer": "This Agreement may be terminated by either party at the expiration of its term or any renewal term upon thirty (30) days written notice to the other party."
        }
      ]
    },
    {
      "query": "\"What is the governing law for the Marketing Affiliate Agreement between Birch First Global Investments Inc. and Mount Knowledge Holdings Inc.?\"",
      "snippets": [
        {
          "file_path": "cuad/CybergyHoldingsInc_20140520_10-Q_EX-10.27_8605784_EX-10.27_Affiliate Agreement.txt",
          "span": [
            28704,
            28895
          ],
          "answer": "This Agreement is accepted by Company in the State of Nevada and shall be governed by and construed in accordance with the laws thereof, which laws shall prevail in the event of any conflict."
        }
      ]
    },
    {
      "query": "\"What is the anti-assignment clause in the Marketing Affiliate Agreement between Birch First Global Investments Inc. and Mount Knowledge Holdings Inc.?\"",
      "snippets": [
        {
          "file_path": "cuad/CybergyHoldingsInc_20140520_10-Q_EX-10.27_8605784_EX-10.27_Affiliate Agreement.txt",
          "span": [
            27529,
            27698
          ],
          "answer": "MA may not assign, sell, lease or otherwise transfer in whole or in party any of the rights granted pursuant to this Agreement without prior written approval of Company."
        }
      ]
    },
    {
      "query": "\"In the Marketing Affiliate Agreement between Birch First Global Investments Inc. and Mount Knowledge Holdings Inc., is there a minimum commitment required?",
      "snippets": [
        {
          "file_path": "cuad/CybergyHoldingsInc_20140520_10-Q_EX-10.27_8605784_EX-10.27_Affiliate Agreement.txt",
          "span": [
            32195,
            32356
          ],
          "answer": "INITIAL ORDER COMMITMENT - MA commits to purchase a minimum of 100 Units in aggregate within the Territory within the first six months of term of this Agreement."
        }
      ]
    },
    {
      "query": "\"Considering the Marketing Affiliate Agreement between Birch First Global Investments Inc. and Mount Knowledge Holdings Inc., what licenses are granted under this contract?\"",
      "snippets": [
        {
          "file_path": "cuad/CybergyHoldingsInc_20140520_10-Q_EX-10.27_8605784_EX-10.27_Affiliate Agreement.txt",
          "span": [
            1993,
            2816
          ],
          "answer": "Subject to the terms and conditions of this Agreement, Company hereby grants to MA the right to advertise, market and sell to corporate users, government agencies and educational facilities (\"Clients\") for their own internal language learning, soft skills and communication purposes only, and not for remarketing or redistribution, and not for use in a data center environment for multiple users Clients, unless otherwise agreed to by Company prior in writing, the Technology listed in Schedule A of this Agreement, and to sell and/or bundle Technology Maintenance for the Technology and to provide first line technical support and implementation services for the Technology in the territories listed in Schedule A of this Agreement, providing MA meets the criteria required for delivering services according to Schedule A."
        },
        {
          "file_path": "cuad/CybergyHoldingsInc_20140520_10-Q_EX-10.27_8605784_EX-10.27_Affiliate Agreement.txt",
          "span": [
            14690,
            14913
          ],
          "answer": "Company hereby grants MA, during the term of this Agreement, the right to use Company and/or Company trade names, trademarks or service marks on Technology or in advertising or promotion relating directly to these products."
        },
        {
          "file_path": "cuad/CybergyHoldingsInc_20140520_10-Q_EX-10.27_8605784_EX-10.27_Affiliate Agreement.txt",
          "span": [
            33649,
            33769
          ],
          "answer": "MA is authorized to resell Technology within the following territory according to the terms of the Agreement:\n\nWorldwide"
        }
      ]
    },
    {
      "query": "\"Finally, what is the audit rights under the Marketing Affiliate Agreement between Birch First Global Investments Inc and Mount Knowledge Holdings Inc?\"",
      "snippets": [
        {
          "file_path": "cuad/CybergyHoldingsInc_20140520_10-Q_EX-10.27_8605784_EX-10.27_Affiliate Agreement.txt",
          "span": [
            5924,
            6182
          ],
          "answer": "MA shall keep accurate records of the sales of the Technology and Maintenance, including Client Registration Cards and shall make these records available for review by a representative of Company within ten (10) business days following the end of each month."
        }
      ]
    },
    {
      "query": "\"Can you please explain the \"Marketing Affiliate Agreement\" between Birch First Global Investments Inc. and Mount Knowledge Holdings Inc.?\"",
      "snippets": [
        {
          "file_path": "cuad/CybergyHoldingsInc_20140520_10-Q_EX-10.27_8605784_EX-10.27_Affiliate Agreement.txt",
          "span": [
            14096,
            14399
          ],
          "answer": "Company is not liable for incidental, special or consequential damages for any reason (including loss of data or other business or property damage), even if foreseeable or if MA or Customer has advised of such a claim. Company's liability shall not exceed the fees that MA has paid under this Agreement."
        },
        {
          "file_path": "cuad/CybergyHoldingsInc_20140520_10-Q_EX-10.27_8605784_EX-10.27_Affiliate Agreement.txt",
          "span": [
            16147,
            16261
          ],
          "answer": "The foregoing states the entire liability of Company with respect to infringement of intellectual property rights."
        },
        {
          "file_path": "cuad/CybergyHoldingsInc_20140520_10-Q_EX-10.27_8605784_EX-10.27_Affiliate Agreement.txt",
          "span": [
            20020,
            20494
          ],
          "answer": "COMPANY'S SOLE AND EXCLUSIVE LIABILITY FOR THE WARRANTY PROVIDED IN SUBPARAGRAH (A) HEREOF SHALL BE TO CORRECT THE TECHNOLOGY TO OPERATE IN SUBSTANTIAL ACCORDANCE WITH ITS THEN CURRENT SPECIFICATIONS OR REPLACE, AT ITS OPTION, THE TECHNOLOGY NOT IN COMPLIANCE WITH COMPANY'S AND COMPANY' PUBLISHED SPECIFICATIONS REGARDING THE TECHNOLOGY; PROVIDED, ANY CLAIM FOR BREACH OF WARRANTY UNDER SUBPARAGRAPH (A) HEREOF MUST BE MADE IN WRITING WITHIN (90) DAYS FROM DATE OF SHIPMENT"
        },
        {
          "file_path": "cuad/CybergyHoldingsInc_20140520_10-Q_EX-10.27_8605784_EX-10.27_Affiliate Agreement.txt",
          "span": [
            20497,
            20884
          ],
          "answer": "IN NO EVENT SHALL COMPANY BE LIABLE TO \"MA\", ITS CLIENTS, OR ANY THIRD PARTY FOR ANY TORT OR CONTRACT DAMAGES OR INDIRECT, SPECIAL, GENERAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING BUT NOT LIMITED TO, LOSS OF PROFITS OR ANTICIPATED PROFITS AND LOSS OF GOODWILL, ARISING IN CONNECTION WITH THE USE (OR INABILITY TO USE) OR DISTRIBUTION OF THE TECHNOLOGY FOR ANY PURPOSE WHATSOEVER."
        }
      ]
    },
    {
      "query": "\"What is the duration of any warranties that are included in the Marketing Affiliate Agreement between Birch First Global Investments Inc. and Mount Knowledge Holdings Inc.?\"",
      "snippets": [
        {
          "file_path": "cuad/CybergyHoldingsInc_20140520_10-Q_EX-10.27_8605784_EX-10.27_Affiliate Agreement.txt",
          "span": [
            20020,
            20495
          ],
          "answer": "COMPANY'S SOLE AND EXCLUSIVE LIABILITY FOR THE WARRANTY PROVIDED IN SUBPARAGRAH (A) HEREOF SHALL BE TO CORRECT THE TECHNOLOGY TO OPERATE IN SUBSTANTIAL ACCORDANCE WITH ITS THEN CURRENT SPECIFICATIONS OR REPLACE, AT ITS OPTION, THE TECHNOLOGY NOT IN COMPLIANCE WITH COMPANY'S AND COMPANY' PUBLISHED SPECIFICATIONS REGARDING THE TECHNOLOGY; PROVIDED, ANY CLAIM FOR BREACH OF WARRANTY UNDER SUBPARAGRAPH (A) HEREOF MUST BE MADE IN WRITING WITHIN (90) DAYS FROM DATE OF SHIPMENT."
        }
      ]
    },
    {
      "query": "\"What is the purpose of Video-on-Demand Content License Agreement between Rogers Cable Communications Inc. and EuroMedia Holdings Corp.?\"",
      "snippets": [
        {
          "file_path": "cuad/EuromediaHoldingsCorp_20070215_10SB12G_EX-10.B(01)_525118_EX-10.B(01)_Content License Agreement.txt",
          "span": [
            6970,
            7157
          ],
          "answer": "The term of this Agreement (the \"Initial Term\") shall commence as of the Effective Date and, unless earlier terminated in accordance with this Agreement, shall terminate on June 30, 2010."
        }
      ]
    },
    {
      "query": "\"What is the renewal term for the Video on Demand Content License Agreement between Rogers Cable Communications Inc. and EuroMedia Holdings Corp.?\"",
      "snippets": [
        {
          "file_path": "cuad/EuromediaHoldingsCorp_20070215_10SB12G_EX-10.B(01)_525118_EX-10.B(01)_Content License Agreement.txt",
          "span": [
            7158,
            7299
          ],
          "answer": "At Rogers' option, this Agreement shall renew for a subsequent term of two (2) years on the terms and conditions herein (the \"Renewal Term\")."
        }
      ]
    },
    {
      "query": "\"What is the notice period required to terminate the Video-on-Demand Content License Agreement between Rogers Cable Communications Inc. and EuroMedia Holdings Corp.?\"",
      "snippets": [
        {
          "file_path": "cuad/EuromediaHoldingsCorp_20070215_10SB12G_EX-10.B(01)_525118_EX-10.B(01)_Content License Agreement.txt",
          "span": [
            7300,
            7967
          ],
          "answer": "Notwithstanding the foregoing, if, at the expiry of this Agreement following the Initial Term or the Renewal Term (if any), as applicable, Licensor and Rogers have not executed a new agreement governing the VOD distribution and exhibition of Licensed Programs and Rogers (or its permitted assigns) continues to distribute and exhibit Licensed Programs on the ROD Service following such expiry, such continued distribution and exhibition shall be governed by the terms of this Agreement in effect at the time of expiry, except that each of Licensor and Rogers shall have the right, on sixty (60) days' prior written notice, to terminate this Agreement, as so extended."
        }
      ]
    },
    {
      "query": "\"What is the governing law for the Video-on-Demand Content License Agreement between Rogers Cable Communications Inc. and EuroMedia Holdings Corp.?\"",
      "snippets": [
        {
          "file_path": "cuad/EuromediaHoldingsCorp_20070215_10SB12G_EX-10.B(01)_525118_EX-10.B(01)_Content License Agreement.txt",
          "span": [
            23438,
            23556
          ],
          "answer": "This Agreement shall be governed by laws of the Province of Ontario and the federal laws of Canada applicable therein."
        },
        {
          "file_path": "cuad/EuromediaHoldingsCorp_20070215_10SB12G_EX-10.B(01)_525118_EX-10.B(01)_Content License Agreement.txt",
          "span": [
            26865,
            27208
          ],
          "answer": "This Agreement is subject to all laws, regulations, license conditions and decisions of the Canadian Radio-television and Telecommunications Commission (\"CRTC\") municipal, provincial and federal governments or other authorities which are applicable to Rogers and/or Licensor, and which are now in force or hereafter adopted (\"Applicable Law\")."
        }
      ]
    },
    {
      "query": "\"What is the most favored nation clause in the Video-on-Demand Content License Agreement between Rogers Cable Communications Inc. and EuroMedia Holdings Corp?",
      "snippets": [
        {
          "file_path": "cuad/EuromediaHoldingsCorp_20070215_10SB12G_EX-10.B(01)_525118_EX-10.B(01)_Content License Agreement.txt",
          "span": [
            2600,
            2971
          ],
          "answer": "In the event that Licensor grants to another VOD or Pay-Per-View (\"PPV\") service provider in the U.S. or the Territory the right to distribute or exhibit any Licensed Program on an earlier availability date, then Licensor shall also grant to Rogers the right to distribute and exhibit such Licensed Program on such earlier availability date, on the terms provided herein."
        },
        {
          "file_path": "cuad/EuromediaHoldingsCorp_20070215_10SB12G_EX-10.B(01)_525118_EX-10.B(01)_Content License Agreement.txt",
          "span": [
            18888,
            20432
          ],
          "answer": "If Licensor enters, or has entered, into an agreement or series of agreements (including side letters, understandings or arrangements, whether oral or written, whether formal or informal, whether now or hereafter effective, or whether on a long-term basis or short-term basis) with a third party for the distribution and exhibition of Licensed Programs in the U.S. or the Territory on a VOD basis, or any other basis that permits the downloading of such Licensed Programs and the subsequent viewing of such Licensed Programs by a residential subscriber, on terms (including, without limitation, license fees, copyright royalty payments, encoding fees and obligations, and marketing support) that are more favourable than those contained in this Agreement, then Rogers has the right to incorporate, or substitute, as the case may be, such term or terms into this Agreement, effective as of the date on which such term or terms were accorded to the third party and for the balance of the period such term or terms are applicable to such third party. Licensor shall provide to Rogers, no later than February 28 in each year, a sworn statement of a senior officer of Licensor, or a certificate of the auditors of Licensor, confirming that, during the immediately preceding calendar year, Licensor did not enter into such an agreement or series of agreements or, if it did enter into such agreement(s), confirming the effective date thereof and identifying the terms contained therein that are more favourable than those contained in this Agreement."
        }
      ]
    },
    {
      "query": "\"How can a contract between Rogers Cable Communications Inc. and EuroMedia Holdings Corp. be terminated for convenience? And what conditions would need to be met for a same to be done?\"",
      "snippets": [
        {
          "file_path": "cuad/EuromediaHoldingsCorp_20070215_10SB12G_EX-10.B(01)_525118_EX-10.B(01)_Content License Agreement.txt",
          "span": [
            16706,
            16866
          ],
          "answer": "Notwithstanding any other provision of this Agreement, Rogers may terminate this Agreement, at any time, upon sixty (60) days' prior written notice to Licensor."
        }
      ]
    },
    {
      "query": "\"What are the specific clauses in the Video-on-Demand Content License Agreement between Rogers Cable Communications Inc. and EuroMedia Holdings Corp.?\"",
      "snippets": [
        {
          "file_path": "cuad/EuromediaHoldingsCorp_20070215_10SB12G_EX-10.B(01)_525118_EX-10.B(01)_Content License Agreement.txt",
          "span": [
            23757,
            24404
          ],
          "answer": "This Agreement may not be assigned, sold or transferred without the prior written consent of the other party. Notwithstanding the foregoing, Rogers may, without consent, assign its rights and obligations under this Agreement in whole or in part to: (i) a person that directly or indirectly controls, is controlled by or is under common control with Rogers; or (ii) a purchaser of all or substantially all of the assets used in connection with the ROD Service. A change of control of Rogers shall not be considered an assignment of this Agreement. Any purported assignment, sale, or transfer in contravention of this Section shall be null and void."
        }
      ]
    },
    {
      "query": "\"What revenue is shared by Rogers Cable Communications Inc. and EuroMedia Holdings Corp. in the Video-on-Demand Content License Agreement?",
      "snippets": [
        {
          "file_path": "cuad/EuromediaHoldingsCorp_20070215_10SB12G_EX-10.B(01)_525118_EX-10.B(01)_Content License Agreement.txt",
          "span": [
            4052,
            4163
          ],
          "answer": "Rogers shall pay to Licensor a fee (the \"License Fee\"), which shall be equal to fifty (50)% of Retail Revenues."
        },
        {
          "file_path": "cuad/EuromediaHoldingsCorp_20070215_10SB12G_EX-10.B(01)_525118_EX-10.B(01)_Content License Agreement.txt",
          "span": [
            12278,
            12557
          ],
          "answer": "In consideration for various services and activities that Rogers performs for the benefit of Licensor during the Term, Licensor agrees to pay to Rogers an amount which shall be equal to ten (10)% of License Fees, calculated on a rolling basis during the Term and payable monthly."
        },
        {
          "file_path": "cuad/EuromediaHoldingsCorp_20070215_10SB12G_EX-10.B(01)_525118_EX-10.B(01)_Content License Agreement.txt",
          "span": [
            12585,
            12978
          ],
          "answer": "For so long as Rogers is required by Applicable Law to contribute a percentage of its gross annual revenues from the ROD Service to an independently-administered Canadian program production fund, Licensor shall reimburse Rogers for 50% of the amount required to be remitted to such production fund by Rogers in respect of the exhibition of Licensed Programs (the \"Production Fund Commitment\")."
        },
        {
          "file_path": "cuad/EuromediaHoldingsCorp_20070215_10SB12G_EX-10.B(01)_525118_EX-10.B(01)_Content License Agreement.txt",
          "span": [
            16318,
            16591
          ],
          "answer": "For so long as Rogers is required by Applicable Law to pay copyright royalties relating to Licensed Programs hereunder, Licensor shall reimburse Rogers for 50% of any such royalties actually paid by Rogers, calculated on a rolling basis during the Term and payable monthly."
        }
      ]
    },
    {
      "query": "Can I talk to a representative from Rogers Cable and EuroMedia Holdings about the Video-on-Demand Content License Agreement?",
      "snippets": [
        {
          "file_path": "cuad/EuromediaHoldingsCorp_20070215_10SB12G_EX-10.B(01)_525118_EX-10.B(01)_Content License Agreement.txt",
          "span": [
            10444,
            10739
          ],
          "answer": "Licensor shall make available to Rogers, on a free trial basis and at no cost to Rogers, not less than ten (10) Licensed Programs at all times during the Term (each, a \"Promotional Program\") for distribution and exhibition on the ROD Service to promote the Licensed Programs and the ROD Service."
        }
      ]
    },
    {
      "query": "\"What is the Video-on-Demand Content License Agreement between Rogers Cable Communications Inc. and EuroMedia Holdings Corp. a contract for?\"",
      "snippets": [
        {
          "file_path": "cuad/EuromediaHoldingsCorp_20070215_10SB12G_EX-10.B(01)_525118_EX-10.B(01)_Content License Agreement.txt",
          "span": [
            304,
            687
          ],
          "answer": "Licensor grants to Rogers the non-exclusive license and right to distribute and exhibit in Canada (the \"Territory\") all entertainment programming to which Licensor owns or controls the VOD distribution and exhibition rights in the Territory (collectively, \"Licensed Programs\") to residential subscribers of Rogers' digital cable television service on a Video-on-Demand (\"VOD\") basis."
        },
        {
          "file_path": "cuad/EuromediaHoldingsCorp_20070215_10SB12G_EX-10.B(01)_525118_EX-10.B(01)_Content License Agreement.txt",
          "span": [
            3284,
            3540
          ],
          "answer": "During the Term, Rogers shall have the non-exclusive right to distribute and exhibit each Licensed Program on a VOD basis for a period of ninety (90) consecutive days, or such longer period as may be agreed to by Rogers and Licensor (the \"License Period\")."
        }
      ]
    },
    {
      "query": "\"What is the Video-on-Demand Content License Agreement between Rogers Cable Communications Inc. and EuroMedia Holdings Corp. if the only thing it does is give you one unlimited license?",
      "snippets": [
        {
          "file_path": "cuad/EuromediaHoldingsCorp_20070215_10SB12G_EX-10.B(01)_525118_EX-10.B(01)_Content License Agreement.txt",
          "span": [
            3772,
            4022
          ],
          "answer": "Multiple viewings of the Licensed Program shall be permitted during the Viewing Period for no additional fee and all such viewings shall be considered a single exhibition of the Licensed Program for the purposes of calculating License Fees hereunder."
        }
      ]
    },
    {
      "query": "\"What is the audit right that Rogers Cable Communications Inc. and EuroMedia Holdings Corp. can have with regard to the Video-on-Demand Content License Agreement?",
      "snippets": [
        {
          "file_path": "cuad/EuromediaHoldingsCorp_20070215_10SB12G_EX-10.B(01)_525118_EX-10.B(01)_Content License Agreement.txt",
          "span": [
            20433,
            20763
          ],
          "answer": "During the Term, and for a period of twelve (12) months thereafter, Rogers (and its representatives) shall have the right, upon reasonable prior written notice to Licensor, and during regular business hours, to inspect and/or audit Licensor's books and records to confirm compliance with Licensor's obligations under this Section."
        }
      ]
    },
    {
      "query": "\"What is the Video-on-Demand Content License Agreement between Rogers Cable Communications Inc. and EuroMedia Holdings Corp.? Is there any uncapped liability?\"",
      "snippets": [
        {
          "file_path": "cuad/EuromediaHoldingsCorp_20070215_10SB12G_EX-10.B(01)_525118_EX-10.B(01)_Content License Agreement.txt",
          "span": [
            15954,
            16203
          ],
          "answer": "Except with respect to any claim or liability arising from an infringement of any third party intellectual property right, in no event shall either party be liable for any special, indirect, consequential, punitive or incidental damages of any kind."
        }
      ]
    },
    {
      "query": "The Video-on-Demand Content License Agreement between Rogers Cable Communications Inc. and EuroMedia Holdings Corp. outlines the liability limits for each party. Can you comment on each of these?",
      "snippets": [
        {
          "file_path": "cuad/EuromediaHoldingsCorp_20070215_10SB12G_EX-10.B(01)_525118_EX-10.B(01)_Content License Agreement.txt",
          "span": [
            15954,
            16202
          ],
          "answer": "Except with respect to any claim or liability arising from an infringement of any third party intellectual property right, in no event shall either party be liable for any special, indirect, consequential, punitive or incidental damages of any kind"
        }
      ]
    },
    {
      "query": "\"What is the renewal term for the Content Distribution and License Agreement between ConvergTV and Fulucai Productions Ltd.\"?",
      "snippets": [
        {
          "file_path": "cuad/FulucaiProductionsLtd_20131223_10-Q_EX-10.9_8368347_EX-10.9_Content License Agreement.txt",
          "span": [
            702,
            787
          ],
          "answer": "License Term Perpetual, unlimited runs x Other: 2 years Commencing: November 15, 2012"
        }
      ]
    },
    {
      "query": "\"What country has the governing law for the Content Distribution and License Agreement between ConvergTV, Inc. and Fulucai Productions Ltd.\"?",
      "snippets": [
        {
          "file_path": "cuad/FulucaiProductionsLtd_20131223_10-Q_EX-10.9_8368347_EX-10.9_Content License Agreement.txt",
          "span": [
            15422,
            15596
          ],
          "answer": "All questions with respect to the construction of this Agreement, and the rights and liabilities of the Parties hereto, shall be governed by the laws of the State of Florida."
        }
      ]
    },
    {
      "query": "\"In the Content Distribution and License Agreement between ConvergTV, Inc. and Fulucai Productions Ltd., does this contract include an exclusivity agreement?\"",
      "snippets": [
        {
          "file_path": "cuad/FulucaiProductionsLtd_20131223_10-Q_EX-10.9_8368347_EX-10.9_Content License Agreement.txt",
          "span": [
            6977,
            7244
          ],
          "answer": "During the License Term (which is identified in the Deal Terms), Producer agrees that ConvergTV has the exclusive right to exercise the rights granted to it under this Agreement with respect to the Program, including those in Section 1, within the Licensed Territory."
        }
      ]
    },
    {
      "query": "\"What revenue or profit sharing terms are outlined in the Content Distribution and License Agreement between ConvergTV, Inc. and Fulucai Productions Ltd.??\"",
      "snippets": [
        {
          "file_path": "cuad/FulucaiProductionsLtd_20131223_10-Q_EX-10.9_8368347_EX-10.9_Content License Agreement.txt",
          "span": [
            860,
            938
          ],
          "answer": "Revenue Share as specified in this CONTENT DISTRIBUTION AND LICENSE AGREEMENT."
        },
        {
          "file_path": "cuad/FulucaiProductionsLtd_20131223_10-Q_EX-10.9_8368347_EX-10.9_Content License Agreement.txt",
          "span": [
            6665,
            6722
          ],
          "answer": "The revenue share for the Program is stated in Exhibit B."
        }
      ]
    },
    {
      "query": "\"In the Content Distribution and License Agreement between ConvergTV, Inc. and Fulucai Productions Ltd., Does the licensee's affiliate have any rights under this contract?\"",
      "snippets": [
        {
          "file_path": "cuad/FulucaiProductionsLtd_20131223_10-Q_EX-10.9_8368347_EX-10.9_Content License Agreement.txt",
          "span": [
            3836,
            4188
          ],
          "answer": "Producer further grants to ConvergTV the right and license to Distribute the Program on any ConvergTV channel, and/or other distribution outlets, that exists today or that is created or developed in the future and this right includes the right to Distribute on any channels of a ConvergTV affiliate and/or other distribution outlets without limitation."
        }
      ]
    },
    {
      "query": "\"How are the audit rights granted under the Content Distribution and License Agreement between ConvergTV, Inc. and Fulucai Productions Ltd.?\"",
      "snippets": [
        {
          "file_path": "cuad/FulucaiProductionsLtd_20131223_10-Q_EX-10.9_8368347_EX-10.9_Content License Agreement.txt",
          "span": [
            17542,
            17731
          ],
          "answer": "Each of the Parties may, at its own expense, audit the other Party's compliance with this Agreement, including but not limited to, auditing the other Party's representations and warranties."
        }
      ]
    },
    {
      "query": "\"What is the expiration date for the Content License Agreement between Empirical Ventures, Inc. and PSiTech Corporation?\"",
      "snippets": [
        {
          "file_path": "cuad/GopageCorp_20140221_10-K_EX-10.1_8432966_EX-10.1_Content License Agreement.txt",
          "span": [
            17382,
            17622
          ],
          "answer": "The initial term of this Agreement commences as of the Effective Date and, unless terminated earlier pursuant to any express provision of this Agreement, shall continue until five (5) years following the Effective Date (the \"Initial Term\")."
        }
      ]
    },
    {
      "query": "What is the renewal term for this Content License Agreement between PSiTech Corporation and Empirical Ventures, Inc.?",
      "snippets": [
        {
          "file_path": "cuad/GopageCorp_20140221_10-K_EX-10.1_8432966_EX-10.1_Content License Agreement.txt",
          "span": [
            17623,
            17946
          ],
          "answer": "Thereafter, this Agreement shall renew automatically for one (1) additional three (3) year period (the \"Renewal Term\" and collectively, together with the Initial Term, the \"Term\") unless either party provides the other with written notice of non-renewal at least ninety (90) days before the expiration of the Initial Term]."
        }
      ]
    },
    {
      "query": "\"What is the amount of notice required to terminate the Content License Agreement between Empirical Ventures, Inc. and PSiTech Corporation?\"",
      "snippets": [
        {
          "file_path": "cuad/GopageCorp_20140221_10-K_EX-10.1_8432966_EX-10.1_Content License Agreement.txt",
          "span": [
            17623,
            17946
          ],
          "answer": "Thereafter, this Agreement shall renew automatically for one (1) additional three (3) year period (the \"Renewal Term\" and collectively, together with the Initial Term, the \"Term\") unless either party provides the other with written notice of non-renewal at least ninety (90) days before the expiration of the Initial Term]."
        }
      ]
    },
    {
      "query": "\"In the Content License Agreement between PSiTech Corporation and Empirical Ventures, Inc., What is the governing law for this contract?\"",
      "snippets": [
        {
          "file_path": "cuad/GopageCorp_20140221_10-K_EX-10.1_8432966_EX-10.1_Content License Agreement.txt",
          "span": [
            36761,
            36944
          ],
          "answer": "This Agreement shall be governed by and construed in accordance with the internal laws of the State of Nevada without giving effect to any choice or conflict of law provision or rule."
        }
      ]
    },
    {
      "query": "\"What are some specific terms in the Content License Agreement between PSiTech Corporation and Empirical Ventures, Inc.?\"",
      "snippets": [
        {
          "file_path": "cuad/GopageCorp_20140221_10-K_EX-10.1_8432966_EX-10.1_Content License Agreement.txt",
          "span": [
            5472,
            6080
          ],
          "answer": "Subject to Licensee's on\u00adgoing compliance with Section 3.2 and all other terms and conditions of this Agreement, Licensor grants to Licensee an exclusive (save for rights reserved to Licensor hereunder), non-transferable (except as provided in Section 11.7) and non- sublicensable license, during the License Term, to reproduce, perform, display, transmit and distribute the Licensed Content on the Licensee Siteand Related Media intended solely for use by End Usersin the Territory within the scope set forth in Schedule 1 (License Scope), which is attached hereto and incorporated herein by this reference."
        }
      ]
    },
    {
      "query": "\"What happens if one of the parties to the contract changes control? Is this contract governed by the terms of the new entity?\"",
      "snippets": [
        {
          "file_path": "cuad/GopageCorp_20140221_10-K_EX-10.1_8432966_EX-10.1_Content License Agreement.txt",
          "span": [
            33871,
            34228
          ],
          "answer": "For purposes of the preceding sentence, and without limiting its generality, any merger, consolidation or reorganization involving Licensee (regardless of whether Licensee is a surviving or disappearing entity) will be deemed to be a transfer of rights, obligations or performance under this Agreement for which Licensor's prior written consent is required."
        }
      ]
    },
    {
      "query": "\"What is the Anti-assignment Clause in the Content License Agreement between PSiTech Corporation and Empirical Ventures, Inc?\"",
      "snippets": [
        {
          "file_path": "cuad/GopageCorp_20140221_10-K_EX-10.1_8432966_EX-10.1_Content License Agreement.txt",
          "span": [
            33584,
            33870
          ],
          "answer": "Licensee shall not assign or otherwise transfer any of its rights, or delegate or otherwise transfer any of its obligations or performance, under this Agreement, in each case whether voluntarily, involuntarily, by operation of law or otherwise, without Licensor's prior written consent."
        },
        {
          "file_path": "cuad/GopageCorp_20140221_10-K_EX-10.1_8432966_EX-10.1_Content License Agreement.txt",
          "span": [
            34346,
            34488
          ],
          "answer": "Any purported assignment, delegation or transfer in violation of this Section 11.7 is void from the outset and shall be of no force or effect."
        }
      ]
    },
    {
      "query": "\"What are the revenue and profit-sharing arrangements between PSiTech Corporation and Empirical Ventures, Inc.\"?",
      "snippets": [
        {
          "file_path": "cuad/GopageCorp_20140221_10-K_EX-10.1_8432966_EX-10.1_Content License Agreement.txt",
          "span": [
            14071,
            14446
          ],
          "answer": "In addition to the License Fee payable in accordance with Section 5.1, Licensee shall pay a royalty (\"Royalty\") to Licensor according to the following schedule (\"Royalty Schedule\"):   Subscribers Royalty Payable as Percentage of Gross Revenue 0 - 5000 6.25% 5001 - 7500 6.75% 7501 - 10,000 7.00% 10,001 - 15,000 8.00% 15,001 - 20,000 8.50% 20,001 - 25,000 9.25% 25,001+ 9.75%"
        }
      ]
    },
    {
      "query": "\"What types of licenses are granted under the Content License Agreement between PSiTech Corporation and Empirical Ventures, Inc.?\"",
      "snippets": [
        {
          "file_path": "cuad/GopageCorp_20140221_10-K_EX-10.1_8432966_EX-10.1_Content License Agreement.txt",
          "span": [
            5472,
            6080
          ],
          "answer": "Subject to Licensee's on\u00adgoing compliance with Section 3.2 and all other terms and conditions of this Agreement, Licensor grants to Licensee an exclusive (save for rights reserved to Licensor hereunder), non-transferable (except as provided in Section 11.7) and non- sublicensable license, during the License Term, to reproduce, perform, display, transmit and distribute the Licensed Content on the Licensee Siteand Related Media intended solely for use by End Usersin the Territory within the scope set forth in Schedule 1 (License Scope), which is attached hereto and incorporated herein by this reference."
        },
        {
          "file_path": "cuad/GopageCorp_20140221_10-K_EX-10.1_8432966_EX-10.1_Content License Agreement.txt",
          "span": [
            9020,
            9719
          ],
          "answer": "Licensor grants to Licensee a limited, non-exclusive, non-transferable (except as provided in Section 11.7) and non-sublicensable royalty-free license during the Term to those of Licensor's Marks designated by Licensor from time to time to:   (i)display such Marks on the Licensee Site: (x) with the Licensed Content to provide source attribution; or (y) as links to the Licensed Content;   (ii)comply with its express obligations under this Agreement; and   (iii)advertise, market and promote the availability of the Licensed Content or the Licensee Site and identify the Licensor as a content provider;   provided, that all uses of Licensor's Marks shall require Licensor's prior written approval."
        }
      ]
    },
    {
      "query": "\"In the Content License Agreement between PSiTech Corporation and Empirical Ventures, Inc., Are the licenses granted under this contract non-transferable?\"",
      "snippets": [
        {
          "file_path": "cuad/GopageCorp_20140221_10-K_EX-10.1_8432966_EX-10.1_Content License Agreement.txt",
          "span": [
            5472,
            6080
          ],
          "answer": "Subject to Licensee's on\u00adgoing compliance with Section 3.2 and all other terms and conditions of this Agreement, Licensor grants to Licensee an exclusive (save for rights reserved to Licensor hereunder), non-transferable (except as provided in Section 11.7) and non- sublicensable license, during the License Term, to reproduce, perform, display, transmit and distribute the Licensed Content on the Licensee Siteand Related Media intended solely for use by End Usersin the Territory within the scope set forth in Schedule 1 (License Scope), which is attached hereto and incorporated herein by this reference."
        },
        {
          "file_path": "cuad/GopageCorp_20140221_10-K_EX-10.1_8432966_EX-10.1_Content License Agreement.txt",
          "span": [
            9020,
            9719
          ],
          "answer": "Licensor grants to Licensee a limited, non-exclusive, non-transferable (except as provided in Section 11.7) and non-sublicensable royalty-free license during the Term to those of Licensor's Marks designated by Licensor from time to time to:   (i)display such Marks on the Licensee Site: (x) with the Licensed Content to provide source attribution; or (y) as links to the Licensed Content;   (ii)comply with its express obligations under this Agreement; and   (iii)advertise, market and promote the availability of the Licensed Content or the Licensee Site and identify the Licensor as a content provider;   provided, that all uses of Licensor's Marks shall require Licensor's prior written approval."
        }
      ]
    },
    {
      "query": "\"What are the audit rights under the Content License Agreement between PSiTech Corporation and Empirical Ventures, Inc.?\"",
      "snippets": [
        {
          "file_path": "cuad/GopageCorp_20140221_10-K_EX-10.1_8432966_EX-10.1_Content License Agreement.txt",
          "span": [
            16232,
            16745
          ],
          "answer": "Licensee shall make such books and records, and appropriate personnel, available during normal business hours for audit by Licensor or its authorized representative; provided that Licensor shall:   (a) provide Licensee with reasonable prior notice of any audit;   (b) undertake an audit no more than once per calendar year, unless a prior audit has disclosed a balance due; and   (c) conduct or cause to be conducted such audit in a manner designed to minimize disruption of Licensee's normal business operations."
        },
        {
          "file_path": "cuad/GopageCorp_20140221_10-K_EX-10.1_8432966_EX-10.1_Content License Agreement.txt",
          "span": [
            16809,
            17036
          ],
          "answer": "Licensor will pay the cost of such audits unless an audit reveals a discrepancy in payment or reporting of five percent (5%) or more, in which case the Licensee shall reimburse the Licensor for the reasonable cost of the audit."
        }
      ]
    },
    {
      "query": "\"What is the Content License Agreement between PSiTech Corporation and Empirical Ventures, Inc.'s uncapped liability?",
      "snippets": [
        {
          "file_path": "cuad/GopageCorp_20140221_10-K_EX-10.1_8432966_EX-10.1_Content License Agreement.txt",
          "span": [
            25255,
            25454
          ],
          "answer": "The provisions of Section 9.1 and Section 9.2 will not apply to limit the Licensee's indemnification obligations under Section 8.2, or in the case of Licensee's gross negligence or wilful misconduct."
        }
      ]
    },
    {
      "query": "\"Is there a cap on liability in the Content License Agreement between PSiTech Corporation and Empirical Ventures, Inc.\"?",
      "snippets": [
        {
          "file_path": "cuad/GopageCorp_20140221_10-K_EX-10.1_8432966_EX-10.1_Content License Agreement.txt",
          "span": [
            24564,
            24938
          ],
          "answer": "NEITHER PARTY SHALL BE LIABLE UNDER OR IN CONNECTION WITH THIS AGREEMENT FOR INDIRECT, INCIDENTAL, CONSEQUENTIAL, LIQUIDATED, SPECIAL OR EXEMPLARY DAMAGES OR PENALTIES, INCLUDING WITHOUT LIMITATION, LOSSES OF BUSINESS, REVENUE OR ANTICIPATED PROFITS, REGARDLESS OF WHETHER SUCH DAMAGE WAS FORESEEABLE AND WHETHER LICENSOR HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES."
        },
        {
          "file_path": "cuad/GopageCorp_20140221_10-K_EX-10.1_8432966_EX-10.1_Content License Agreement.txt",
          "span": [
            25018,
            25236
          ],
          "answer": "EACH PARTY'S LIABILITY ARISING OUT OF OR RELATED TO THIS AGREEMENT WILL NOT EXCEED AN AMOUNT EQUAL TO THE AGGREGATE AMOUNTS PAID OR PAYABLE TO LICENSOR IN THE TWELVE (12) MONTHS PRECEDING THE COMMENCEMENT OF THE CLAIM."
        }
      ]
    },
    {
      "query": "\"What is the expiration date of the Content License Agreement between Beijing Sun Seven Stars Culture Development Limited and You On Demand Holdings, Inc.?\"",
      "snippets": [
        {
          "file_path": "cuad/IdeanomicsInc_20160330_10-K_EX-10.26_9512211_EX-10.26_Content License Agreement.txt",
          "span": [
            17465,
            17667
          ],
          "answer": "The Term of this Agreement (the \"Term\") shall commence on the Effective Date listed above and continue for twenty (20) years, unless sooner terminated as provided in Section 7(b) [Term and Termination]."
        }
      ]
    },
    {
      "query": "\"What is the governing law for the Content License Agreement between Beijing Sun Seven Stars Culture Development Limited and You On Demand Holdings, Inc.\"?",
      "snippets": [
        {
          "file_path": "cuad/IdeanomicsInc_20160330_10-K_EX-10.26_9512211_EX-10.26_Content License Agreement.txt",
          "span": [
            32754,
            32932
          ],
          "answer": "This Agreement shall be governed by and construed in all respects in accordance with the laws of the State of New York, without giving effect to any conflicts of laws principles."
        }
      ]
    },
    {
      "query": "\"In the Content License Agreement between Beijing Sun Seven Stars Culture Development Limited and You On Demand Holdings, Inc. is there any right of first refusal?",
      "snippets": [
        {
          "file_path": "cuad/IdeanomicsInc_20160330_10-K_EX-10.26_9512211_EX-10.26_Content License Agreement.txt",
          "span": [
            16232,
            16833
          ],
          "answer": "If, during the Term, Licensor develops or obtains the rights to license any live action or animated feature-length motion picture (each an \"Additional Title\"), Licensor shall give Licensee the first right of negotiation for each Additional Title (i.e., the preferred vendor). Licensor will promptly provide written notice to Licensee in which Licensor lists each Additional Title. Should Licensee agree to be the vendor for an Additional Title, Licensor and Licensee will negotiate in good faith to mutually agree upon the pricing and terms for each Additional Title in an amendment to this Agreement."
        }
      ]
    },
    {
      "query": "\"In the Content License Agreement between Beijing Sun Seven Stars Culture Development Limited and You On Demand Holdings, Inc., Is there an anti-assignment clause in this contract?\"",
      "snippets": [
        {
          "file_path": "cuad/IdeanomicsInc_20160330_10-K_EX-10.26_9512211_EX-10.26_Content License Agreement.txt",
          "span": [
            7869,
            8207
          ],
          "answer": "Licensee shall have the right to assign or sublicense any or all of its rights granted under this Agreement, in whole or in part, to third parties exhibiting the Titles in the ordinary course of Licensee's business with prior written notice to Licensor and subject to the applicable limitations (if any) in Section 2(a)(i) [License Grant]"
        },
        {
          "file_path": "cuad/IdeanomicsInc_20160330_10-K_EX-10.26_9512211_EX-10.26_Content License Agreement.txt",
          "span": [
            8209,
            8440
          ],
          "answer": "Except as otherwise specified in the previous sentence, Licensee may not sublicense any of its rights under Section 2(a) [License Grant] without Licensor's prior written consent, which shall not be unreasonably withheld or delayed."
        },
        {
          "file_path": "cuad/IdeanomicsInc_20160330_10-K_EX-10.26_9512211_EX-10.26_Content License Agreement.txt",
          "span": [
            37152,
            37863
          ],
          "answer": "Neither party may assign its rights, duties or obligations under this Agreement to any third party in whole or in part, without the other party's prior written consent, except that (i) Licensee may assign its rights and obligations to this Agreement to any of its Affiliate or subsidiaries with the prior written consent of the Licensor, and (ii) Licensor may assign its rights and obligations in this Agreement to its Affiliates or subsidiaries and either party may assign this Agreement in its entirety to any purchaser of all or substantially all of its business or assets pertaining to the line of business to which this Agreement relates or to any Affiliate of the party without the other party's approval."
        }
      ]
    },
    {
      "query": "\"In the Content License Agreement between Beijing Sun Seven Stars Culture Development Limited and You On Demand Holdings, Inc., does this contract include any revenue or profit-sharing arrangements?\"",
      "snippets": [
        {
          "file_path": "cuad/IdeanomicsInc_20160330_10-K_EX-10.26_9512211_EX-10.26_Content License Agreement.txt",
          "span": [
            9865,
            10082
          ],
          "answer": "For content listed in Schedule A6 of Schedule A (each a \"Project\"), Licensor will only grant Licensee certain profit participation rights, for certain durations, as detailed and set forth in Schedule A6 of Schedule A."
        },
        {
          "file_path": "cuad/IdeanomicsInc_20160330_10-K_EX-10.26_9512211_EX-10.26_Content License Agreement.txt",
          "span": [
            20743,
            21034
          ],
          "answer": "The consideration for the licenses granted by Licensor to Licensee under this Agreement is the issuance of the IP Common Shares as defined in the Amended and Securities Purchase Agreement, dated as of December 21, 2015, by and among the Licensee and the Licensor (the \"Share Consideration\")."
        }
      ]
    },
    {
      "query": "What are the audit rights under the Content License Agreement between Beijing Sun Seven Stars Culture Development Limited and You On Demand Holdings, Inc.?",
      "snippets": [
        {
          "file_path": "cuad/IdeanomicsInc_20160330_10-K_EX-10.26_9512211_EX-10.26_Content License Agreement.txt",
          "span": [
            12743,
            12966
          ],
          "answer": "Until one (1) year after the expiration of the Profit Participation of each Project, the books and records will be available for inspection by a certified accounting firm or CPA once per year upon reasonable advance notice."
        }
      ]
    },
    {
      "query": "\"What is the Content License Agreement between Beijing Sun Seven Stars Culture Development Limited and You On Demand Holdings, Inc.? Are there any uncapped liability provisions in the contract?\"",
      "snippets": [
        {
          "file_path": "cuad/IdeanomicsInc_20160330_10-K_EX-10.26_9512211_EX-10.26_Content License Agreement.txt",
          "span": [
            32282,
            32713
          ],
          "answer": "EXCEPT FOR THE ABOVE INDEMNIFICATION OBLIGATIONS AND FOR BREACHES OF SECTION 14, NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY INCIDENTAL, CONSEQUENTIAL, SPECIAL OR PUNITIVE DAMAGES ARISING OUT OF THIS AGREEMENT (INCLUDING, BUT NOT LIMITED TO, LOSS OF PROFITS), WHETHER IN AN ACTION OR ARISING OUT OF BREACH OF CONTRACT, TORT OR ANY OTHER CAUSE OF ACTION EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES."
        }
      ]
    },
    {
      "query": "\"How many liability points does the Content License Agreement between Beijing Sun Seven Stars Culture Development Limited and You On Demand Holdings, Inc. have?",
      "snippets": [
        {
          "file_path": "cuad/IdeanomicsInc_20160330_10-K_EX-10.26_9512211_EX-10.26_Content License Agreement.txt",
          "span": [
            32282,
            32713
          ],
          "answer": "EXCEPT FOR THE ABOVE INDEMNIFICATION OBLIGATIONS AND FOR BREACHES OF SECTION 14, NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY INCIDENTAL, CONSEQUENTIAL, SPECIAL OR PUNITIVE DAMAGES ARISING OUT OF THIS AGREEMENT (INCLUDING, BUT NOT LIMITED TO, LOSS OF PROFITS), WHETHER IN AN ACTION OR ARISING OUT OF BREACH OF CONTRACT, TORT OR ANY OTHER CAUSE OF ACTION EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES."
        }
      ]
    },
    {
      "query": "\"What is the expiration date of the Co-Branding and Services Agreement between RSL COM PrimeCall and deltathree.com, Inc.\"",
      "snippets": [
        {
          "file_path": "cuad/DeltathreeInc_19991102_S-1A_EX-10.19_6227850_EX-10.19_Co-Branding Agreement_ Service Agreement.txt",
          "span": [
            1515,
            2043
          ],
          "answer": "The term of this Agreement shall be effective as of the date first stated above and shall continue for a term of three (3) years, unless terminated earlier in accordance with the provisions of this Agreement (the \"Term\"); provided, however, that PrimeCall may elect to terminate this Agreement, upon thirty (30) days' written notice, at any time from and after the time that collectively RSL Communications, Ltd. and/or its Affiliates holds less than fifty percent (50%) of the voting control of DeltaThree's outstanding shares."
        }
      ]
    },
    {
      "query": "Are there any laws governing the Co-Branding and Services Agreement between RSL COM PrimeCall, Inc. and deltathree.com?",
      "snippets": [
        {
          "file_path": "cuad/DeltathreeInc_19991102_S-1A_EX-10.19_6227850_EX-10.19_Co-Branding Agreement_ Service Agreement.txt",
          "span": [
            26053,
            26224
          ],
          "answer": "This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York, without giving effect to the conflict of laws principles thereof."
        }
      ]
    },
    {
      "query": "\"What happens in the event of a change of control of one of the parties in the Co-Branding and Services Agreement between RSL COM PrimeCall, Inc. and deltathree.com, Inc?\"",
      "snippets": [
        {
          "file_path": "cuad/DeltathreeInc_19991102_S-1A_EX-10.19_6227850_EX-10.19_Co-Branding Agreement_ Service Agreement.txt",
          "span": [
            1515,
            2043
          ],
          "answer": "The term of this Agreement shall be effective as of the date first stated above and shall continue for a term of three (3) years, unless terminated earlier in accordance with the provisions of this Agreement (the \"Term\"); provided, however, that PrimeCall may elect to terminate this Agreement, upon thirty (30) days' written notice, at any time from and after the time that collectively RSL Communications, Ltd. and/or its Affiliates holds less than fifty percent (50%) of the voting control of DeltaThree's outstanding shares."
        }
      ]
    },
    {
      "query": "\"Is the Co-Branding and Services Agreement between RSL COM PrimeCall, Inc. and deltathree.com, Inc. an anti-assignment clause?\"",
      "snippets": [
        {
          "file_path": "cuad/DeltathreeInc_19991102_S-1A_EX-10.19_6227850_EX-10.19_Co-Branding Agreement_ Service Agreement.txt",
          "span": [
            25061,
            25157
          ],
          "answer": "This Agreement may not be assigned by DeltaThree without the prior written consent of PrimeCall."
        },
        {
          "file_path": "cuad/DeltathreeInc_19991102_S-1A_EX-10.19_6227850_EX-10.19_Co-Branding Agreement_ Service Agreement.txt",
          "span": [
            25348,
            25490
          ],
          "answer": "Except as provided in the preceding sentence, this Agreement may not be assigned by PrimeCall without the prior written consent of DeltaThree."
        }
      ]
    },
    {
      "query": "\"What licenses are granted under the Co-Branding and Services Agreement between RSL COM PrimeCall, Inc. and deltathree.com, Inc.\"?",
      "snippets": [
        {
          "file_path": "cuad/DeltathreeInc_19991102_S-1A_EX-10.19_6227850_EX-10.19_Co-Branding Agreement_ Service Agreement.txt",
          "span": [
            3574,
            3840
          ],
          "answer": "Throughout the Term of this Agreement, the parties hereby agree to grant to each other a limited license to use each other's proprietary marks solely in connection with the sale, distribution, marketing and promotion of each party's calling cards by the other party."
        }
      ]
    },
    {
      "query": "\"What are the details of the Co-Branding and Services Agreement between RSL COM PrimeCall, Inc. and deltathree.com, Inc.?\"",
      "snippets": [
        {
          "file_path": "cuad/DeltathreeInc_19991102_S-1A_EX-10.19_6227850_EX-10.19_Co-Branding Agreement_ Service Agreement.txt",
          "span": [
            15192,
            15684
          ],
          "answer": "IN NO EVENT SHALL PRIMECALL BE LIABLE TO DELTATHREE FOR ANY SPECIAL, INCIDENTIAL OR CONSEQUENTIAL DAMAGES, INCLUDING, WITHOUT LIMITATION, LOSS OF PROFITS, REVENUES OR DATA WHETHER BASED ON BREACH OF CONTRACT, TORT OR OTHERWISE, WHETHER OR NOT DELTATHREE HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGE. THE LIABILITY OF PRIMECALL FOR DAMAGES OR ALLEGED DAMAGES HEREUNDER, WHETHER IN CONTRACT, TORT OR ANY OTHER LEGAL THEORY, IS LIMITED TO, AND WILL NOT EXCEED, DELTATHREE'S DIRECT DAMAGES."
        },
        {
          "file_path": "cuad/DeltathreeInc_19991102_S-1A_EX-10.19_6227850_EX-10.19_Co-Branding Agreement_ Service Agreement.txt",
          "span": [
            16101,
            16592
          ],
          "answer": "IN NO EVENT SHALL DELTATHREE BE LIABLE TO PRIMECALL FOR ANY SPECIAL, INCIDENTIAL OR CONSEQUENTIAL DAMAGES, INCLUDING, WITHOUT LIMITATION, LOSS OF PROFITS, REVENUES OR DATA WHETHER BASED ON BREACH OF CONTRACT, TORT OR OTHERWISE, WHETHER OR NOT PRIMECALL HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGE. THE LIABILITY OF DELTATHREE FOR DAMAGES OR ALLEGED DAMAGES HEREUNDER, WHETHER IN CONTRACT, TORT OR ANY OTHER LEGAL THEORY, IS LIMITED TO, AND WILL NOT EXCEED, PRIMECALL'S DIRECT DAMAGES."
        }
      ]
    },
    {
      "query": "\"What is the renewal term for the Co-Branding Agreement between Women.com Networks, Inc. and eDiets.com, Inc. for the Establishment of a Diet Center?\"",
      "snippets": [
        {
          "file_path": "cuad/EdietsComInc_20001030_10QSB_EX-10.4_2606646_EX-10.4_Co-Branding Agreement.txt",
          "span": [
            24987,
            25249
          ],
          "answer": "This agreement shall automatically renew for additional successive terms of twelve (12) months each at the end of the Initial Term (\"Renewal Terms\"), unless either party notifies the other in writing at least sixty (60) days prior to the end of the Initial Term."
        }
      ]
    },
    {
      "query": "\"To terminate the Co-Branding Agreement between Women.com Networks, Inc. and eDiets.com, Inc. for the Establishment of a Diet Center, what is the notice period?\"",
      "snippets": [
        {
          "file_path": "cuad/EdietsComInc_20001030_10QSB_EX-10.4_2606646_EX-10.4_Co-Branding Agreement.txt",
          "span": [
            24987,
            25249
          ],
          "answer": "This agreement shall automatically renew for additional successive terms of twelve (12) months each at the end of the Initial Term (\"Renewal Terms\"), unless either party notifies the other in writing at least sixty (60) days prior to the end of the Initial Term."
        }
      ]
    },
    {
      "query": "\"What is the governing law for the Co-Branding Agreement between Women.com Networks, Inc. and eDiets.com, Inc. for the Establishment of a Diet Center?\"",
      "snippets": [
        {
          "file_path": "cuad/EdietsComInc_20001030_10QSB_EX-10.4_2606646_EX-10.4_Co-Branding Agreement.txt",
          "span": [
            44612,
            45013
          ],
          "answer": "This Agreement shall be interpreted and enforced in accordance with the laws of the State of California as applied to agreements made, entered into and performed entirely in California by California residents, notwithstanding the actual residence of the parties, without giving effect to any choice of laws of California that would require the application of the laws of a state other than California."
        }
      ]
    },
    {
      "query": "\"What are the exceptions to competitive restrictions in the Co-Branding Agreement between Women.com Networks and eDiets.com for the Establishment of a Diet Center?\"",
      "snippets": [
        {
          "file_path": "cuad/EdietsComInc_20001030_10QSB_EX-10.4_2606646_EX-10.4_Co-Branding Agreement.txt",
          "span": [
            11916,
            12336
          ],
          "answer": "Notwithstanding the foregoing, Women.com shall be entitled to (aa) provide mini and micro web sites and Women.com promotions and sponsorships to Jenny Craig; (bb) sell, display, or distribute advertisements, including banner advertisements, newsletter placements, internet radio, commerce placements and market research, or otherwise promote Competitive Companies on pages other than the Gateway Page of the Diet Center."
        }
      ]
    },
    {
      "query": "\"What are the terms of the Co-Branding Agreement between Women.com Networks and eDiets.com for the Establishment of a Diet Center?\"",
      "snippets": [
        {
          "file_path": "cuad/EdietsComInc_20001030_10QSB_EX-10.4_2606646_EX-10.4_Co-Branding Agreement.txt",
          "span": [
            12707,
            13543
          ],
          "answer": "During the Term, Women.com agrees to give eDiets the right of first refusal to participate in all diet and diet-counseling related promotion opportunities created or otherwise made available by Women.com on channels or sub-channels created after the Effective Date of this Agreement, including sponsorships, anchor placements and any other content integration opportunities (\"Diet Promos\"). If Women.com proposes to create and make available Diet Promos after the Effective Date, it shall give eDiets written notice of its intention, describing the terms and conditions of participation in the Diet Promos. eDiets shall have fifteen (15) days from the giving of such notice to agree to participate in the applicable Diet Promo upon the terms and conditions specified in the notice by giving written notice of its agreement to Women.com."
        },
        {
          "file_path": "cuad/EdietsComInc_20001030_10QSB_EX-10.4_2606646_EX-10.4_Co-Branding Agreement.txt",
          "span": [
            51944,
            52140
          ],
          "answer": "eDiets.com will have the first right to substitute any of the following content features for any of the eight (8) content features selected above once inventory on such features becomes available."
        }
      ]
    },
    {
      "query": "\"What happens when a change in control occurs? What happens if that change of control is not accounted for in the Co-Branding Agreement between Women.com Networks, Inc. and eDiets.com, Inc.\"",
      "snippets": [
        {
          "file_path": "cuad/EdietsComInc_20001030_10QSB_EX-10.4_2606646_EX-10.4_Co-Branding Agreement.txt",
          "span": [
            43739,
            44244
          ],
          "answer": "For purposes of this Agreement, \"Change in Control\" means a merger or consolidation of the party with, or any sale of all or substantially all of the assets of such party to, any other person, corporation or entity, unless as a result of such merger, consolidation or sale of assets the holders of such party's voting securities prior thereto hold at least fifty percent (50%) of the total voting power represented by the voting securities of the surviving or successor corporation after such transaction."
        }
      ]
    },
    {
      "query": "\"Regarding the Co-Branding Agreement between Women.com Networks and eDiets.com, is there any price restrictions or controls specified in this contract?\"",
      "snippets": [
        {
          "file_path": "cuad/EdietsComInc_20001030_10QSB_EX-10.4_2606646_EX-10.4_Co-Branding Agreement.txt",
          "span": [
            14703,
            15105
          ],
          "answer": "Following the Initial Term, Women.com shall have the right, upon no fewer than sixty (60) days prior written notice to eDiets, to increase the amount of the Payment Schedule; provided, that (i) Women.com may not increase the Payment Schedule more than once in any period of twelve (12) consecutive months; and (ii) such increase may not exceed twenty percent (20%) of the then current Payment Schedule."
        }
      ]
    },
    {
      "query": "\"What is the minimum commitment required by Women.com Networks, Inc. and eDiets.com, Inc. during the time of co-branding of a Diet Center?\"",
      "snippets": [
        {
          "file_path": "cuad/EdietsComInc_20001030_10QSB_EX-10.4_2606646_EX-10.4_Co-Branding Agreement.txt",
          "span": [
            8397,
            9546
          ],
          "answer": "If Women.com does not deliver at least 80% of the Quarterly Impression Guarantee for Advertsing Promotions as set forth on Exhibit B (11,250,000 per quarter; 45,000,000 per year); 80% of the Quarterly Impression Guarantee for the Diet Center Logo as set forth on Exhibit B (3,250,000 per quarter; 13,000,000 per year); and 80% of the Quarterly Impression Guarantee for Other Campaigns as set forth on Exhibit B (3,000,000 per quarter; 12,000,000 per year) each quarter following the Launch Date, within sixty (60) days of the end of the applicable quarter, Women.com shall deliver an amount equal to the under-delivery within the same campaign elements, including newsletters, promotions, exclusive sponsorships, targeted rotations, ROS, channel and sub-channel center logo placements, or mutually agreed upon comparable elements. If Women.com does not deliver the shortfall within sixty (60) days of the end of the applicable quarter, eDiets may terminate this Agreement in its entirety immediately or authorize Women.com to deliver the shortfall within an extended number of days to be mutually agreed upon by the parties (the \"Make Good Period\")."
        },
        {
          "file_path": "cuad/EdietsComInc_20001030_10QSB_EX-10.4_2606646_EX-10.4_Co-Branding Agreement.txt",
          "span": [
            54959,
            55581
          ],
          "answer": "During the Term, eDiets.com will be guaranteed 12 million circulation per year from and after the Effective Date via newsletters, including but not limited to:      >>  Fashion & Beauty Newsletter: 300,000 subscribers per month      >>  Food News: 180,000 subscribers per month      >>  Prevention: 1,600,000 subscribers per month      >>  Internet Scopes:  2,400,000 subscribers per month      >>  Sex & Romance: 120,000 subscribers per month      >>  What's New: 1,100,000 subscribers per month      >>  Women.com Member Newsletter: 1,700,000 subscribers per month\n\nGuaranteed Circulation Per Year:            12,000,000"
        },
        {
          "file_path": "cuad/EdietsComInc_20001030_10QSB_EX-10.4_2606646_EX-10.4_Co-Branding Agreement.txt",
          "span": [
            60777,
            60914
          ],
          "answer": "Notwithstanding the foregoing, Women.com does guarantee a minimum of 13,000,000 impressions promoting eDiets per year on the Diet Center."
        }
      ]
    },
    {
      "query": "\"What licenses are granted under the Co-Branding Agreement between Women.com Networks, Inc. and eDiets.com, Inc. for the Establishment of a Diet Center??\"",
      "snippets": [
        {
          "file_path": "cuad/EdietsComInc_20001030_10QSB_EX-10.4_2606646_EX-10.4_Co-Branding Agreement.txt",
          "span": [
            4360,
            5041
          ],
          "answer": "eDiets hereby grants to Women.com, subject to the terms and conditions of this Agreement, a non-exclusive, nontransferable, worldwide, royalty-free license to use, copy, reproduce and display the editorial content and other data, branding and other identification provided by eDiets to Women.com in connection with this Agreement (the \"eDiets Content\") on the Women.com Sites: (i) for publication in the Diet Center and elsewhere throughout the Women.com Sites; (ii) for the promotion of eDiets and the Diet Center on the Women.com Sites and in collateral advertising materials; and (iii) for such other purposes as are consistent with or otherwise authorized under this Agreement."
        },
        {
          "file_path": "cuad/EdietsComInc_20001030_10QSB_EX-10.4_2606646_EX-10.4_Co-Branding Agreement.txt",
          "span": [
            19748,
            20096
          ],
          "answer": "Women.com hereby grants eDiets a non-exclusive, non-transferable, royalty-free worldwide right and license without the right to sublicense to use the Women.com Marks during the Term solely in connection with (i) the fulfillment of eDiets' obligations under this Agreement, and (ii) in advertising and marketing collateral related to this Agreement."
        },
        {
          "file_path": "cuad/EdietsComInc_20001030_10QSB_EX-10.4_2606646_EX-10.4_Co-Branding Agreement.txt",
          "span": [
            21364,
            21713
          ],
          "answer": "eDiets hereby grants Women.com a non-exclusive, non-transferable, royalty-free worldwide right and license without the right to sublicense to use the eDiets Marks during the Term solely in connection with (i) the fulfillment of Women.com's obligations under this Agreement, and (ii) in advertising and marketing collateral related to this Agreement."
        }
      ]
    },
    {
      "query": "\"What kind of license could be granted under the Co-Branding Agreement between Women.com Networks, Inc. and eDiets.com, Inc. for the Establishment of a Diet Center?\"",
      "snippets": [
        {
          "file_path": "cuad/EdietsComInc_20001030_10QSB_EX-10.4_2606646_EX-10.4_Co-Branding Agreement.txt",
          "span": [
            4360,
            5041
          ],
          "answer": "eDiets hereby grants to Women.com, subject to the terms and conditions of this Agreement, a non-exclusive, nontransferable, worldwide, royalty-free license to use, copy, reproduce and display the editorial content and other data, branding and other identification provided by eDiets to Women.com in connection with this Agreement (the \"eDiets Content\") on the Women.com Sites: (i) for publication in the Diet Center and elsewhere throughout the Women.com Sites; (ii) for the promotion of eDiets and the Diet Center on the Women.com Sites and in collateral advertising materials; and (iii) for such other purposes as are consistent with or otherwise authorized under this Agreement."
        },
        {
          "file_path": "cuad/EdietsComInc_20001030_10QSB_EX-10.4_2606646_EX-10.4_Co-Branding Agreement.txt",
          "span": [
            19748,
            20095
          ],
          "answer": "Women.com hereby grants eDiets a non-exclusive, non-transferable, royalty-free worldwide right and license without the right to sublicense to use the Women.com Marks during the Term solely in connection with (i) the fulfillment of eDiets' obligations under this Agreement, and (ii) in advertising and marketing collateral related to this Agreement"
        },
        {
          "file_path": "cuad/EdietsComInc_20001030_10QSB_EX-10.4_2606646_EX-10.4_Co-Branding Agreement.txt",
          "span": [
            21364,
            21713
          ],
          "answer": "eDiets hereby grants Women.com a non-exclusive, non-transferable, royalty-free worldwide right and license without the right to sublicense to use the eDiets Marks during the Term solely in connection with (i) the fulfillment of Women.com's obligations under this Agreement, and (ii) in advertising and marketing collateral related to this Agreement."
        }
      ]
    },
    {
      "query": "\"Is the Co-Branding Agreement between Women.com Networks, Inc. and eDiets.com, Inc. for the Establishment of a Diet Center exclusive or exempt from any liability limits?\"",
      "snippets": [
        {
          "file_path": "cuad/EdietsComInc_20001030_10QSB_EX-10.4_2606646_EX-10.4_Co-Branding Agreement.txt",
          "span": [
            41949,
            42621
          ],
          "answer": "EXCEPT FOR BREACHES OF SECTION 11 OR BREACHES OF ANY LICENSE GRANT SET FORTH IN THIS AGREEMENT, IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY SPECIAL, INCIDENTAL, INDIRECT OR CONSEQUENTIAL DAMAGES, WHETHER BASED ON BREACH OF CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE, WHETHER OR NOT THAT PARTY HAS BEEN ADVISED OF, KNEW, OR SHOULD HAVE KNOWN OF, THE POSSIBILITY OF SUCH DAMAGE AND NOTWITHSTANDING THE FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY. THE LIMITATIONS ON LIABILITY FOR DAMAGES SET FORTH IN THIS AGREEMENT SHALL BE INAPPLICABLE TO EACH PARTY'S CONTRACTUAL OBLIGATION TO INDEMNIFY THE OTHER PARTY AS SET FORTH IN SECTIONS 2.6 AND 13."
        }
      ]
    },
    {
      "query": "\"Are there any specific limitations on the liability under the Co-Branding Agreement between Women.com Networks and eDiets.com, Inc.\"?",
      "snippets": [
        {
          "file_path": "cuad/EdietsComInc_20001030_10QSB_EX-10.4_2606646_EX-10.4_Co-Branding Agreement.txt",
          "span": [
            36715,
            36887
          ],
          "answer": "Each party agrees that the sole and exclusive remedy for a breach of the warranties set forth in this Section 12 shall be the indemnification set forth in Section 13 below."
        },
        {
          "file_path": "cuad/EdietsComInc_20001030_10QSB_EX-10.4_2606646_EX-10.4_Co-Branding Agreement.txt",
          "span": [
            41949,
            42425
          ],
          "answer": "EXCEPT FOR BREACHES OF SECTION 11 OR BREACHES OF ANY LICENSE GRANT SET FORTH IN THIS AGREEMENT, IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY SPECIAL, INCIDENTAL, INDIRECT OR CONSEQUENTIAL DAMAGES, WHETHER BASED ON BREACH OF CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE, WHETHER OR NOT THAT PARTY HAS BEEN ADVISED OF, KNEW, OR SHOULD HAVE KNOWN OF, THE POSSIBILITY OF SUCH DAMAGE AND NOTWITHSTANDING THE FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY."
        }
      ]
    },
    {
      "query": "\"What are the Co Branding Agreement provisions of the Agreement between Women.com Networks, Inc. and eDiets.com, Inc.: are any covenants to not sue included?\"",
      "snippets": [
        {
          "file_path": "cuad/EdietsComInc_20001030_10QSB_EX-10.4_2606646_EX-10.4_Co-Branding Agreement.txt",
          "span": [
            17023,
            17250
          ],
          "answer": "Women.com acknowledges that eDiets owns all right, title and interest in and to the eDiets Content, and Women.com shall not now or in the future contest the validity of the eDiets' ownership rights in and to the eDiets Content."
        },
        {
          "file_path": "cuad/EdietsComInc_20001030_10QSB_EX-10.4_2606646_EX-10.4_Co-Branding Agreement.txt",
          "span": [
            23667,
            23964
          ],
          "answer": "At no time during the term of the Agreement or thereafter shall eDiets attack, challenge or file any application with respect to any Women.com Mark. At no time during the term of the Agreement or thereafter shall Women.com attack, challenge or file any application with respect to any eDiets Mark."
        }
      ]
    },
    {
      "query": "\"What is the contract date for the Product Development and Co-Branding Agreement between Integrity Incorporated and Time Life, Inc. for 'Songs 4 Worship' Series?\"",
      "snippets": [
        {
          "file_path": "cuad/IntegrityMediaInc_20010329_10-K405_EX-10.17_2373875_EX-10.17_Co-Branding Agreement.txt",
          "span": [
            19511,
            19640
          ],
          "answer": "This agreement shall commence as of date first above written, and          shall Continue through December 31, 2004 (\"the Term\")."
        }
      ]
    },
    {
      "query": "\"What is the governing law in the Product Development and Co Branding Agreement between Integrity Incorporated and Time Life, Inc. for 'Songs 4 Worship' Series?\"",
      "snippets": [
        {
          "file_path": "cuad/IntegrityMediaInc_20010329_10-K405_EX-10.17_2373875_EX-10.17_Co-Branding Agreement.txt",
          "span": [
            26467,
            26816
          ],
          "answer": "This Agreement has been entered into in the State of                   Tennessee, and the validity, interpretation and legal effect                   of this Agreement will be governed by the laws of the State of                   Tennessee applicable to contracts entered into and performed                   entirely within the State of Tennessee."
        }
      ]
    },
    {
      "query": "\"What language is in the Product Development and Co-Branding Agreement between Integrity Incorporated and Time Life, Inc. for Songs 4 Worship Series? Is it a most favored nation clause?\"",
      "snippets": [
        {
          "file_path": "cuad/IntegrityMediaInc_20010329_10-K405_EX-10.17_2373875_EX-10.17_Co-Branding Agreement.txt",
          "span": [
            11474,
            11682
          ],
          "answer": "If for any reason, Integrity and TL are subject to lower \"free                   goods\" limits by any third party license, the foregoing shall                   be adjusted to comply with any such license(s)."
        }
      ]
    },
    {
      "query": "\"What are the specific terms of the Product Development and Co-Branding Agreement between Integrity Incorporated and Time Life, Inc. for the 'Songs 4 Worship' Series?",
      "snippets": [
        {
          "file_path": "cuad/IntegrityMediaInc_20010329_10-K405_EX-10.17_2373875_EX-10.17_Co-Branding Agreement.txt",
          "span": [
            5158,
            5500
          ],
          "answer": "TL will hold exclusive worldwide                   rights to promote and sell the product through the following                   distribution channels: Outgoing telemarketing, General Market                   retail, and General Market catalogs, and exclusive rights                   within the United States for Television Direct response."
        },
        {
          "file_path": "cuad/IntegrityMediaInc_20010329_10-K405_EX-10.17_2373875_EX-10.17_Co-Branding Agreement.txt",
          "span": [
            6086,
            6457
          ],
          "answer": "Integrity will hold exclusive                   worldwide rights to promote and sell the product to/through                   the following distribution channels: Christian retail (CBA or                   Christian Booksellers Association markets), direct mail                   (including continuity sales, church sales, digital and                   e-commerce sales.)"
        }
      ]
    },
    {
      "query": "\"What is the agreement on which Integrity Incorporated and Time Life, Inc. are incumbered with in case of an increase in revenue, profit or loss?\"",
      "snippets": [
        {
          "file_path": "cuad/IntegrityMediaInc_20010329_10-K405_EX-10.17_2373875_EX-10.17_Co-Branding Agreement.txt",
          "span": [
            12272,
            12788
          ],
          "answer": "On sales of recorded products pursuant to this Agreement (less                   any returns) Integrity will pay to TL royalties in the amount                   of [**]/1/ ($[**]/1/) for each and every unit of the product                   sold by Integrity in the United States pursuant to this                   Agreement, and [**]/1/ the foregoing rate or [**]/1/ percent                   ([**]/1/%) of Integrity's net receipts, whichever is less, on                   subject products outside the United States."
        },
        {
          "file_path": "cuad/IntegrityMediaInc_20010329_10-K405_EX-10.17_2373875_EX-10.17_Co-Branding Agreement.txt",
          "span": [
            13043,
            13589
          ],
          "answer": "On sales of printed products (song books) pursuant to this                   Agreement (less any returns) Integrity will pay to TL                   royalties in the amount of [**]/1/ ($[**]/1/) for each and                   every unit of the product sold by Integrity in the United                   States pursuant to this Agreement, and [**]/1/ the foregoing                   rate or [**]/1/ percent ([**]/1/%) of Integrity's net                   receipts, whichever is less, on subject products outside the                   United States."
        },
        {
          "file_path": "cuad/IntegrityMediaInc_20010329_10-K405_EX-10.17_2373875_EX-10.17_Co-Branding Agreement.txt",
          "span": [
            14031,
            14273
          ],
          "answer": "On sales of products pursuant to this          Agreement (less any returns) TL will pay to Integrity royalties in the          amount of [**]/1/ ($[**]/1/) for each and every unit of the product          sold by it pursuant to this Agreement."
        }
      ]
    },
    {
      "query": "\"In the Product Development and Co-Branding Agreement between Integrity Incorporated and Time Life, Inc. for 'Songs 4 Worship' Series, Is there a minimum commitment required under this contract?\"",
      "snippets": [
        {
          "file_path": "cuad/IntegrityMediaInc_20010329_10-K405_EX-10.17_2373875_EX-10.17_Co-Branding Agreement.txt",
          "span": [
            10306,
            10671
          ],
          "answer": "In consideration of the above pricing, TL guarantees to                   purchase from Integrity a minimum of ten thousand (10,000)                   units of each recorded Product during the first thirty-two                   (32) months of release. TL's initial order for each recorded                   Product shall be a minimum of five thousand (5,000) units."
        }
      ]
    },
    {
      "query": "\"What are the limits of the Product Development Agreement between Integrity Incorporated and Time Life, Inc. for the 'Songs 4 Worship' Series?\"",
      "snippets": [
        {
          "file_path": "cuad/IntegrityMediaInc_20010329_10-K405_EX-10.17_2373875_EX-10.17_Co-Branding Agreement.txt",
          "span": [
            10851,
            11455
          ],
          "answer": "TL may purchase from Integrity limited quantities of the                   Product for its promotional use, at the Manufacturing cost set                   forth in paragraph 3(a) above, provided the quantity of such                   purchases does not exceed seven percent (7%) of the total                   royalty bearing units of such Product title purchased by TL,                   TL warrants that any units so purchased, whether or not                   labeled \"promotional only\" or cut-out, will be given away for                   purposes of promotion of the Products, and will not be sold."
        }
      ]
    },
    {
      "query": "\"What are the specific facts regarding the Product Development and Co-Branding Agreement between Integrity Incorporated and Time Life, Inc. for \"Songs 4 Worship\" Series, and if they provide for joint intellectual property ownership?\"",
      "snippets": [
        {
          "file_path": "cuad/IntegrityMediaInc_20010329_10-K405_EX-10.17_2373875_EX-10.17_Co-Branding Agreement.txt",
          "span": [
            19158,
            19372
          ],
          "answer": "The parties hereby agree that the                   copyright in the Product sound recording compilation will be                   jointly registered by Integrity in the names of Integrity                   and TL."
        },
        {
          "file_path": "cuad/IntegrityMediaInc_20010329_10-K405_EX-10.17_2373875_EX-10.17_Co-Branding Agreement.txt",
          "span": [
            19407,
            19494
          ],
          "answer": "TL will trademark the series name in joint                   names of TL and Integrity."
        }
      ]
    },
    {
      "query": "\"What are the licenses granted under the Product Development and Co-Branding Agreement between Integrity Incorporated and Time Life, Inc. for Songs 4 Worship\" Series?",
      "snippets": [
        {
          "file_path": "cuad/IntegrityMediaInc_20010329_10-K405_EX-10.17_2373875_EX-10.17_Co-Branding Agreement.txt",
          "span": [
            5158,
            5500
          ],
          "answer": "TL will hold exclusive worldwide                   rights to promote and sell the product through the following                   distribution channels: Outgoing telemarketing, General Market                   retail, and General Market catalogs, and exclusive rights                   within the United States for Television Direct response."
        },
        {
          "file_path": "cuad/IntegrityMediaInc_20010329_10-K405_EX-10.17_2373875_EX-10.17_Co-Branding Agreement.txt",
          "span": [
            15994,
            16456
          ],
          "answer": "Integrity hereby grants to TL the right                   to use its \"Integrity Music\" name and logo (\"the Integrity                   Trademarks') in connection with the products produced during                   the Term of this Agreement for as long as the parties continue                   to sell and distribute such products at no additional cost to                   TL, and in accordance with the terms and conditions contained                   herein."
        },
        {
          "file_path": "cuad/IntegrityMediaInc_20010329_10-K405_EX-10.17_2373875_EX-10.17_Co-Branding Agreement.txt",
          "span": [
            17679,
            18134
          ],
          "answer": "TL hereby grants to Integrity the right to use                   its \"TL Music\" name and logo (\"the TL Trademarks\") in                   connection with the products produced during the Term of this                   Agreement for as long as the parties continue to sell and                   distribute such products at no additional cost to Integrity,                   and in accordance with the terms and conditions contained                   herein."
        }
      ]
    },
    {
      "query": "\"What audit rights does the Product Development and Co-Branding Agreement between Integrity Incorporated and Time Life, Inc. ('Songs 4 Worship' Series)?\"",
      "snippets": [
        {
          "file_path": "cuad/IntegrityMediaInc_20010329_10-K405_EX-10.17_2373875_EX-10.17_Co-Branding Agreement.txt",
          "span": [
            14909,
            15257
          ],
          "answer": "Either party, at its sole expense, upon at least          thirty (30) days written notice (and not more than once in respect of          any accounting period) will have the right to inspect the other party's          books regarding the obligations hereunder for a period of two (2) years          from the date on which any statement is rendered."
        }
      ]
    },
    {
      "query": "\"What is the Product Development and Co-Branding Agreement between Integrity Incorporated and Time Life, Inc. for 'Songs 4 Worship' Series? And is it in the covenant not to sue?\"",
      "snippets": [
        {
          "file_path": "cuad/IntegrityMediaInc_20010329_10-K405_EX-10.17_2373875_EX-10.17_Co-Branding Agreement.txt",
          "span": [
            16951,
            17214
          ],
          "answer": "TL recognizes Integrity's title                   to the Integrity Trademarks and will not at any time do or                   suffer to be done any act or thing which will in any way                   impair Integrity's rights in and to the Integrity Trademarks."
        },
        {
          "file_path": "cuad/IntegrityMediaInc_20010329_10-K405_EX-10.17_2373875_EX-10.17_Co-Branding Agreement.txt",
          "span": [
            18629,
            18871
          ],
          "answer": "Integrity recognizes TL's title to the                   TL Trademarks and will not at any time do or suffer to be done                   any act or thing which will in any way impair TL's rights in                   and to the TL Trademarks."
        }
      ]
    },
    {
      "query": "What is the expiration date of the Co-Branding and Endorsement Licensing Agreement between MusclePharm Corporation, Arnold Schwarzenegger, Marine MP, LLC, and Fitness Publications, Inc.?",
      "snippets": [
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            2710,
            2924
          ],
          "answer": "This Agreement shall have an Initial Term of three (3) years. The Term shall commence on July 23, 2013 and shall expire on July 22, 2016, unless otherwise terminated earlier pursuant to Section 9 of this Agreement."
        }
      ]
    },
    {
      "query": "\"Is there a renewal term to the Co-Branding and Endorsement Licensing Agreement between MusclePharm Corporation, Arnold Schwarzenegger, Marine MP, LLC, and Fitness Publications, Inc.?\"",
      "snippets": [
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            3226,
            4397
          ],
          "answer": "In the event that MusclePharm shall achieve Net Sales (as defined below) of $20 million (the \"First Renewal Threshold\") in the aggregate during the Third Contract Year, then this Agreement shall automatically be renewed for an additional term of three (3) years (the \"First Additional Term\") on the same terms and conditions for the Initial Term except that: (i) no additional Stock Compensation (as defined below) shall be issued in connection with the renewal Term, (ii) the Cash Compensation for the First Additional Term shall be as set forth in Section 7 and Exhibit \"C\" Section (2) attached hereto, (iii) Endorser shall only be obligated to make two (2) Appearances in each Contract Year during the First Additional Term pursuant to Section 4(a)(ii) below and (iv) the marketing budget to promote the Licensed Products shall be $5.0 million during each Contract Year of the First Additional Term (subject to Section 12(b) of this Agreement). If this Agreement is renewed for the First Additional Term, then the First Additional Term shall commence on July 23, 2016, and the Agreement shall expire and terminate automatically without further notice on July 22, 2019."
        },
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            4404,
            5540
          ],
          "answer": "In the event that MusclePharm shall achieve Net Sales of $50 million (the \"Second Renewal Threshold\") in the aggregate during the sixth Contract Year, then this Agreement shall automatically be renewed for an additional term of three (3) years (the \"Second Additional Term\") on the same terms and conditions for the initial Term except that: (i) no additional Stock Compensation (as defined below) shall be issued in connection with the renewal Term, (ii) the Cash Compensation for the renewal Term shall be as set forth in Section 7 and Exhibit \"C\" Section (3) attached hereto, (iii) Endorser shall only be obligated to make two (2) Appearances in each Contract Year during the Second Additional Term pursuant to Section 4(a)(ii) below and (iv) the marketing budget to promote the Licensed Products shall be $5.0 in each Contract Year of the Second Additional Term (subject to Section 12(b) of this Agreement). If this Agreement is renewed for the Second Additional Term, then the Second Additional Term shall commence on July 23, 2019 and the Agreement shall expire and terminate automatically without further notice on July 22, 2022."
        }
      ]
    },
    {
      "query": "\"What is the name of the contract between MusclePharm Corporation, Arnold Schwarzenegger, Marine MP, LLC, and Fitness Publications, Inc. and is the governing law in the State of California?\"",
      "snippets": [
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            72138,
            72371
          ],
          "answer": "This Agreement has been executed and delivered in Los Angeles County in the State of California, and its interpretation, validity and performance shall be construed and enforced in accordance with the laws of the State of California."
        }
      ]
    },
    {
      "query": "Do the terms of the Co-Branding and Endorsement Licensing Agreement between MusclePharm Corporation, Arnold Schwarzenegger, Marine MP, LLC, and Fitness Publications, Inc. mention any exceptions to competitive restrictions?",
      "snippets": [
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            67052,
            67713
          ],
          "answer": "Notwithstanding the foregoing, the following will not be a breach of this Agreement: (i) Endorser's performance of services or appearing in the news or informational portion of any radio, TV or film or entertainment program regardless of products or services therein or sponsorship thereof; (ii) Endorser's participation in movies or TV programs as well as merchandising, commercial tie-ins and/or product placements utilizing Endorser, or (iii) Endorser's performance of services, appearance or use of his name, likeness in connection with charitable events, sports events, organizations, regardless of usage of products or services and/or sponsorship thereof."
        },
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            68305,
            68819
          ],
          "answer": "Notwithstanding the foregoing or anything else contained herein, this Agreement shall not prevent or shall in any manner restrict Endorser from advertising, marketing and or endorsing products (or other companies which manufacture such products) which incidentally contain dietary supplements (including without limitation protein, vitamins, minerals, amino acids, herbs, legal performance enhancing substances) provided the primary purpose of such product or company is not to sell or market a dietary supplement."
        }
      ]
    },
    {
      "query": "\"Is there any non-compete clause in the Co-Branding and Endorsement Licensing Agreement between MusclePharm Corporation, Arnold Schwarzenegger, Marine MP, LLC, and Fitness Publications, Inc?\"",
      "snippets": [
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            67720,
            68298
          ],
          "answer": "Endorser shall not use or provide endorsements or testimonials for products that compete with MusclePharm Products or the Licensed Products. Any failure of Endorser to disclose such conflicting interests, or any breach of this Section, shall be deemed a material breach of the Agreement. Endorser's duty not to compete with the business of MusclePharm shall continue for a period of one year following the expiration or termination of this Agreement. Endorser's non-competition obligation shall not be required in the event of a material breach of this Agreement by MusclePharm."
        }
      ]
    },
    {
      "query": "\"Do the two Co-Branding and Endorsement Licensing Agreements include exclusivity agreements? ?",
      "snippets": [
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            66703,
            67049
          ],
          "answer": "During the term of this Agreement, or any extensions of this Agreement, Endorser and the Lender hereby agree and warrant that it will not enter into any other endorsement agreement for the use of Endorser's name, image and/or likeness for advertising, marketing and/or endorsement of any other dietary supplements during the Term of this Agreemen"
        }
      ]
    },
    {
      "query": "\"With regard to the Co-Branding and Endorsement Licensing Agreement between MusclePharm Corporation, Arnold Schwarzenegger, Marine MP, LLC, and Fitness Publications, Inc., what are the rights of first refusal in the contract?",
      "snippets": [
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            6804,
            7539
          ],
          "answer": "During the Term (including any renewal Term, if any), in the event that MusclePharm shall determine to develop and introduce a new Product into the market, MusclePharm shall provide the AS Parties with a sample of the name, design, marketing plan and an actual sample of such new Product (the \"Sample\") and the AS Parties shall have a right of first refusal (exercisable by written notice to MusclePharm within 15 days after receipt of the Sample) to include such new Product in the AS Product Line, it being understood that there shall initially be no less than four (4) Products at the start of the Term and thereafter no more than 8 (eight) Products in the AS Product Line without the mutual written agreement of the parties hereto."
        }
      ]
    },
    {
      "query": "\"What happens to the Co-Branding and Endorsement Licensing Agreement between MusclePharm Corp, Arnold Schwarzenegger, Marine MP, LLC, and Fitness Publications, Inc; when there is a change of control of one of the parties in this contract?\"",
      "snippets": [
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            69144,
            69360
          ],
          "answer": "Neither party shall voluntarily or by operation of law assign or otherwise transfer the rights and/or obligations incurred pursuant to the terms of this Agreement without the prior written consent of the other party."
        },
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            69480,
            69921
          ],
          "answer": "Nothwithstanding the foregoing, this Agreement may be assigned without the AS Parties' consent by MusclePharm in connection with a change of control transaction; provided that the acquirer of MusclePharm shall have financial resources substantially similar or greater than MusclePharm and shall specifically assume the obligations of MusclePharm under this Agreement in writing prior to the consummation of the change of control transaction."
        }
      ]
    },
    {
      "query": "\"Do the Co-Branding and Endorsement Licensing Agreement between MusclePharm Corporation, Arnold Schwarzenegger, Marine MP, LLC, and Fitness Publications, Inc. contain an anti-assignment clause?\"",
      "snippets": [
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            40897,
            41222
          ],
          "answer": "This Agreement may also be terminated by MusclePharm, upon fifteen days prior written notice, if death, or physical disability, physical injury, or other incapacity lasting more than eight (8) weeks, causes Endorser to be unable to perform a material amount of the personal or consulting services described in this Agreement."
        },
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            68858,
            69479
          ],
          "answer": "The license granted by this Agreement is personal to MusclePharm. Except as set forth below, MusclePharm shall not assign or otherwise transfer, license, sublicense, or delegate any rights or obligations under this Agreement without the express prior written consent of the AS Parties. Neither party shall voluntarily or by operation of law assign or otherwise transfer the rights and/or obligations incurred pursuant to the terms of this Agreement without the prior written consent of the other party. Any attempted assignment or transfer by a party of their rights and/or obligations without such consent shall be void."
        }
      ]
    },
    {
      "query": "\"What is the revenue or profit-sharing arrangement in the Co-Branding and Endorsement Licensing Agreement between MusclePharm Corporation, Arnold Schwarzenegger, Marine MP, LLC, and Fitness Publications, Inc.?\"",
      "snippets": [
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            10550,
            11016
          ],
          "answer": "In the event that Endorser shall agree to produce the Training Video (such decision shall be made by the Endorser exercisable in his sole discretion) and Products (other than the Licensed Products) are featured and sold in connection with such Training Video then Endorser shall receive ten percent (10%) of Net Sales (as defined below) from the sale of any Products other than the Licensed Products featured and sold directly in conjunction with the Training Video."
        },
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            15128,
            15312
          ],
          "answer": "In the event that MusclePharm shall sell any Promotional Products above its cost then Endorser shall be entitled to receive 10% of Net Sales from the sale of such Promotional Products."
        },
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            23047,
            23503
          ],
          "answer": "During the Term of this Agreement and during any sell-off period, MusclePharm shall pay Lender a royalty (the \"Royalty\") of 10% on Net Sales (as defined below) of Licensed Products sold through its wholesale Distribution Channels or retail Distribution Channels, as the case may be and 10% on Net Sales of the Training Video and any Products sold in connection with any Training Video as contemplated pursuant to the last sentence of Section 4(a)(i) above."
        }
      ]
    },
    {
      "query": "\"The Co-Branding and Endorsement Licensing Agreement between MusclePharm Corporation, Arnold Schwarzenegger, Marine MP, LLC, and Fitness Publications, Inc. specifies the minimum commitment required. Is this agreement a written contract or an electronic document?\"",
      "snippets": [
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            16019,
            16313
          ],
          "answer": "Endorser shall also supply MusclePharm with at least fifty (50) signed items for each Contract Year, on the Licensed Products or on other items to be mutually agreed upon by the parties hereto, to be used by MusclePharm in connection with the promotion of the Products and/or Licensed Products."
        },
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            26987,
            27235
          ],
          "answer": "Notwithstanding the foregoing, Lender shall be entitled to receive a guaranteed minimum royalty for each Contract Year including the Additional Term, if any (the \"Guaranteed Minimum Royalty\"), payable in accordance with Exhibit \"C\" attached hereto."
        },
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            84373,
            84825
          ],
          "answer": "Guaranteed Minimum Royalty during the initial Term:   Contract Year   Minimum Royalty   Timing of Payment One   $1,500,000   $500,000 payment due on the following dates: July 23, 2013; October 1, 2013; February 1, 2014 Two   $2,000,000   $666,666.66 payment due on the following dates: July 23, 2014; October 1, 2014; February 1, 2015 Three   $2,500,000   $833,333.33 payment due on the following dates: July 23, 2015; October 1, 2015; February 1, 2016"
        },
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            84895,
            85537
          ],
          "answer": "Guaranteed Minimum Royalty during the First Additional Term:   In the event that the Renewal Threshold is achieved in the Third Contract Year, during the First Additional Term the Minimum Royalty and Timing of Payment shall be as follows:   Contract Year   Minimum Royalty   Timing of Payment Four   $2,500,000   $833,333.33 payment due on the following dates: July 23, 2016; October 1, 2016; February 1, 2017 Five   $2,500,000   $833,333.33 payment due on the following dates: July 23, 2017; October 1, 2017; February 1, 2018 Six   $2,500,000   $833,333.33 payment due on the following dates: July 23, 2018; October 1, 2018; February 1, 2019"
        },
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            85607,
            86267
          ],
          "answer": "Guaranteed Minimum Royalty during the Second Additional Term:   In the event that the Second Renewal Threshold is achieved in the Sixth Contract Year, during the Second Additional Term the Minimum Royalty and Timing of Payment shall be as follows:   Contract Year   Minimum Royalty   Timing of Payment Seven   $5,000,000   $1,666,666.66 payment due on the following dates: July 23, 2019; October 1, 2019; February 1, 2020 Eight   $5,000,000   $1,666,666.66 payment due on the following dates: July 23, 2020; October 1, 2020; February 1, 2021 Nine   $5,000,000   $1,666,666.66 payment due on the following dates: July 23, 2021; October 1, 2021; February 1, 2022"
        }
      ]
    },
    {
      "query": "\"What are the limitations of the Co-Branding and Endorsement Licensing Agreement between MusclePharm Corporation, Arnold Schwarzenegger, Marine MP, LLC, and Fitness Publications, Inc.?\"",
      "snippets": [
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            6804,
            7539
          ],
          "answer": "During the Term (including any renewal Term, if any), in the event that MusclePharm shall determine to develop and introduce a new Product into the market, MusclePharm shall provide the AS Parties with a sample of the name, design, marketing plan and an actual sample of such new Product (the \"Sample\") and the AS Parties shall have a right of first refusal (exercisable by written notice to MusclePharm within 15 days after receipt of the Sample) to include such new Product in the AS Product Line, it being understood that there shall initially be no less than four (4) Products at the start of the Term and thereafter no more than 8 (eight) Products in the AS Product Line without the mutual written agreement of the parties hereto."
        }
      ]
    },
    {
      "query": "\"How is intellectual property ownership assigned in the Co-Branding and Endorsement Licensing Agreement between MusclePharm Corporation, Arnold Schwarzenegger, Marine MP, LLC, and Fitness Publications, Inc.\"?",
      "snippets": [
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            60425,
            60626
          ],
          "answer": "MusclePharm agrees that any copyrights in works created based upon the Trademarks and/or Name and Appearance Rights shall become the rights of the AS Parties (as among them to be determined among them)"
        },
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            60628,
            61762
          ],
          "answer": "MusclePharm irrevocably and unconditionally transfers and assigns to the AS Parties in perpetuity and throughout the universe any and all of MusclePharm's right, title, and interest, if any (including, without limitation, the rights generally known as 'moral rights') in and to all works, including any packaging, advertising and promotional materials, and other materials based upon the Trademarks and/or Name and Appearance Rights, all of which shall, upon their creation, become and remain the property of the AS Parties. All such works based upon the Trademarks and/or Name and Appearance Rights shall be prepared by an employee-for- hire of MusclePharm (under MusclePharms's sole supervision, responsibility, and monetary obligation) or as a work-for-hire by a third party who assigns to the AS Parties in writing and in perpetuity throughout the universe all right, title, and interest in the same provided however, nothing herein shall preclude MusclePharm from using any of the intellectual property to be retained by MusclePharm contemplated pursuant to Section 9(f) of this Agreement after the termination of this Agreement."
        }
      ]
    },
    {
      "query": "\"What is the Co-Branding and Endorsement Licensing Agreement between MusclePharm Corporation, Arnold Schwarzenegger, Marine MP, LLC, and Fitness Publications, Inc.?",
      "snippets": [
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            5859,
            6160
          ],
          "answer": "Endorser also agrees to the use on a world-wide basis (as specified pursuant to Section 6 below and subject to the terms and conditions of this Agreement), during the Term, of his Name and Appearance Rights to advertise and promote the business of MusclePharm, its Products, and the Licensed Products."
        },
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            12869,
            13839
          ],
          "answer": "Endorser agrees that during the Term MusclePharm shall have the right to use, worldwide, Endorser's Name and Appearance Rights (as specified in Section 6) to advertise MusclePharm and its Products and Licensed Products in print media, and in all other forms of media (other than telephone marketing or texting campaigns) including, but not limited to, point of sale material, premiums and novelties, direct marketing material, and radio, television, electronic, and computer media (including but not limited to MusclePharm's Internet and social media websites). Print media will also include promotional items on which Endorser's approved picture; approved likeness, or facsimile signature may appear. Endorser will have the right to approve, in writing via his representative's office, all advertising materials which utilize Endorser's Name and Appearance Rights, but Endorser will not unreasonably withhold approval and will promptly respond to all approval requests."
        },
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            14814,
            14926
          ],
          "answer": "During the Term, MusclePharm shall have the right to create and distribute the Promotional Products world- wide."
        },
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            17765,
            18948
          ],
          "answer": "As provided below, during the Term, the AS Parties grant to MusclePharm the right to use the Trademarks as defined in this Agreement and the Name and Appearance Rights, which shall include Endorser's name, approved photograph, approved picture (including, without limitation, any copyrighted pictures and video images of the Endorser owned by the Endorser which Endorser agrees to make available for use hereunder), approved appearance, or approved likeness, including video and other recordings of Endorser's appearance, along with the right to use Endorser's voice, including audio or other recordings of Endorser's voice, Endorser's signature, personal or professional background and experience, reputation, approved quotations and approved endorsements, or approved paraphrases of Endorser's approved quotations and endorsements, including approved touch-ups, approved simulations or approved compositions of any of the above whether generated by computer or by any other means, for the period of time and for the purposes set forth in this Agreement. MusclePharm acknowledges that the use of some works may require that MusclePharm obtain a copyright license from third parties."
        },
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            18973,
            19622
          ],
          "answer": "During the Term of this Agreement, the AS Parties grant to MusclePharm and consent to MusclePharm's commercial use of the Name and Appearance Rights to advertise, promote, endorse and publicize Products, Licensed Products, and MusclePharm's business, worldwide in any media selected by MusclePharm (excluding telephone or texting campaigns), including but not limited to print, radio, television, electronic, wireless or internet, pursuant to the terms and conditions set forth herein. MusclePharm acknowledges that any use on products requires approval and that use of the Name and Appearance Rights on products is limited to the Licensed Products."
        },
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            19698,
            20320
          ],
          "answer": "Endorser also grants to MusclePharm and consents to MusclePharm's editorial use world-wide of Endorser's Name and Appearance in MusclePharm published materials approved by Endorser. For purposes of this Agreement, MusclePharm's editorial use of Endorser's Name and Appearance shall mean a use that does not directly promote, advertise or endorse MusclePharm's business, its Products or Licensed Products. Nothing in this Section 6(c) shall entitle MusclePharm to reduce Endorser's compensation pursuant to Section 7 and Section 8 of this Agreement (including, without limitation, with respect to any renewal Term, if any)."
        },
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            20785,
            21131
          ],
          "answer": "MusclePharm shall have the rights to use Endorser's Name and Appearance Rights and the Right to Publicize Endorser's Name and Appearance, as provided in this Agreement, unless Endorser and MusclePharm enter into a separate written agreement in which MusclePharm waives or releases some or all of the rights Endorser has granted in this Agreement."
        }
      ]
    },
    {
      "query": "\"Critical thinking is required regarding the Co-Branding and Endorsement Licensing Agreement between MusclePharm Corporation, Arnold Schwarzenegger, Marine MP, LLC, and Fitness Publications, Inc. Is there any service to be provided after the termination of this contract?\"",
      "snippets": [
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            14287,
            14785
          ],
          "answer": "During the Term, the right to use Endorser's Name and Appearance Rights granted to MusclePharm in this Section shall extend for six (6) months beyond the expiration of this Agreement (the \"Use-up Period\"). MusclePharm shall create no new advertising during the Use-up Period using Endorser's Name and Appearance, but shall have the right to use during the Use-up Period Endorser's Name and Appearance in advertisements and promotional materials created before the expiration date of this Agreement."
        },
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            23047,
            23503
          ],
          "answer": "During the Term of this Agreement and during any sell-off period, MusclePharm shall pay Lender a royalty (the \"Royalty\") of 10% on Net Sales (as defined below) of Licensed Products sold through its wholesale Distribution Channels or retail Distribution Channels, as the case may be and 10% on Net Sales of the Training Video and any Products sold in connection with any Training Video as contemplated pursuant to the last sentence of Section 4(a)(i) above."
        },
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            26699,
            26984
          ],
          "answer": "MusclePharm's obligations for the payment of a Royalty and the Guaranteed Minimum Royalty (as defined below) shall survive expiration or termination of this Agreement and will continue for so long as MusclePharm continues to manufacture, sell or otherwise market the Licensed Products."
        },
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            44982,
            45381
          ],
          "answer": "Notwithstanding the foregoing, in the event the expiration of this Agreement or termination of this Agreement by Musclepharm pursuant to paragraph 9(a), MusclePharm shall be entitled to sell-off the remaining Licensed Products for six (6) months after such expiration of this Agreement pursuant to paragraph 4(d) herein and shall continue to pay Endorser the Royalty set forth in paragraph 7 herein."
        },
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            48945,
            49157
          ],
          "answer": "MusclePharm agrees to preserve and keep accessible and available to the AS Parties all relevant books and records for a period of at least three (3) years following the expiration or termination of the Agreement."
        }
      ]
    },
    {
      "query": "\"What are the audit rights under the Co-Branding and Endorsement Licensing Agreement between MusclePharm Corporation, Arnold Schwarzenegger, Marine MP, LLC, and Fitness Publications, Inc?\"",
      "snippets": [
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            33253,
            33456
          ],
          "answer": "Lender understands that all books, records, and documents of MusclePharm relating to it have been and remain available for inspection by him or his business and financial advisors upon reasonable notice."
        },
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            47865,
            48251
          ],
          "answer": "The AS Parties shall have the right, upon at least five (5) days written notice and no more than once each Contract Year of the Term to inspect MusclePharm's books and records and all other documents and material in the possession of or under the control of MusclePharm with respect to the Licensed Products at the place or places where such records are normally retained by MusclePharm"
        },
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            48712,
            48938
          ],
          "answer": "In the event a shortfall in the amount of five percent (5%) or more is discovered, MusclePharm shall reimburse the AS Parties for the cost of the audit including any reasonable attorney's fees incurred in connection therewith."
        },
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            54619,
            55190
          ],
          "answer": "MusclePharm shall at all reasonable times during the Term (but no more than once during each Contract Year of the Term), and upon reasonable notice, permit the AS Parties to send their authorized representatives to inspect the facilities of MusclePharm or its agents in order to confirm that the production of the Licensed Products hereunder is in compliance with the quality standards set out herein and, at MusclePharm's expense, randomly test the formulas of the Licensed Products for quality control purposes, although the AS Parties will have no obligation to do so."
        }
      ]
    },
    {
      "query": "\"Is the Co-Branding and Endorsement Licensing Agreement between MusclePharm Corporation, Arnold Schwarzenegger, Marine MP, LLC, and Fitness Publications, Inc. a single consolidated contract, or is there a limit on liability?\"",
      "snippets": [
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            64976,
            65156
          ],
          "answer": "In no event shall the AS Parties' indemnification obligations to MusclePharm hereunder exceed the after-tax value of the Cash Consideration received by Lender under this Agreement."
        },
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            75729,
            75820
          ],
          "answer": "IN NO EVENT SHALL THE AS PARTIES BE LIABLE FOR SPECIAL, CONSEQUENTIAL, OR PUNITIVE DAMAGES."
        }
      ]
    },
    {
      "query": "\"What are the insurance requirements for the Co-Branding and Endorsement Licensing Agreement between MusclePharm Corporation, Arnold Schwarzenegger, Marine MP, LLC, and Fitness Publications, Inc.?\"",
      "snippets": [
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            77807,
            78536
          ],
          "answer": "MusclePharm shall, throughout the Term of the Agreement and for a period of not less than four years thereafter, obtain and maintain at its own cost and expense from a qualified insurance company licensed to do business in California and New York, a commercial general liability insurance policy including coverage for contractual liability (applying to the terms and conditions of this agreement), product liability, personal injury liability, and advertiser's liability, in a form approved by the AS Parties, in the amount of at least Five Million Dollars (US$5,000,000) per occurrence naming the AS Parties (for the avoidance of doubt, specifically including each of Lender, Endorser, and Fitness) as additional named insureds"
        },
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            78538,
            79878
          ],
          "answer": "Without limiting the generality of the foregoing, such policy shall provide protection against any and all claims, demands, and causes of action arising out of any defects or failure to perform, alleged or otherwise, of the Products and Licensed Products or any material used in connection therewith or any use thereof. The policy shall provide for ten (10) days notice to the AS Parties from the insurer by Registered or Certified Mail, return receipt requested, in the event of any modification, cancellation, or termination thereof. MusclePharm agrees to furnish the AS Parties a certificate of insurance evidencing same within thirty (30) days after execution of this Agreement and, in no event, shall MusclePharm manufacture, distribute, advertise, or sell the Licensed Products prior to receipt by the AS Parties of such evidence of insurance. MusclePharm shall be responsible to provide for any appearances pursuant to this Agreement by Endorser appropriate certificates of insurance with coverage limits of at least Five Million Dollars (US$5,000,000) per occurrence endorsed to name the AS Parties as additional named insureds with respect to claims arising out of appearances by Endorser. MusclePharm shall be responsible to pay the deductible under any such insurance policies with respect to any claims made under such policies."
        }
      ]
    },
    {
      "query": "\"Are there any covenants not to sue, or any other provisions, in the Co-Branding and Endorsement Licensing Agreement between MusclePharm Corporation, Arnold Schwarzenegger, Marine MP, LLC, and Fitness Publications, Inc.\"",
      "snippets": [
        {
          "file_path": "cuad/MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.txt",
          "span": [
            58960,
            59217
          ],
          "answer": "During the Term and after expiration or termination of this Agreement, MusclePharm shall not contest or otherwise challenge or attack the AS Parties' rights in the Trademarks or Name and Appearance Rights or the validity of the license being granted herein."
        }
      ]
    },
    {
      "query": "\"What is the date of termination of this Co-Branding Agreement between Skype Communications, Skype Technologies, TOM Online (BVI) Limited, TOM Online Inc., and Tel-Online Limited?\"",
      "snippets": [
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            63762,
            63972
          ],
          "answer": "The term of this Agreement shall continue for a period of five years following the initial date of execution of the Memorandum, unless terminated earlier pursuant to Section 6.2 or Section 2.8 (\"Initial Term\")."
        }
      ]
    },
    {
      "query": "\"What was the renewal term for the Co-Branding Agreement between Skype Communications, Skype Technologies, TOM Online (BVI) Limited, TOM Online Inc., and Tel-Online Limited?\"",
      "snippets": [
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            63973,
            64323
          ],
          "answer": "This Agreement shall automatically continue following the Initial Term, for an additional period of three (3) years, unless a party to this Agreement provides written notice of termination to the other parties at least sixty (60) days prior to the expiration of the Initial Term or this Agreement (\"Extended Term\" and, with the Initial Term, \"Term\")."
        }
      ]
    },
    {
      "query": "\"What is the notice period required to terminate the Co-Branding Agreement between Skype Communications, Skype Technologies, TOM Online (BVI) Limited, TOM Online Inc., and Tel-Online Limited?\"",
      "snippets": [
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            63973,
            64323
          ],
          "answer": "This Agreement shall automatically continue following the Initial Term, for an additional period of three (3) years, unless a party to this Agreement provides written notice of termination to the other parties at least sixty (60) days prior to the expiration of the Initial Term or this Agreement (\"Extended Term\" and, with the Initial Term, \"Term\")."
        }
      ]
    },
    {
      "query": "\"What is the governing law for the Co-Branding Agreement between Skype Communications, Skype Technologies, TOM Online (BVI) Limited, TOM Online Inc., and Tel-Online Limited?\"",
      "snippets": [
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            98605,
            98750
          ],
          "answer": "This Agreement will be governed by and construed in accordance with the laws of England and Wales, without regard to conflict of laws principles."
        }
      ]
    },
    {
      "query": "\"What is the name of the Co-Branding Agreement between Skype Communications, Skype Technologies, TOM Online (BVI) Limited, TOM Online Inc., and Tel-Online Limited? Is it identical to the previous example??",
      "snippets": [
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            31067,
            31879
          ],
          "answer": "The Company will, and Online BVI will cause the Company to, use its commercially reasonable efforts to make available and promote the Online Group's existing payment processing and customer billing and payment gateway methods for the purchase of Skype premium features by Company-Skype Branded Customers, including, without limitation, prepaid card distribution networks, vouchers and mobile payment methods, provided, that all payment processing and customer billing and payment gateway charges for such payment methods are on terms that are as or more favourable than the most favourable pricing and terms for such services otherwise provided at the applicable time by any member of the Online Group, and provided further that such pricing and terms have first been mutually approved in writing by the Parties."
        }
      ]
    },
    {
      "query": "\"What are the exceptions to competitive restrictions in this contract?\"",
      "snippets": [
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            74776,
            76567
          ],
          "answer": "In the case of Skype and its Affiliates, the foregoing restrictions shall not apply:\n\n8.2.1 (a) (i) for the avoidance of doubt, to the operations of Skype as existing now or hereafter undertaken with respect to any non co- branded version of the Skype Software distributed by Skype except where those operations provide for distribution in the PRC of the Skype Software in simplified Chinese by a Primarily PRC Based Service Provider, or (ii) the operations of Skype customers and Affiliates under any agreement existing as of the date hereof (e.g., with HGC), or (b) to any agreement now existing or hereafter entered into with an entity that operates in multiple international markets, which may include the PRC, so long as such agreement applies to multiple territories, which may include the PRC in addition to other territories, and does not, directly or indirectly, allow or provide for distribution in the PRC of the Skype Software in simplified Chinese by a Primarily PRC Based Service Provider (other than any service provider formed for the sole purpose of performing such agreement and not operating in the PRC prior to the date of such agreement), or (c) to any (i) Affiliate Program or (ii) any agreement or activity under the Affiliate Program by or with any third party, except in the case where the Affiliate Program, directly or indirectly, allows or provides for distribution in the PRC of the Skype Software in simplified Chinese by a Primarily PRC Based Service Provider (other than any service provider formed for the sole purpose of performing such agreement and not operating in the PRC prior to the date of such agreement); or\n\n8.2.2 with respect to the provisions of Section 8.1.2, during any period following the expiration of the Enterprise Non-Competition Period."
        }
      ]
    },
    {
      "query": "\"What is the Co-Branding Agreement between Skype Communications, Skype Technologies, TMO (BVI), TMO Inc., and Tel-Online Limited? Does it cover a non-compete clause?\"",
      "snippets": [
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            71593,
            72923
          ],
          "answer": "Each Party agrees that, for a period of five years (\"Non-Competition Period\") from the Effective Date (\"End Date\"), no Party, nor any of their respective Affiliates, will enter into an agreement with any third party, or otherwise carry on any business, directly or indirectly, which is focused on, and targets, primarily Consumers within the PRC, and (i) in the case of Skype and Skype Holding, which provides for a co-branded Internet-based application in simplified Chinese similar in functionality and features as the Company-Skype Branded Application (as may be updated or upgraded from time to time) (and for the avoidance of doubt, a co-branded Internet-based application in simplified Chinese shall be similar in functionality and features as the Company-Skype Branded Application only in the event such application is a customized co-branded version of the Skype Software having one or more functionality or features contained in the Company-Skype Branded Application), or provides for distribution in the PRC of the Skype Software in simplified Chinese by a Primarily PRC Based Service Provider; and (ii) in the case of Online BVI, Tom Holding and the Company, which provides for any voice over internet protocol and/or instant messaging products or services that compete or are likely to compete with the Skype Software."
        },
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            72931,
            74187
          ],
          "answer": "Each Party agrees that, from the Effective Date and through the three (3) month period (\"Enterprise Non-Competition Period\") immediately following the date (\"Enterprise Launch Date\") that Skype launches an enterprise version of the Skype Software primarily targeted for non-Consumer customers (\"Enterprise Skype Software\"), no Party, nor any of their respective Subsidiaries, will (i) discuss, negotiate or enter into (whether verbal or in writing) with any third Person or other third party (\"Other Party\") any understanding, arrangement, or memorandum of understanding, letter of intent, agreement or any other documents (whether or not legally binding); and/or (ii) voluntarily accept or solicit any offer made by any Other Party in respect of or in relation to, (a) in the case of Skype, an enterprise co-branded Internet-based application in simplified Chinese that is focused on, and targeted primarily at, non-Consumers within the PRC, and that is substantially similar in functionality and features as the Enterprise Skype Software, and (b) in the case of Online BVI, Tom Holding and the Company, any voice over internet protocol and/or instant messaging products or services that compete or are likely to compete with the Enterprise Skype Software"
        },
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            76612,
            76907
          ],
          "answer": "Notwithstanding any portion of the foregoing to the contrary, the Non-Competition Period shall terminate prior to the End Date, and for the avoidance of doubt, no party shall be obligated to comply with the restrictions set out in Section 8.1 after the termination of the Non-Competition Period:"
        }
      ]
    },
    {
      "query": "\"What happens in the event of a change of control of one of the parties in this contract?",
      "snippets": [
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            102769,
            103196
          ],
          "answer": "Notwithstanding the foregoing, Skype or Skype Holding may assign this Agreement to a third party without such consent in the event of a merger, reorganization or sale of all or substantially all of Skype's or Skype Holding's assets or voting securities, provided that written notice of such assignment is delivered to Online BVI and the Company and the assignee assumes all the responsibilities and obligations provided herein."
        }
      ]
    },
    {
      "query": "\"What are the provisions of the Co-Branding Agreement between Skype Communications, Skype Technologies, TOM Online (BVI), TOM Online Inc., and Tel-Online Limited?",
      "snippets": [
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            36649,
            37032
          ],
          "answer": "Notwithstanding the foregoing, upon the prior written approval of Online BVI, which approval may be withheld in its sole discretion, the Company shall be permitted to sublicense its rights hereunder to a wholly-owned Subsidiary of the Company or a majority-owned Subsidiary of Tom Holding, for the same purpose and under the same terms and conditions as the license set forth herein."
        },
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            102526,
            102768
          ],
          "answer": "This Agreement may not be assigned by a party to this Agreement to any other Person without the express written approval of the other parties to this Agreement and any attempt at assignment in violation of this section shall be null and void."
        }
      ]
    },
    {
      "query": "\"What is the Co-Branding Agreement between Skype Communications, Skype Technologies, TOM Online (BVI) Limited, TOM Online Inc., and Tel-Online Limited?\"",
      "snippets": [
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            52314,
            52530
          ],
          "answer": "In consideration of the licenses and other agreements set forth herein, Skype shall be entitled to receive 50% of all Adjusted Net Revenue, and the Company shall be entitled to receive 50% of all Adjusted Net Revenue"
        },
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            52532,
            53473
          ],
          "answer": "Notwithstanding the foregoing, Online BVI shall be entitled to receive 50% of all Adjusted Net Revenue, in lieu of the Company's right to be paid hereunder, in the event that (A) this Agreement remains in effect, (B) Online BVI assumes the obligations of the Company hereunder, and (C) (i) the Deed is terminated pursuant to the terms thereof, or (ii)) the Company is being or has been wound up, liquidated or dissolved. Unless otherwise mutually agreed by the Parties in writing, the Company and Online BVI shall provide for, or make available, the payment methods, fraud prevention mechanisms, and other services related to the receipt of payments in connection with SkypeOut, SkypeIn or Skype Plus services provided through the Company-Skype Branded Application or Company-Skype Branded Web Site (\"Payment Services\"), in each case as shall be previously approved in writing by Skype, which approval may be withheld in its sole discretion."
        },
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            56461,
            56877
          ],
          "answer": "The respective Parties shall use their best efforts to accompany each respective Statement with payment, to Skype, if provided by the Company or Online BVI (or their associated third parties set forth above), or to the Company (or Online BVI, as applicable), if provided by Skype (or its associated third parties set forth above), as applicable, of 50% of the Adjusted Net Revenue shown on the respective Statements."
        }
      ]
    },
    {
      "query": "\"How is intellectual property ownership assigned in the Co-Branding Agreement between Skype Communications, Skype Technologies, TOM Online (BVI) Limited, TOM Online Inc., and Tel-Online Limited?\"",
      "snippets": [
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            43705,
            44178
          ],
          "answer": "The Company and Online BVI each assign to Skype, with full title guarantee, all copyrights, patents, trade marks, service marks, rights of publicity, authors' rights, contract and licensing rights, goodwill and all other intellectual property rights in and to the foregoing translations as may exist now and/or hereafter come into existence and arising under the laws of any jurisdiction for the entire term of such rights and all renewals, revivals and extensions thereof."
        },
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            45634,
            45973
          ],
          "answer": "The right, title and interest in and to the Company-Skype Branded Content shall be owned by Skype to the extent made up of the Skype Rights which have been integrated into the Company-Skype Branded Content, and by the Online Group to the extent made up of the Group Rights which have been integrated into the Company-Skype Branded Content."
        },
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            46233,
            47687
          ],
          "answer": "if such rights comprise (i) intellectual property that constitutes predominantly communication software or related communication hardware or other technology, including without limitation, any upgrades and Improvements thereof, or (ii) any \"user\" names, and other \"user profile\" information included within the Company-Skype Branded Application (i.e., dates of birth, addresses, languages spoken, etc.), of Company-Skype Branded Customers collected as part of the registration process for the Company-Skype Branded Application (it being understood that Skype will make such user information available to Online BVI and the Company for use consistent with the applicable privacy policies and the EULA) and any database incorporating the same, then such rights shall be owned exclusively by Skype and neither Online BVI nor the Company will grant, nor claim for itself or its affiliated entities, independent contractors, or employees, either expressly or impliedly, any rights, title, interest, or licenses to such rights and each assigns to Skype, with full title guarantee, all copyrights, patents, trade marks, service marks, rights of publicity, authors' rights, contract and licensing rights, goodwill and all other intellectual property rights in and to the same as may exist now and/or hereafter come into existence and arising under the laws of any jurisdiction for the entire term of such rights and all renewals, revivals and extensions thereof."
        },
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            47749,
            48598
          ],
          "answer": "if such rights comprise any data specifically provided to the Group by Customers during the billing process (\"Billing Data\"), then such rights shall be owned exclusively by the Online Group and neither Skype nor the Company will grant, nor claim for itself or its affiliated entities, independent contractors, or employees, either expressly or impliedly, any rights, title, interest, or licenses to such rights and each assigns to Online BVI, with full title guarantee, all copyrights, patents, trade marks, service marks, rights of publicity, authors' rights, contract and licensing rights, goodwill and all other intellectual property rights in and to the same as may exist now and/or hereafter come into existence and arising under the laws of any jurisdiction for the entire term of such rights and all renewals, revivals and extensions thereof."
        }
      ]
    },
    {
      "query": "\"What are the legal provisions of the Co-Branding Agreement between Skype Communications, Skype Technologies, TOM Online (BVI) Limited, TOM Online Inc., and Tel-Online Limited?",
      "snippets": [
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            48611,
            49530
          ],
          "answer": "if such rights comprise (i) analysis prepared for or on behalf of the Parties as participants in the Company-Skype Branded Application, or (ii) any intellectual property right co-developed by the Parties, or (iii) of any Support Information, or (iv) any data as specifically provided to Skype or the Online Group by Company-Skype Branded Customers (\"Joint Data\"), other than that set forth in Sections 4.2.3.2.1 and 4.2.3.2.2 above and other than any Group Rights or Skype Rights, then such rights shall be jointly owned by the Parties, and may be exploited by any Party in accordance with this Agreement, and outside of this Agreement to the extent such exploitation would not, (x) in the case of Online BVI, violate or infringe upon the Skype Rights, (y) in the case of Skype, violate or infringe upon the Group Rights, or (z) in the case of the Company, violate or infringe upon the Group Rights or the Skype Rights."
        }
      ]
    },
    {
      "query": "\"What licenses are granted under the Co-Branding Agreement between Skype Communications, Skype Technologies, TOM Online (BVI) Limited, TOM Online Inc., and Tel-Online Limited?\"",
      "snippets": [
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            35994,
            36648
          ],
          "answer": "Subject to the terms and conditions of this Agreement, Online BVI hereby grants to Skype and the Company a limited, non-exclusive, non-sublicensable (except as set forth herein), non-transferable, non-assignable (except as provided in Section 14.4), royalty- free (but subject to the provisions of Section 5), license during the Term to use, market, provide access to, promote, reproduce and display the Online BVI Intellectual Property solely as incorporated in, and for the development of and for transmission pursuant to this Agreement of the Company-Skype Branded Application, the Company-Skype Branded Content and the Company-Skype Branded Web Site."
        },
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            37121,
            39367
          ],
          "answer": "Skype hereby grants to Online BVI and the Company a limited, non-exclusive, non-sublicensable (except as set forth herein), non-transferable, non-assignable (except as provided in Section 14.4), royalty-free (but subject to the provisions of Section 5), license during the Term to use, market, provide access to, promote, reproduce and display the Skype Intellectual Property solely (i) as incorporated in the Company-Skype Branded Application and/or the Company-Skype Toolbar, and (ii) as incorporated in, for the development of, and for transmission pursuant to this Agreement of, the Company-Skype Branded Content and the Company-Skype Branded Web Site, in each case for the sole purposes (unless otherwise mutually agreed by the Parties) of promoting and distributing, pursuant to this Agreement, the Company-Skype Branded Application, the Company-Skype Toolbar, the Company-Skype Branded Content and the Company-Skype Branded Web Site in the Territory; (a) provided, that it is understood that the Company-Skype Branded Customers will have the right under the EULA to use the Company- Skype Branded Application and the Company-Skype Toolbar and will have the right to access the Company-Skype Branded Content, the Company-Skype Branded Web Site and the Online BVI Web Site through the Internet and to otherwise receive support from the Company anywhere in the world, and that the Company shall be permitted to provide access to and reproduce and display the Skype Intellectual Property through the Internet anywhere in the world, and (b) provided further, that Online BVI and the Company shall ensure that no Company-Skype Branded Customer (or potential Company-Skype Branded Customer) shall be permitted to access, using the Company-Skype Branded Application or the Company-Skype Toolbar or through the Company-Skype Branded Web Site, any Skype premium features requiring payment by the Company-Skype Branded Customer (or potential Company-Skype Branded Customer), including, but not limited to, SkypeIn, SkypeOut, or Skype Plus, unless such Company-Skype Branded Customer (or potential Company-Skype Branded Customer) uses the payment methods made available by the Company pursuant to Section 2.5 for the purchase of such premium features."
        }
      ]
    },
    {
      "query": "\"What are the characteristics of the Co-Branding Agreement between Skype Communications, Skype Technologies, TOM Online (BVI) Limited, TOM Online Inc., and Tel-Online Limited? Is the licensor's affiliates obligated to enforce this contract?\"",
      "snippets": [
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            24600,
            25332
          ],
          "answer": "Skype further agrees that in the event that, prior to such time as the Company-Skype Branded Application is updated or upgraded to include the Mobile Technology, Skype or any of its Affiliates makes available to Skype users a new software product which allows access to services available through the Skype Software but on or through mobile communication devices (but in any event excluding Skype Zones), it will license that software product to the Company and Online BVI on the terms and conditions set forth in this Agreement with respect to the Skype Software and the Company-Skype Branded Application customized therefrom, and references to the Skype Software in this Agreement shall be deemed to include such software product."
        }
      ]
    },
    {
      "query": "\"Does the Co-Branding Agreement between Skype Communications, Skype Technologies, TOM Online (BVI) Limited, TOM Online Inc., and Tel-Online Limited provide any licensees with any rights to the Co-Branding Agreement?",
      "snippets": [
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            36649,
            37032
          ],
          "answer": "Notwithstanding the foregoing, upon the prior written approval of Online BVI, which approval may be withheld in its sole discretion, the Company shall be permitted to sublicense its rights hereunder to a wholly-owned Subsidiary of the Company or a majority-owned Subsidiary of Tom Holding, for the same purpose and under the same terms and conditions as the license set forth herein."
        },
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            39426,
            39846
          ],
          "answer": "Notwithstanding the foregoing, upon the prior written approval of Skype, which approval may be withheld in its sole discretion, the Company shall be permitted to sublicense its rights hereunder to a wholly-owned Subsidiary, a majority-owned Subsidiary of Tom Holding, or to an unaffiliated third party distributor or reseller, for the same purpose and under the same terms and conditions as the license set forth herein."
        }
      ]
    },
    {
      "query": "\"How are Skype Communications, Skype Technologies, TOM Online (BVI) Limited, TOM Online Inc., and Tel-Online Limited different companies in this Co-Branding Agreement?\"",
      "snippets": [
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            59956,
            60676
          ],
          "answer": "The Parties (including Online BVI on behalf of the Online Group) agree to maintain records (i) of all information reasonably necessary to verify all calculations to be made under Section 8.3.2, and (ii) supporting, verifying and necessary to demonstrate the calculation and collection of fees and/or revenue, as well as any deductions thereto, and payments made hereunder, including, without limitation, budgets, purchase orders, expense records, invoices, correspondence, banking and financial and other records pertaining to the determination of Gross Revenue, Direct Expenses and Adjusted Net Revenue, during the term of this Agreement and for a period of two (2) years following the expiration or termination hereof."
        },
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            67176,
            68379
          ],
          "answer": "Each Party shall (i) immediately stop displaying, featuring, linking or in any other manner using the Company-Skype Branded Application (provided in the case of Skype, other than the Skype Software in the Company-Skype Branded Application), Company-Skype Toolbar, Company-Skype Branded Web Site, Company-Skype Branded Content, any co-branded materials or any other Intellectual Property of the other Parties (including, without limitation, Intellectual Property deemed to be owned by the other Parties under Section 4.2.3.2); (ii) return such materials directly to the other Parties, or delete and overwrite any electronically stored copies of such materials within thirty (30) days from the date of termination of this Agreement; (iii) within such thirty (30) day period, deliver to the other Parties a certificate duly executed by its authorised officer certifying its compliance with the foregoing, and (iv) provide the other Parties with such information and access to data and databases as may be necessary to permit such other Parties to fulfil any contractual obligations by them to users of the Company-Skype Branded Application undertaken by such other Parties prior to the time of termination."
        },
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            68873,
            69558
          ],
          "answer": "The Parties agree that notwithstanding any termination or expiration of this Agreement, the rights and licenses granted to any Company- Skype Branded Customers prior to termination or expiration of this Agreement pursuant to any EULA shall continue during the 24 months after such termination or expiration for the sole purpose of permitting such users to continue to access and utilize the Company-Skype Branded Application and the Company-Skype Toolbar, and so long as any Gross Revenue is received with respect to the Company-Skype Branded Application and/or the Company-Skype Toolbar, the provisions of Section 5 shall continue to be applicable after any termination or expiration."
        }
      ]
    },
    {
      "query": "\"What are the audit rights under the Co-Branding Agreement between Skype Communications, Skype Technologies, TOM Online (BVI) Limited, TOM Online Inc., and Tel-Online Limited?\"",
      "snippets": [
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            60677,
            61429
          ],
          "answer": "Not more than once per calendar quarter, each Party or its independent auditor (who shall be a certified public accountant) shall have the right, on not less than fifteen (15) calendar days prior notice and not during the first twenty (20) days after the close of any fiscal quarter of the other Parties, or within sixty (60) day of the close of such Parties' respective fiscal years, to audit the books of account and records of any and all such Parties. Such audit shall be conducted at the premises where the audited Party maintains consolidated books of account; provided however, that the auditing Party may conduct all or any part of such audit at any of the audited Party's premises where any relevant books of account and/or records are located"
        },
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            61431,
            61579
          ],
          "answer": "During such audits, the auditing Party shall have the right to take extracts and/or make copies of the audited Party's records as it deems necessary"
        },
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            61581,
            62101
          ],
          "answer": "Such audits shall be at the auditing Party's cost, except that, subject to Section 5.5, if an audit by an independent accounting firm establishes a deficiency of more than three percent (3%) between the amount shown to be due to the auditing Party and the amount actually paid for the period being audited, all actual and reasonable costs and expenses incurred by the auditing Party in connection with such audit shall be paid by the audited Party, along with the amount of any deficiency, within five (5) business days."
        },
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            62152,
            62718
          ],
          "answer": "The exercise by any Party in whole or in part, at any time of the right to inspect and/or audit records and accounts or of any other right herein granted, or the acceptance by such Party of any statement or statements or the receipt and/or deposit by such Party, of any payment tendered by or on behalf of an audited Party shall be without prejudice to any rights or remedies of the accepting Party and such acceptance, receipt and/or deposit shall not preclude or prevent such accepting Party from thereafter disputing the accuracy of any such statement or payment."
        },
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            62720,
            62988
          ],
          "answer": "Each Party shall cause any Subsidiary or other Affiliate (including, without limitation, a Subsidiary or other Affiliate of the Online Group or Skype Group, as applicable) to grant to the other Party the audit rights granted hereunder with respect to such other Party."
        }
      ]
    },
    {
      "query": "\"How does the Co-Branding Agreement between Skype Communications, Skype Technologies, TOM Online (BVI) Limited, TOM Online Inc., and Tel-Online Limited relate to Uncapped Liability?",
      "snippets": [
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            90347,
            91549
          ],
          "answer": "TO THE MAXIMUM EXTENT PERMISSIBLE UNDER APPLICABLE LAW, EXCEPT FOR THE WILFUL MISAPPROPRIATION OR INFRINGEMENT OF THE INTELLECTUAL PROPERTY OF A PARTY TO THIS AGREEMENT, OR THE OBLIGATIONS OF THE PARTIES TO THIS AGREEMENT PURSUANT TO SECTION 13, (A) THE LIABILITY OF ANY PARTY TO THIS AGREEMENT, IF ANY, FOR DAMAGES FOR ANY CLAIM OF ANY KIND WHATSOEVER AND REGARDLESS OF THE LEGAL THEORY, WITH REGARD TO THE RIGHTS GRANTED HEREUNDER OR THE SERVICES PERFORMED HEREUNDER, SHALL NOT INCLUDE COMPENSATION, REIMBURSEMENT OR DAMAGES ON ACCOUNT OF THE LOSS OF PRESENT OR PROSPECTIVE PROFITS, EXPENDITURES, DATA, OPPORTUNITY, ANTICIPATED SAVINGS, INVESTMENTS OR COMMITMENTS, WHETHER MADE IN ESTABLISHMENT, DEVELOPMENT OR MAINTENANCE OF REPUTATION OR GOODWILL OR FOR ANY OTHER REASON WHATSOEVER; AND (B) IN NO EVENT SHALL ANY PARTY TO THIS AGREEMENT BE LIABLE TO THE OTHER PARTIES TO THIS AGREEMENT FOR SPECIAL, INDIRECT, CONSEQUENTIAL, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES. THE PARTIES ACKNOWLEDGE AND AGREE THAT NOTHING IN THIS SECTION 12.2 SHALL LIMIT A PARTY'S OBLIGATION TO PAY ANY AMOUNTS DUE AND OWING TO THE OTHER PARTY UNDER SECTION 5 ON OR BEFORE ANY DATE OF EXPIRATION OR TERMINATION HEREOF."
        }
      ]
    },
    {
      "query": "\"What are the Co-Branding Agreements between Skype Communications, Skype Technologies, TOM Online (BVI) Limited, TOM Online Inc., and Tel-Online Limited?\"",
      "snippets": [
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            90347,
            91321
          ],
          "answer": "TO THE MAXIMUM EXTENT PERMISSIBLE UNDER APPLICABLE LAW, EXCEPT FOR THE WILFUL MISAPPROPRIATION OR INFRINGEMENT OF THE INTELLECTUAL PROPERTY OF A PARTY TO THIS AGREEMENT, OR THE OBLIGATIONS OF THE PARTIES TO THIS AGREEMENT PURSUANT TO SECTION 13, (A) THE LIABILITY OF ANY PARTY TO THIS AGREEMENT, IF ANY, FOR DAMAGES FOR ANY CLAIM OF ANY KIND WHATSOEVER AND REGARDLESS OF THE LEGAL THEORY, WITH REGARD TO THE RIGHTS GRANTED HEREUNDER OR THE SERVICES PERFORMED HEREUNDER, SHALL NOT INCLUDE COMPENSATION, REIMBURSEMENT OR DAMAGES ON ACCOUNT OF THE LOSS OF PRESENT OR PROSPECTIVE PROFITS, EXPENDITURES, DATA, OPPORTUNITY, ANTICIPATED SAVINGS, INVESTMENTS OR COMMITMENTS, WHETHER MADE IN ESTABLISHMENT, DEVELOPMENT OR MAINTENANCE OF REPUTATION OR GOODWILL OR FOR ANY OTHER REASON WHATSOEVER; AND (B) IN NO EVENT SHALL ANY PARTY TO THIS AGREEMENT BE LIABLE TO THE OTHER PARTIES TO THIS AGREEMENT FOR SPECIAL, INDIRECT, CONSEQUENTIAL, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES."
        },
        {
          "file_path": "cuad/TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.txt",
          "span": [
            97579,
            97795
          ],
          "answer": "THE FOREGOING PROVISIONS OF THIS SECTION 13.5 STATE THE ENTIRE LIABILITY AND THE EXCLUSIVE REMEDY OF THE PARTIES TO THIS AGREEMENT WITH RESPECT TO INFRINGEMENT OR ALLEGED INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS."
        }
      ]
    },
    {
      "query": "\"What is the expiration date of the agreement between Howmedica Osteonics Corp. (\"Stryker\") and Conformis, Inc. for Patient-Specific Instrumentation?\"",
      "snippets": [
        {
          "file_path": "cuad/ConformisInc_20191101_10-Q_EX-10.6_11861402_EX-10.6_Development Agreement.txt",
          "span": [
            44113,
            44438
          ],
          "answer": "The term of this Agreement shall begin as of the Effective Date and continue until Acceptance of all Deliverables   for Milestones #1 and #2 pursuant to Section 3.4 and completion of Milestone #3, unless earlier terminated under Section 8.2, as   provided for under the Other Agreements, or as mutually agreed by the Parties."
        }
      ]
    },
    {
      "query": "\"What legal entity is Stryker's Development Agreement with Conformis?",
      "snippets": [
        {
          "file_path": "cuad/ConformisInc_20191101_10-Q_EX-10.6_11861402_EX-10.6_Development Agreement.txt",
          "span": [
            57013,
            57168
          ],
          "answer": "This Agreement shall be governed and construed in accordance with the laws of New York State   (without regard to the conflict of laws provisions thereof)."
        }
      ]
    },
    {
      "query": "\"What are the competitive restrictions in the Agreement between Stryker and Conformis for patient-specific instrumentation?",
      "snippets": [
        {
          "file_path": "cuad/ConformisInc_20191101_10-Q_EX-10.6_11861402_EX-10.6_Development Agreement.txt",
          "span": [
            19522,
            20563
          ],
          "answer": "Except as specifically provided in the Distribution Agreement, Conformis shall be prohibited from   developing or assisting another in developing, or causing another to develop, Patient-Specific Instrumentation for Off-The-Shelf   Knee Implants for any Third Party in the field of orthopedics until January 1, 2032 (or earlier, to the extent set forth in Section   2.3.3.4 or Section 2.3.5 of the Distribution Agreement), with the exception that Conformis (including any entity involved in a   Change of Control of Conformis, any such entity an \"Acquirer\"), may develop Patient-Specific Instrumentation for any Off-The-   Shelf Implants of Conformis, an Acquirer or any of their Affiliates. For purposes of clarity, the foregoing does not prevent   Conformis from granting any license, release, covenant not to sue or other immunity to any third party under any Patents, including   any such immunity that would authorize manufacture, use or sale of Patient-Specific Instrumentation for Off-The-Shelf Knee   Implants outside the Buyer Field."
        }
      ]
    },
    {
      "query": "\"Look at the Development Agreement between Stryker and Conformis for Patient-Specific Instrumentation; does this contract include an exclusivity agreement?\"",
      "snippets": [
        {
          "file_path": "cuad/ConformisInc_20191101_10-Q_EX-10.6_11861402_EX-10.6_Development Agreement.txt",
          "span": [
            19522,
            20212
          ],
          "answer": "Except as specifically provided in the Distribution Agreement, Conformis shall be prohibited from   developing or assisting another in developing, or causing another to develop, Patient-Specific Instrumentation for Off-The-Shelf   Knee Implants for any Third Party in the field of orthopedics until January 1, 2032 (or earlier, to the extent set forth in Section   2.3.3.4 or Section 2.3.5 of the Distribution Agreement), with the exception that Conformis (including any entity involved in a   Change of Control of Conformis, any such entity an \"Acquirer\"), may develop Patient-Specific Instrumentation for any Off-The-   Shelf Implants of Conformis, an Acquirer or any of their Affiliates."
        }
      ]
    },
    {
      "query": "Does the Development Agreement between Howmedica Osteonics Corp. (Stryker) and Conformis, Inc. for Patient-Specific Instrumentation include a right of first refusal, right of first offer, or right of first negotiation?",
      "snippets": [
        {
          "file_path": "cuad/ConformisInc_20191101_10-Q_EX-10.6_11861402_EX-10.6_Development Agreement.txt",
          "span": [
            31349,
            31969
          ],
          "answer": "Notwithstanding the foregoing, in the event that the applicable Party decides not to file at all or not to file a continuing or other   application to maintain the viability of the U.S part of a family of patents to which an application belongs, or decides to abandon or   discontinue the prosecution or maintenance of any of the Joint IP Rights, such Party shall notify the other Party thereof, and such   other Party may elect to continue the prosecution (including non-provisional application and PCT entry) or maintenance of such   Joint IP Rights at its sole expense and in the name(s) of both Stryker and Conformis"
        }
      ]
    },
    {
      "query": "\"How the development agreement between Stryker and Conformis, Inc. for Patient-Specific Instrumentation is structured?",
      "snippets": [
        {
          "file_path": "cuad/ConformisInc_20191101_10-Q_EX-10.6_11861402_EX-10.6_Development Agreement.txt",
          "span": [
            21791,
            23305
          ],
          "answer": "All right, title and interest in and to the Improved Conformis Background IP and KIB Product IP (\"Joint IP\") shall be   owned jointly by the Parties. Subject to the limitations set forth in this Agreement, the Joint IP may be used freely by either Party or   its Affiliates and licensed to Third Parties by Conformis and its Affiliates, on the one hand, outside of the Buyer Field or by Stryker   and its Affiliates, on the other hand, within the Buyer Field, in each case, without the consent of, or duty to account to or notify, the   other Party, but, except with respect to external licenses of the Improved Conformis Background IP by Conformis or its Affiliates   to Third Parties, any external Third Party license shall be governed in accordance with the last sentence of Section 4.3(c) of the   APA. Each Party to whom ownership is to vest in Joint IP by operation of law or by assignment by its employees or Agents agrees   to assign and hereby assigns to the other Party an undivided one-half right, title and interest in and to all Joint IP; and to facilitate   such assignment, the Party possessing such ownership agrees (i) to regularly ensure that its employees and consultants timely make   any appropriate assignments to it; and (ii) at the other Party's reasonable request, to execute and have its employees and   consultants execute, as necessary, all assignments and any other documentation to perfect the undivided one-half right, title and   interest in and to the other Party of such Joint IP."
        }
      ]
    },
    {
      "query": "\"What licenses are granted under the development agreement between Howmedica Osteonics Corp. (Stryker) and Conformis, Inc. for Patient-Specific Instrumentation?\"",
      "snippets": [
        {
          "file_path": "cuad/ConformisInc_20191101_10-Q_EX-10.6_11861402_EX-10.6_Development Agreement.txt",
          "span": [
            24651,
            24963
          ],
          "answer": "To the extent required and for the avoidance of doubt, Stryker hereby grants Conformis, and Conformis hereby   accepts, a non-exclusive license to the Stryker Background IP and Improved Stryker Background IP solely for purposes of   performing any obligations under this Agreement and the Distribution Agreement."
        }
      ]
    },
    {
      "query": "\"Does the development agreement between Stryker and Conformis for Patient-Specific Instrumentation give any rights to the licensee's affiliates?",
      "snippets": [
        {
          "file_path": "cuad/ConformisInc_20191101_10-Q_EX-10.6_11861402_EX-10.6_Development Agreement.txt",
          "span": [
            19522,
            20212
          ],
          "answer": "Except as specifically provided in the Distribution Agreement, Conformis shall be prohibited from   developing or assisting another in developing, or causing another to develop, Patient-Specific Instrumentation for Off-The-Shelf   Knee Implants for any Third Party in the field of orthopedics until January 1, 2032 (or earlier, to the extent set forth in Section   2.3.3.4 or Section 2.3.5 of the Distribution Agreement), with the exception that Conformis (including any entity involved in a   Change of Control of Conformis, any such entity an \"Acquirer\"), may develop Patient-Specific Instrumentation for any Off-The-   Shelf Implants of Conformis, an Acquirer or any of their Affiliates."
        }
      ]
    },
    {
      "query": "\"What is the scope of liability in the Stryker-Conformis development agreement for Patient-Specific Instrumentation?\"",
      "snippets": [
        {
          "file_path": "cuad/ConformisInc_20191101_10-Q_EX-10.6_11861402_EX-10.6_Development Agreement.txt",
          "span": [
            38669,
            38834
          ],
          "answer": "EXCEPT FOR [**], IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE   OTHER PARTY FOR [**], EVEN IF SUCH PARTY WAS ADVISED OR AWARE OF THE POSSIBILITY OF SUCH   DAMAGES."
        }
      ]
    },
    {
      "query": "\"Is there a cap on liability under the Development Agreement between Stryker and Conformis, Inc. for Patient-Specific Instrumentation?\"",
      "snippets": [
        {
          "file_path": "cuad/ConformisInc_20191101_10-Q_EX-10.6_11861402_EX-10.6_Development Agreement.txt",
          "span": [
            17393,
            17799
          ],
          "answer": "Such termination, together with the provisions of Section 5.2 of the License Agreement,   constitutes as Stryker's sole remedy and Conformis' exclusive liability in the event of any such rejection or failure by Conformis to   deliver materially conforming Deliverables hereunder so long as such rejection or failure does not arise from Conformis' fraud,   willful misconduct, gross negligence or bad faith."
        },
        {
          "file_path": "cuad/ConformisInc_20191101_10-Q_EX-10.6_11861402_EX-10.6_Development Agreement.txt",
          "span": [
            38669,
            39102
          ],
          "answer": "EXCEPT FOR [**], IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE   OTHER PARTY FOR [**], EVEN IF SUCH PARTY WAS ADVISED OR AWARE OF THE POSSIBILITY OF SUCH   DAMAGES. CONFORMIS' LIABILITY ON A PER OCCURRENCE BASIS UNDER SECTION 7.3(A)(IV) SHALL NOT   EXCEED THE GREATER OF (I) $[**] AND (II) THE AMOUNT OF INSURANCE COVERAGE ACTUALLY PAID TO   CONFORMIS UNDER THEN-CURRENT INSURANCE POLICIES OF CONFORMIS IN RESPECT OF SUCH   DAMAGES."
        },
        {
          "file_path": "cuad/ConformisInc_20191101_10-Q_EX-10.6_11861402_EX-10.6_Development Agreement.txt",
          "span": [
            41342,
            41589
          ],
          "answer": "Notwithstanding   anything to the contrary, Stryker's sole remedy and Conformis' exclusive liability for breach of Section 3.2 with respect to a   Product or a Stryker Product shall be as set forth in Section 10.1(i) of the Distribution Agreement."
        }
      ]
    },
    {
      "query": "\"What is the date of termination of the Exclusive License and Product Development Agreement between Aucta Pharmaceuticals, Inc. and Eton Pharmaceuticals, Inc.?\"",
      "snippets": [
        {
          "file_path": "cuad/EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement.txt",
          "span": [
            36378,
            37095
          ],
          "answer": "The term of this Agreement shall automatically become effective upon the occurrence of (i) ETON executing a commercial supply agreement with a contract manufacturing organization within forty-five (45) days of the Execution Date, provided that ETON has exercised best efforts to execute such agreement and the failure to execute is solely caused by the refusal or inability of the proposed manufacturing organization to sign a reasonable agreement; and (ii) acceptance for review of the Dossier or marketing application for [ * * * ] by the FDA no later than September 2, 2019 (such date, the \"Effective Date\") and shall end upon the termination or expiration of the Agreement as set forth in Section 11 (the \"Term\")."
        }
      ]
    },
    {
      "query": "\"What is the governing law for the Exclusive License and Product Development Agreement between Eton Pharmaceuticals, Inc. and Aucta Pharmaceuticals, Inc.?\"",
      "snippets": [
        {
          "file_path": "cuad/EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement.txt",
          "span": [
            57519,
            57733
          ],
          "answer": "This Agreement shall be governed, interpreted and construed in accordance with the substantive laws of the Delaware, in the country of the United State of America, without regard to its conflict of laws principles."
        }
      ]
    },
    {
      "query": "\"What is the non-compete clause established in the Exclusive License and Product Development Agreement between Aucta Pharmaceuticals, Inc. and Eton Pharmaceuticals, Inc.?\"",
      "snippets": [
        {
          "file_path": "cuad/EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement.txt",
          "span": [
            15708,
            16057
          ],
          "answer": "During the Term of this Agreement, and for a period of two (2) years thereafter, Aucta shall not research, develop, manufacture, file, sell, market, or distribute more than two products containing the active ingredient Lamotrigine; nor will Aucta directly or indirectly assist any other Person or entity in carrying or any such activities. [ * * * ]"
        }
      ]
    },
    {
      "query": "\"Which clauses are included in the Exclusive License and Product Development Agreement between Eton Pharmaceuticals, Inc. and Aucta Pharmaceuticals, Inc.?\"",
      "snippets": [
        {
          "file_path": "cuad/EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement.txt",
          "span": [
            11332,
            11919
          ],
          "answer": "Aucta, for itself and its Affiliates, hereby grants to ETON in accordance with the terms and conditions of this Agreement, an exclusive (even as to and against Aucta in the Territory) right and license, including the right to sublicense, to the Products (or any components thereof), Dossiers, and all current and future Aucta Background Intellectual Property that is owned or controlled by Aucta or its Affiliates for ETON to develop, manufacture, import, use, promote, distribute, market, advertise, offer for sale or sell (collectively, \"Market\") the Products in and for the Territory."
        }
      ]
    },
    {
      "query": "\"Can this exclusive license and product development agreement between Eton Pharmaceuticals, Inc. and Aucta Pharmaceuticals, Inc. be terminated for convenience? and what conditions?\"",
      "snippets": [
        {
          "file_path": "cuad/EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement.txt",
          "span": [
            40868,
            41104
          ],
          "answer": "ETON has the right to terminate this Agreement after approval of the Dossier or marketing application for the Product (or added new product), at its sole discretion, upon providing one hundred eighty (180) days' written notice to Aucta."
        }
      ]
    },
    {
      "query": "\"What happens in the event of a change of control of one of the parties in this agreement??\"",
      "snippets": [
        {
          "file_path": "cuad/EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement.txt",
          "span": [
            63599,
            64087
          ],
          "answer": "Notwithstanding the foregoing, each Party may assign the rights and obligations under this Agreement in whole, without consent of the other Party, to a Third Party or Affiliate in connection with the transfer or sale of all or substantially all of its business or in the event of a merger, consolidation or change in control provided that the assignee assumes in writing and becomes directly obligated to the other Party to perform all of the obligations of assignor under this Agreement."
        }
      ]
    },
    {
      "query": "\"What is the exact meaning of the Anti-assignment clause in the exclusive license and product development agreement between Eton Pharmaceuticals, Inc. and Aucta Pharmaceuticals, Inc.?\"",
      "snippets": [
        {
          "file_path": "cuad/EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement.txt",
          "span": [
            63431,
            63598
          ],
          "answer": "The Parties shall not assign, encumber or otherwise transfer this Agreement or any part of it to any Third Party, without the prior written consent of the other Party."
        }
      ]
    },
    {
      "query": "\"What is included in the Exclusive License and Product Development Agreement between Eton Pharmaceuticals, Inc. and Aucta Pharmaceuticals, Inc.?\"",
      "snippets": [
        {
          "file_path": "cuad/EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement.txt",
          "span": [
            19365,
            19449
          ],
          "answer": "ETON shall pay to Aucta a royalty payment of [ * * * ] of Net Sales of the Products."
        },
        {
          "file_path": "cuad/EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement.txt",
          "span": [
            37298,
            37468
          ],
          "answer": "Aucta should continue to receive 15% of Net Sales Royalty for as long as ETON is selling the Product(s) in the Territory, unless otherwise agreed to under this Agreement."
        }
      ]
    },
    {
      "query": "\"What is the minimum commitment required under the exclusive license and product development agreement that was drawn between Eton Pharmaceuticals, Inc. and Aucta Pharmaceuticals, Inc.?\"",
      "snippets": [
        {
          "file_path": "cuad/EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement.txt",
          "span": [
            19472,
            19826
          ],
          "answer": "If the amount of royalty payment under Section 6.3.1 is less than the amount of royalty payment under Section 6.3.2, then ETON shall pay Aucta the difference between royalty payments in Sections 6.3.1 and 6.3.2 within sixty (60) days of the calendar year end, but in no event shall the difference paid be greater than the minimum amount in Section 6.3.2."
        }
      ]
    },
    {
      "query": "Is the contract between Eton Pharmaceuticals, Inc. and Aucta Pharmaceuticals, Inc. in jeopardy for any volume restrictions?",
      "snippets": [
        {
          "file_path": "cuad/EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement.txt",
          "span": [
            15708,
            16047
          ],
          "answer": "During the Term of this Agreement, and for a period of two (2) years thereafter, Aucta shall not research, develop, manufacture, file, sell, market, or distribute more than two products containing the active ingredient Lamotrigine; nor will Aucta directly or indirectly assist any other Person or entity in carrying or any such activities."
        }
      ]
    },
    {
      "query": "\"How many patents are granted under the exclusive license and product development agreement between Eton Pharmaceuticals Inc. and Aucta Pharmaceuticals, Inc.?\"",
      "snippets": [
        {
          "file_path": "cuad/EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement.txt",
          "span": [
            11332,
            11919
          ],
          "answer": "Aucta, for itself and its Affiliates, hereby grants to ETON in accordance with the terms and conditions of this Agreement, an exclusive (even as to and against Aucta in the Territory) right and license, including the right to sublicense, to the Products (or any components thereof), Dossiers, and all current and future Aucta Background Intellectual Property that is owned or controlled by Aucta or its Affiliates for ETON to develop, manufacture, import, use, promote, distribute, market, advertise, offer for sale or sell (collectively, \"Market\") the Products in and for the Territory."
        },
        {
          "file_path": "cuad/EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement.txt",
          "span": [
            12185,
            12558
          ],
          "answer": "ETON, for itself and its Affiliates, hereby grants to Aucta in accordance with the terms and conditions of this Agreement, a right and license, to its trademark, including to its name and logo, that is owned or controlled by ETON or its Affiliates for Aucta (or its authorized Third Party) to make the packs, labels, and leaflets for the Products for sale in the Territory."
        }
      ]
    },
    {
      "query": "\"How much time do Eton Pharmaceuticals, Inc. and Aucta Pharmaceuticals, Inc. have together? Are there any services that the two companies agreed to provide when the agreement is terminated?\"",
      "snippets": [
        {
          "file_path": "cuad/EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement.txt",
          "span": [
            21951,
            22250
          ],
          "answer": "In addition, within twenty-five (25) months after the termination or expiration of the Term and on a Product-by-Product basis, ETON shall perform a final \"true-up\" reconciliation and shall provide Aucta with a written report of such outlining the deductions specified in the definition of Net Sales."
        },
        {
          "file_path": "cuad/EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement.txt",
          "span": [
            41372,
            41838
          ],
          "answer": "After termination is effective and Aucta assumes control of the Product, ETON will provide, to the extent practicable, transition services to Aucta to include assistance with Product distribution, processing of rebates, drug safety, etc. at Aucta's cost for such services, for a reasonable period of time as mutually determined by the Parties but not to exceed one hundred eighty (180) days following termination so that Aucta can get its own such services in place."
        },
        {
          "file_path": "cuad/EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement.txt",
          "span": [
            43092,
            43949
          ],
          "answer": "If this Agreement is terminated by Aucta under Section 11.2 or 11.3, then (a) ETON shall have the right to, and Aucta shall hereby grant ETON a license to, Market or otherwise dispose of any existing inventory of any Products then in ETON's possession subject to paying all Royalties and other amounts due hereunder for such sales, (b) Aucta may keep all the payments under Section 6 paid by ETON up to the point of termination and for ETON's disposal of remaining inventory and Aucta is free to commercialize or relicense the Product with no further obligations owed to ETON, (c) ETON shall refrain from holding itself out as Aucta's distributor, in particular, eliminate any reference to the Product and Aucta from its business, trade style and promotional material, and (d) ETON shall transfer all rights, licenses within thirty (30) days of termination."
        }
      ]
    },
    {
      "query": "\"In the Exclusive License and Product Development Agreement between Eton Pharmaceuticals, Inc. and Aucta Pharmaceuticals, Inc., What are the audit rights under this contract?\"",
      "snippets": [
        {
          "file_path": "cuad/EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement.txt",
          "span": [
            23387,
            24269
          ],
          "answer": "Each Party shall permit an independent certified public accounting firm selected by the auditing Party and reasonably acceptable to the non-auditing Party, that has agreed to be bound by a confidentiality agreement reasonably acceptable to the Parties, to have access, during normal business hours and upon reasonable prior notice (not more often than once in any calendar year), to those books and records maintained by the non-auditing Party necessary for the auditing Party to verify the accuracy of the non-auditing Party's calculations under this Section 6 and/or cost of Product(s) for any period ending not more than two (2) years prior to the date of such request, subject to any limitations in scope necessary to comply with Applicable Law, Third Party confidentiality restrictions, or maintain legal privilege, including but not limited to Third Party pricing information."
        }
      ]
    },
    {
      "query": "\"What is the extent of liability under the two-party, exclusive licensing and product development agreement between Eton Pharmaceuticals and Aucta Pharmaceuticals?",
      "snippets": [
        {
          "file_path": "cuad/EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement.txt",
          "span": [
            57234,
            57462
          ],
          "answer": "NOTWITHSTANDING ANYTHING TO THE CONTRARY HEREIN, NEITHER PARTY SHALL BE LIABLE FOR ANY INDIRECT, SPECIAL, INCIDENTAL, CONSEQUENTIAL OR EXEMPLARY DAMAGES, WHETHER FORESEEABLE OR NOT, THAT ARE IN ANY WAY RELATED TO THIS AGREEMENT."
        }
      ]
    },
    {
      "query": "\"What are the insurance requirements for the Exclusive License and Product Development Agreement between Eton Pharmaceuticals, Inc. and Aucta Pharmaceuticals, Inc.\"",
      "snippets": [
        {
          "file_path": "cuad/EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement.txt",
          "span": [
            30980,
            31581
          ],
          "answer": "At all times from the first commercial sale of any Product(s) or after the Effective Date through the date which is five (5) years after the final sale of such Product(s), the Parties will maintain general liability insurance in amounts that are reasonable and customary in the pharmaceutical industry, provided in no event shall the general liability insurance amounts be less than five million dollars ($5,000,000) per occurrence and ten million dollars ($10,000,000) in the aggregate limit of liability per year. The Parties shall provide written proof of such insurance to each other upon request."
        }
      ]
    },
    {
      "query": "\"What is the expiration date of the joint development agreement between FuelCell Energy, Inc. and ExxonMobil Research and Engineering Company for Molten Carbonate Fuel Cells?\"",
      "snippets": [
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            52592,
            52770
          ],
          "answer": "Unless sooner terminated in accordance with this Article, this Agreement will continue in full force beginning on the Effective Date and ending two (2) years thereafter (\"Term\")."
        }
      ]
    },
    {
      "query": "\"What governing law exists for the Joint Development Agreement between FuelCell and ExxonMobil Research?",
      "snippets": [
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            62105,
            62301
          ],
          "answer": "The validity and interpretation of this Agreement and the legal relations of the Parties to it will be governed by the laws of the State of New York without recourse to its conflicts of law rules."
        }
      ]
    },
    {
      "query": "\"Is the Joint Development Agreement between FuelCell Energy, Inc. and ExxonMobil Research and Engineering Company for Molten Carbonate Fuel Cells competitive?",
      "snippets": [
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            4164,
            4462
          ],
          "answer": "Notwithstanding the foregoing, ExxonMobil hereby grants approval for FCE solely to conduct Authorized Work using Generation 1 Technology with Authorized Third Parties for Carbon Capture Applications and any Work using Generation 2 Technology solely for Power Applications and Hydrogen Applications."
        }
      ]
    },
    {
      "query": "\"What is the non-compete clause in the joint development agreement between FuelCell Energy, Inc. and Exxon Mobil Research and Engineering Company for Molten Carbonate Fuel Cells?",
      "snippets": [
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            3887,
            4163
          ],
          "answer": "During the Term of this Agreement, FCE will not conduct any Work using Generation 1 Technology in Carbon Capture Applications or any Work using Generation 2 Technology, independently or with third parties outside this Agreement, without prior written approval from ExxonMobil."
        }
      ]
    },
    {
      "query": "\"How does the MFCO - ExxonMobil Joint Development Agreement for Molten Carbonate Fuel Cells compare to the MFCO - ExxonMobil Joint Development Agreement for Molten Carbonate Fuel Cells?",
      "snippets": [
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            52909,
            53085
          ],
          "answer": "Accordingly, either Party may terminate this Agreement or all/part of a Project for any reason and at any time upon giving the other Party sixty (60) days prior written notice."
        }
      ]
    },
    {
      "query": "\"Is the Molten Carbonate Fuel Cell Joint Development Agreement between FuelCell Energy, Inc. and ExxonMobil Research and Engineering Company for Molten Carbonate Fuel Cells included in any of these rights?\"",
      "snippets": [
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            24538,
            24978
          ],
          "answer": "Notwithstanding the foregoing, in the event ExxonMobil decides not to prosecute, defend, enforce, maintain or decides to abandon any Program Patent, then ExxonMobil will provide notice thereof to FCE, and FCE will then have the right, but not the obligation, to prosecute or maintain the Program Patent and sole responsibility for the continuing costs, taxes, legal fees, maintenance fees and other fees associated with that Program Patent."
        },
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            27221,
            27611
          ],
          "answer": "During the Term of this Agreement and for two (2) years thereafter, in the event that either Party decides to sell or convey its interest in or otherwise dispose of any Prior JDA Project Patent to any Non-Affiliated Third Party, such Party will inform the other Party, who will then have the right of first refusal to purchase or otherwise acquire the sole interest at same or better terms."
        }
      ]
    },
    {
      "query": "\"What happens in the event of a change of control of one of the parties in this contract?\"",
      "snippets": [
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            55108,
            56015
          ],
          "answer": "ExxonMobil may terminate this Agreement upon fifteen (15) days written notice, without penalty, payment or prejudice to claims and obligations then accrued, if FCE undergoes a Change in Control. Subject to requirements of applicable law, FCE will provide notice to ExxonMobil prior to, or promptly after, it becomes aware of any such Change in Control, and if prior notice is prohibited by applicable Law, as soon as practicable or after such notice is no longer prohibited, but in no event later than one (1) business day after any public announcement with respect to any such asset transfer or Change in Control. Notwithstanding anything else in this Agreement, in the event of termination under this Paragraph 12.04 ExxonMobil may terminate any licenses granted to FCE under this Agreement that would otherwise survive termination, taking into account the circumstances surrounding the Change in Control."
        }
      ]
    },
    {
      "query": "\"Does the Joint Development Agreement between FuelCell Energy, Inc. and ExxonMobil Research and Engineering Company for Molten Carbonate Fuel Cells include an anti-assignment clause?\"",
      "snippets": [
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            64958,
            65187
          ],
          "answer": "The Agreement is not assignable, including any assignment by operation of law (including but not limited to as a result of a merger or other corporate action), by either Party without the prior written consent of the other Party."
        },
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            65308,
            65948
          ],
          "answer": "Notwithstanding the foregoing, ExxonMobil may assign this Agreement to its Affiliates and FCE may assign this Agreement to any of its wholly-owned and wholly-controlled Affiliates, with prior written notice to the other Party, provided that (i) such assignment by FCE shall be void if at any point such Affiliate ceases to be both wholly-owned and wholly- controlled by FCE, (ii) Article 12, including but not limited to Paragraphs 12.03, 12.04 and 12.05, shall be applicable to both FCE and any Affiliate assignee of FCE, and (iii) no assignment pursuant to this sentence will relieve the Parties of their obligations under this Agreement."
        }
      ]
    },
    {
      "query": "\"What is the intellectual property ownership assignment for the Joint Development Agreement between FuelCell Energy, Inc. and ExxonMobil Research and Engineering Company for Molten Carbonate Fuel Cells?\"",
      "snippets": [
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            21614,
            21694
          ],
          "answer": "FCE will assign, and hereby assigns, to ExxonMobil ownership of Program Results."
        },
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            22711,
            23452
          ],
          "answer": "For Program Patents, if one or more employees or other representatives of FCE are determined to be inventors, then FCE will:\n\n(i) cause its employees, contractors, and consultants to render reasonable and timely assistance to ExxonMobil and its attorneys or agents;\n\n(ii) assign, and will cause its and its Affiliates' employees, contractors, and consultants to assign, its right, title, and interest in and to such Program Patent to ExxonMobil for filing; and\n\n(iii) cause its and its Affiliate employees, contractors, and consultants, to execute any documents as may be required to effect such assignments, or file, prosecute, and maintain any patent applications or patents that are based on, derived from, or protect such Program Patent."
        }
      ]
    },
    {
      "query": "\"What licenses are granted under the Joint Development Agreement between FuelCell Energy, Inc. and ExxonMobil Research and Engineering Company for Molten Carbonate Fuel Cells?\"",
      "snippets": [
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            27872,
            28506
          ],
          "answer": "ExxonMobil grants FCE a worldwide, non-exclusive, royalty-free, non-transferable (except pursuant to Article 14 (Assignment)), non-sub-licensable (except as set forth in this Paragraph 7.01(a)) right and license to practice Program Results solely to conduct research and development for the Program. More particularly, said right and license to practice includes the right to use, reproduce, and create derivative works of Program Information under applicable copyrights and to make, use, and import (but not sell or offer to sell) under the claims of Program Patents, in each case solely for research and development for the Program."
        },
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            28858,
            29238
          ],
          "answer": "ExxonMobil grants FCE a worldwide, non-exclusive, royalty-free, perpetual, irrevocable (except as stated in Paragraphs 12.03 (Failure to Perform), 12.04 (Other Termination), and 12.05 (Bankruptcy)), sub-licensable, non-transferable (except pursuant to Article 14 (Assignment)), right and license to practice Program Results solely for Power Applications and Hydrogen Applications."
        },
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            29609,
            30195
          ],
          "answer": "In the event ExxonMobil notifies FCE that it has formally decided not to pursue Generation 2 Technology for Carbon Capture Applications, then upon FCE's written request, ExxonMobil agrees to negotiate a grant to FCE, under commercially reasonable terms to be determined in good faith, a worldwide, non-exclusive, royalty-bearing (with the royalty to be negotiated), non-sub- licensable (except as set forth in this Paragraph 7.01(b)(2)), non-transferable (except pursuant to Article 14 (Assignment)), right and license to practice Program Results solely for Carbon Capture Applications."
        },
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            31270,
            31693
          ],
          "answer": "To the extent not already granted pursuant to the License Agreement, FCE grants ExxonMobil and its Affiliates a worldwide, non-exclusive, royalty-free, irrevocable, perpetual, sub-licensable, non-transferable (except pursuant to Article 14 (Assignment)) right and license to practice FCE Background Information and FCE Background Patents for Generation 2 Technology in Carbon Capture Applications and Hydrogen Applications."
        },
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            32204,
            33505
          ],
          "answer": "In the event FCE notifies ExxonMobil that it has formally decided not to pursue Generation 2 Technology for Power Applications, then upon ExxonMobil's written request, FCE agrees to negotiate a grant to ExxonMobil and its Affiliates, under commercially reasonable terms to be determined in good faith, a worldwide, royalty-bearing (with the royalty to be negotiated), non-exclusive, sub-licensable right and license to practice FCE Background Information and FCE Background Patents for Generation 2 Technology in any application outside of Carbon Capture Applications and Hydrogen Applications. More particularly, said right and license to practice FCE Background Information and FCE Background Patents for Generation 2 Technology in any application outside of Carbon Capture Applications and Hydrogen Applications will include the right to use, reproduce, and create derivative works of FCE Background Information under applicable copyrights and the right to make, use, import, and sell or offer to sell under the claims of FCE Background Patents. Nothing in this Paragraph 8.02(a)(2) will create an obligation on the part of FCE to grant ExxonMobil a license or right under FCE Background Patents or FCE Background Information if the Parties do not agree on the terms and conditions of such license."
        },
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            33598,
            34548
          ],
          "answer": "ExxonMobil grants FCE a worldwide, non-exclusive, royalty- free, non-sub-licensable (except as set forth herein), perpetual, irrevocable (except as stated in Paragraphs 12.03 (Failure to Perform), 12.04 (Other Termination), and 12.05 (Bankruptcy)), non- transferable (except pursuant to Article 14 (Assignment)) right and license to practice ExxonMobil Background Information and ExxonMobil Background Patents for Generation 1 Technology in any applications outside of Carbon Capture Applications. More particularly, said right and license to practice ExxonMobil Background Information and ExxonMobil Background Patents for Generation 1 Technology in any applications outside of Carbon Capture Applications includes the right to use, reproduce, and create derivative works of ExxonMobil Background Information under applicable copyrights and the right to make, use, import, and sell or offer to sell under the claims of ExxonMobil Background Patents."
        },
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            34734,
            35765
          ],
          "answer": "ExxonMobil grants FCE a worldwide, non-exclusive, royalty-free, non-sub- licensable (except as set forth herein), perpetual, irrevocable (except as stated in Paragraphs 12.03 (Failure to Perform), 12.04 (Other Termination), and 12.05 (Bankruptcy)), non-transferable (except pursuant to Article 14 (Assignment)) right and license to practice ExxonMobil Background Information and ExxonMobil Background Patents for Generation 1 Technology in Carbon Capture Applications, solely to conduct Authorized Work with Authorized Third Parties. More particularly, said right and license to practice ExxonMobil Background Information and ExxonMobil Background Patents for Generation 1 Technology in Carbon Capture Applications includes the right to use, reproduce, and create derivative works of ExxonMobil Background Information under applicable copyrights and the right to make, use, and import (but not sell or offer to sell) under the claims of ExxonMobil Background Patents, solely to conduct Authorized Work with Authorized Third Parties"
        },
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            36019,
            36987
          ],
          "answer": "In the event that ExxonMobil fails to notify FCE before the end of the Term of the Agreement of ExxonMobil's intent to negotiate a subsequent or follow-on commercial agreement, ExxonMobil agrees to negotiate a grant to FCE, under commercially reasonable terms to be determined in good faith, a worldwide, royalty-free, non-exclusive, non-sub-licensable (except as set forth herein) right and license to practice ExxonMobil Background Information and ExxonMobil Background Patents for Generation 1 Technology in Carbon Capture Applications. More particularly, said right and license to practice ExxonMobil Background Information and ExxonMobil Background Patents for Generation 1 Technology in Carbon Capture Applications will include the right to use, reproduce, and create derivative works of ExxonMobil Background Information under applicable copyrights and the right to make, use, import, and sell or offer to sell under the claims of ExxonMobil Background Patents."
        },
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            37482,
            37967
          ],
          "answer": "ExxonMobil grants FCE a worldwide, non-exclusive, royalty-free, non-sub-licensable (except as set forth herein), perpetual, irrevocable (except as stated in Paragraphs 12.03 (Failure to Perform), 12.04 (Other Termination), and 12.05 (Bankruptcy)), non- transferable (except pursuant to Article 14 (Assignment)) right and license to practice ExxonMobil Background Information and ExxonMobil Background Patents for Generation 2 Technology in Power Applications and Hydrogen Applications."
        },
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            38623,
            39638
          ],
          "answer": "In the event ExxonMobil notifies FCE that it has formally decided not to pursue Generation 2 Technology for Carbon Capture Applications, then upon FCE's written request, ExxonMobil agrees to grant to FCE, under commercially reasonable terms to be determined in good faith, a worldwide, royalty-bearing (with the royalty to be negotiated), non- exclusive, sub-licensable, right and license to practice ExxonMobil Background Information and ExxonMobil Background Patents for Generation 2 Technology in any application outside of Power Applications and Hydrogen Applications. More particularly, said right and license to practice ExxonMobil Background Information and ExxonMobil Background Patents for Generation 2 Technology in any application outside of Power Applications includes the right to use, reproduce, and create derivative works of ExxonMobil Background Information under applicable copyrights and the right to make, use, import, and sell or offer to sell under the claims of ExxonMobil Background Patents."
        }
      ]
    },
    {
      "query": "\"What types of licenses are granted under the Joint Development Agreement between FuelCell Energy, Inc. and Exxon Mobil Research and Engineering Company for Molten Carbonate Fuel Cells?\"",
      "snippets": [
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            27872,
            28171
          ],
          "answer": "ExxonMobil grants FCE a worldwide, non-exclusive, royalty-free, non-transferable (except pursuant to Article 14 (Assignment)), non-sub-licensable (except as set forth in this Paragraph 7.01(a)) right and license to practice Program Results solely to conduct research and development for the Program."
        },
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            28507,
            28630
          ],
          "answer": "Said right and license may be extended to contractors performing work on behalf of FCE but is not otherwise sub-licensable."
        },
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            28858,
            29238
          ],
          "answer": "ExxonMobil grants FCE a worldwide, non-exclusive, royalty-free, perpetual, irrevocable (except as stated in Paragraphs 12.03 (Failure to Perform), 12.04 (Other Termination), and 12.05 (Bankruptcy)), sub-licensable, non-transferable (except pursuant to Article 14 (Assignment)), right and license to practice Program Results solely for Power Applications and Hydrogen Applications."
        },
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            29609,
            30195
          ],
          "answer": "In the event ExxonMobil notifies FCE that it has formally decided not to pursue Generation 2 Technology for Carbon Capture Applications, then upon FCE's written request, ExxonMobil agrees to negotiate a grant to FCE, under commercially reasonable terms to be determined in good faith, a worldwide, non-exclusive, royalty-bearing (with the royalty to be negotiated), non-sub- licensable (except as set forth in this Paragraph 7.01(b)(2)), non-transferable (except pursuant to Article 14 (Assignment)), right and license to practice Program Results solely for Carbon Capture Applications."
        },
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            31270,
            31692
          ],
          "answer": "To the extent not already granted pursuant to the License Agreement, FCE grants ExxonMobil and its Affiliates a worldwide, non-exclusive, royalty-free, irrevocable, perpetual, sub-licensable, non-transferable (except pursuant to Article 14 (Assignment)) right and license to practice FCE Background Information and FCE Background Patents for Generation 2 Technology in Carbon Capture Applications and Hydrogen Applications"
        },
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            33598,
            34095
          ],
          "answer": "ExxonMobil grants FCE a worldwide, non-exclusive, royalty- free, non-sub-licensable (except as set forth herein), perpetual, irrevocable (except as stated in Paragraphs 12.03 (Failure to Perform), 12.04 (Other Termination), and 12.05 (Bankruptcy)), non- transferable (except pursuant to Article 14 (Assignment)) right and license to practice ExxonMobil Background Information and ExxonMobil Background Patents for Generation 1 Technology in any applications outside of Carbon Capture Applications."
        },
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            34549,
            34702
          ],
          "answer": "All rights and licenses in this Paragraph (b)(1)(i) may be extended to contractors performing work on behalf of FCE but are not otherwise sub-licensable."
        },
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            34734,
            35202
          ],
          "answer": "ExxonMobil grants FCE a worldwide, non-exclusive, royalty-free, non-sub- licensable (except as set forth herein), perpetual, irrevocable (except as stated in Paragraphs 12.03 (Failure to Perform), 12.04 (Other Termination), and 12.05 (Bankruptcy)), non-transferable (except pursuant to Article 14 (Assignment)) right and license to practice ExxonMobil Background Information and ExxonMobil Background Patents for Generation 1 Technology in Carbon Capture Applications,"
        },
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            35767,
            35921
          ],
          "answer": "All rights and licenses in this Paragraph (b)(1)(ii) may be extended to contractors performing work on behalf of FCE but are not otherwise sub-licensable."
        },
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            36019,
            36558
          ],
          "answer": "In the event that ExxonMobil fails to notify FCE before the end of the Term of the Agreement of ExxonMobil's intent to negotiate a subsequent or follow-on commercial agreement, ExxonMobil agrees to negotiate a grant to FCE, under commercially reasonable terms to be determined in good faith, a worldwide, royalty-free, non-exclusive, non-sub-licensable (except as set forth herein) right and license to practice ExxonMobil Background Information and ExxonMobil Background Patents for Generation 1 Technology in Carbon Capture Applications."
        },
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            36988,
            37147
          ],
          "answer": "The rights and licenses in this Paragraph (b)(1)(iii) will be extendable t o contractors performing work on behalf of FCE but will not otherwise sub-licensable"
        },
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            37482,
            37967
          ],
          "answer": "ExxonMobil grants FCE a worldwide, non-exclusive, royalty-free, non-sub-licensable (except as set forth herein), perpetual, irrevocable (except as stated in Paragraphs 12.03 (Failure to Perform), 12.04 (Other Termination), and 12.05 (Bankruptcy)), non- transferable (except pursuant to Article 14 (Assignment)) right and license to practice ExxonMobil Background Information and ExxonMobil Background Patents for Generation 2 Technology in Power Applications and Hydrogen Applications."
        }
      ]
    },
    {
      "query": "\"What are the affiliates' rights in the Joint Development Agreement between FuelCell Energy, Inc. and ExxonMobil Research and Engineering Company for Molten Carbonate Fuel Cells?\"",
      "snippets": [
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            31270,
            31693
          ],
          "answer": "To the extent not already granted pursuant to the License Agreement, FCE grants ExxonMobil and its Affiliates a worldwide, non-exclusive, royalty-free, irrevocable, perpetual, sub-licensable, non-transferable (except pursuant to Article 14 (Assignment)) right and license to practice FCE Background Information and FCE Background Patents for Generation 2 Technology in Carbon Capture Applications and Hydrogen Applications."
        }
      ]
    },
    {
      "query": "\"What are the terms of the Joint Development Agreement between FuelCell Energy, Inc. and ExxonMobil Research and Engineering Company for Molten Carbonate Fuel Cells? Are any of the licenses granted under this contract irrevocable or perpetual?\"",
      "snippets": [
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            28858,
            29238
          ],
          "answer": "ExxonMobil grants FCE a worldwide, non-exclusive, royalty-free, perpetual, irrevocable (except as stated in Paragraphs 12.03 (Failure to Perform), 12.04 (Other Termination), and 12.05 (Bankruptcy)), sub-licensable, non-transferable (except pursuant to Article 14 (Assignment)), right and license to practice Program Results solely for Power Applications and Hydrogen Applications."
        },
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            31270,
            31693
          ],
          "answer": "To the extent not already granted pursuant to the License Agreement, FCE grants ExxonMobil and its Affiliates a worldwide, non-exclusive, royalty-free, irrevocable, perpetual, sub-licensable, non-transferable (except pursuant to Article 14 (Assignment)) right and license to practice FCE Background Information and FCE Background Patents for Generation 2 Technology in Carbon Capture Applications and Hydrogen Applications."
        },
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            33598,
            34095
          ],
          "answer": "ExxonMobil grants FCE a worldwide, non-exclusive, royalty- free, non-sub-licensable (except as set forth herein), perpetual, irrevocable (except as stated in Paragraphs 12.03 (Failure to Perform), 12.04 (Other Termination), and 12.05 (Bankruptcy)), non- transferable (except pursuant to Article 14 (Assignment)) right and license to practice ExxonMobil Background Information and ExxonMobil Background Patents for Generation 1 Technology in any applications outside of Carbon Capture Applications."
        },
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            34734,
            35267
          ],
          "answer": "ExxonMobil grants FCE a worldwide, non-exclusive, royalty-free, non-sub- licensable (except as set forth herein), perpetual, irrevocable (except as stated in Paragraphs 12.03 (Failure to Perform), 12.04 (Other Termination), and 12.05 (Bankruptcy)), non-transferable (except pursuant to Article 14 (Assignment)) right and license to practice ExxonMobil Background Information and ExxonMobil Background Patents for Generation 1 Technology in Carbon Capture Applications, solely to conduct Authorized Work with Authorized Third Parties."
        },
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            37482,
            37967
          ],
          "answer": "ExxonMobil grants FCE a worldwide, non-exclusive, royalty-free, non-sub-licensable (except as set forth herein), perpetual, irrevocable (except as stated in Paragraphs 12.03 (Failure to Perform), 12.04 (Other Termination), and 12.05 (Bankruptcy)), non- transferable (except pursuant to Article 14 (Assignment)) right and license to practice ExxonMobil Background Information and ExxonMobil Background Patents for Generation 2 Technology in Power Applications and Hydrogen Applications."
        }
      ]
    },
    {
      "query": "\"The Joint Development Agreement between FuelCell Energy and ExxonMobil Research and Engineering Company for Molten Carbonate Fuel Cells, is it a single pact or multiple pacts?\"",
      "snippets": [
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            71249,
            71460
          ],
          "answer": "Such books, records and accounts will be maintained for a period of at least three (3) years following the termination or expiration of this Agreement, provided there are no pending disputes between the Parties."
        }
      ]
    },
    {
      "query": "\"What are the audit rights under the Joint Development Agreement between FuelCell Energy, Inc. and ExxonMobil Research and Engineering Company for Molten Carbonate Fuel Cells?\"",
      "snippets": [
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            71615,
            72916
          ],
          "answer": "At the request of ExxonMobil, FCE will permit, at reasonable intervals and during regular business hours, during the Term of this Agreement and at least three (3) years thereafter, but no more than once per fiscal year, an independent certified public accounting firm of nationally recognized standing selected by ExxonMobil (and approved by FCE, which approval will not be unreasonably withheld) to inspect, during regular business hours, such books, records, and accounts and any part of the applicable operations and facilities of FCE relevant to this Agreement, and to have access to FCE's knowledgeable personnel, as may be necessary to determine the completeness and accuracy of any accounting and payments required to be made under this Agreement and compliance with other terms of this Agreement, subject to the following:\n\n(a) ExxonMobil and its employees or other representatives will have the right to reproduce for its internal records any of the documents kept by FCE in accordance with Paragraph 18.01 (Recordkeeping), such reproduced documents shall be subject to the confidentiality and use provisions contained in Article 4; and\n\n(b) all expenses of each such audit, including any pre-approved reasonable expenses incurred by FCE for such audit, will be for the account of ExxonMobil."
        },
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            72918,
            73083
          ],
          "answer": "FCE will cause any subcontractors to preserve documentation and allow ExxonMobil to audit such books, records, and accounts of subcontractors by way of auditing FCE."
        }
      ]
    },
    {
      "query": "\"What are the potential liabilities that could be included in the joint development agreement between FuelCell and ExxonMobil Research and Engineering Company for Molten Carbonate Fuel Cells?\"",
      "snippets": [
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            51979,
            52543
          ],
          "answer": "Notwithstanding anything to the contrary in this Agreement, each Party will bear full responsibility, without limit, for the following:\n\n(i) Gross Negligence or Willful Misconduct attributable to its personnel, and, in no event, will a Party be required to release or indemnify the other Party for Gross Negligence or Willful Misconduct attributable to the other Party; and\n\n(ii) its legal obligations to third parties wherein nothing in this Agreement is intended to impair a party's contribution and indemnity rights under law with respect to third party claims."
        }
      ]
    },
    {
      "query": "\"How does the Joint Development Agreement between FuelCell Energy, Inc. and ExxonMobil Research and Engineering Company for Molten Carbonate Fuel Cells protect the parties to the Agreement?",
      "snippets": [
        {
          "file_path": "cuad/FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.txt",
          "span": [
            51177,
            51931
          ],
          "answer": "In no event will either Party be liable to the other Party under this Agreement for any consequential, indirect, special, incidental, punitive or exemplary loss or damage, including, without limitation, business interruption, cost of capital, loss of anticipated revenues and profits, loss of goodwill or increased operating costs, whether arising from contract, warranty, tort, strict liability or otherwise regardless of whether the possibility of such losses or damages have been made known to the first Party, and each Party hereby expressly waives all such rights and remedies, except for breach of any confidentiality or restricted use provisions of this Agreement and except as provided in Paragraph 11.04 (Exceptions to Limitations of Liability)."
        }
      ]
    },
    {
      "query": "\"What is the expiration date of the recipe development agreement between Reed's, Inc. and B C Marketing Concepts Inc?",
      "snippets": [
        {
          "file_path": "cuad/ReedsInc_20191113_10-Q_EX-10.4_11888303_EX-10.4_Development Agreement.txt",
          "span": [
            15301,
            15523
          ],
          "answer": "The term of this Agreement shall commence on the Effective Date and shall continue for the longer of the first anniversary of the Effective Date or the duration of the Manufacturing and Distribution Agreement (the \"Term\")."
        }
      ]
    },
    {
      "query": "\"What is the legality of the recipe development agreement between Reed's, Inc. and B C Marketing Concepts, Inc. for Ginger-Based Alcohol Beverages?\".",
      "snippets": [
        {
          "file_path": "cuad/ReedsInc_20191113_10-Q_EX-10.4_11888303_EX-10.4_Development Agreement.txt",
          "span": [
            20132,
            20392
          ],
          "answer": "This Agreement shall be governed by, and any dispute arising hereunder shall be determined in accordance with, the laws of State of New York (without giving effect to conflict of laws principles) including all matters of construction, validity and performance."
        }
      ]
    },
    {
      "query": "\"What is the approximate length of the Recipe Development Agreement between Reed's, Inc. and B C Marketing Concepts Inc. for Ginger-Based Alcohol Beverages?\"",
      "snippets": [
        {
          "file_path": "cuad/ReedsInc_20191113_10-Q_EX-10.4_11888303_EX-10.4_Development Agreement.txt",
          "span": [
            4229,
            4761
          ],
          "answer": "In exchange for Company's contributions and obligations under this Agreement, Reed's grants Company the exclusive right to manufacture, package, promote, sell and distribute the Products (if and to the extent approved by the Development Committee), subject to the terms and conditions of a separate Manufacturing and Distribution Agreement to be entered into by the parties concurrently with this Agreement, as it may be amended, modified, supplemented or restated from time to time (the \"Manufacturing and Distribution Agreement\")."
        }
      ]
    },
    {
      "query": "\"What if Reed's, Inc. is merged into B C Marketing Concepts, Inc.? Is there any possibility that Reed's, Inc. could be absorbed into B C Marketing Concepts, Inc.?\"",
      "snippets": [
        {
          "file_path": "cuad/ReedsInc_20191113_10-Q_EX-10.4_11888303_EX-10.4_Development Agreement.txt",
          "span": [
            19512,
            19962
          ],
          "answer": "Company may not assign or transfer its rights or obligations under this Agreement, whether by operation of law, contract or otherwise, without the prior written consent of Reed's, which shall not be unreasonably withheld (it being understood that a purported assignment to a Reed's competitor identified or referred to in Exhibit D of the Manufacturing and Distribution Agreement shall be considered to be a reasonable basis for withholding consent)."
        }
      ]
    },
    {
      "query": "\"What is the intellectual property ownership assignment in the recipe development agreement between Reed's, Inc. and B C Marketing Concepts Inc. for Ginger-based Alcohol Beverages?",
      "snippets": [
        {
          "file_path": "cuad/ReedsInc_20191113_10-Q_EX-10.4_11888303_EX-10.4_Development Agreement.txt",
          "span": [
            8327,
            8372
          ],
          "answer": "Reed's will exclusively own all Deliverables."
        },
        {
          "file_path": "cuad/ReedsInc_20191113_10-Q_EX-10.4_11888303_EX-10.4_Development Agreement.txt",
          "span": [
            8374,
            8696
          ],
          "answer": "ompany will and hereby does, without further consideration, irrevocably assign to Reed's any and all worldwide right, title or interest that Company may now or hereafter possess in or to the Deliverables in perpetuity (or the maximum period permitted by Applicable Laws and Regulations) and Reed's accepts such assignment."
        },
        {
          "file_path": "cuad/ReedsInc_20191113_10-Q_EX-10.4_11888303_EX-10.4_Development Agreement.txt",
          "span": [
            10186,
            11082
          ],
          "answer": "Company acknowledges and agrees that all Intellectual Property created by Company, its affiliates, representatives, or agents in connection with or resulting from any work or services related to the Products, including the Deliverables (\"Work Product\"), but excluding the Neutral Alcohol Beverage Base and excluding the Company's general know-how and independently developed production processes not specifically related to the Products, have been specially ordered and commissioned by Reed's, are works-made-for-hire from the moment of creation and that all such Work Product is and will be the sole and exclusive property of Reed's. To the extent not a work-for- hire, Company, its employees, subcontractors and agents hereby sell, assign and transfer to Reed's all right, title and interest in and to the Work Product, including without limitation, all rights to Intellectual Property therein."
        }
      ]
    },
    {
      "query": "\"What liability does the Recipe Development Agreement between Reed's, Inc. and B C Marketing Concepts Inc. for Ginger-Based Alcohol Beverages entail?\"",
      "snippets": [
        {
          "file_path": "cuad/ReedsInc_20191113_10-Q_EX-10.4_11888303_EX-10.4_Development Agreement.txt",
          "span": [
            17591,
            18213
          ],
          "answer": "EXCEPT WITH RESPECT TO THE INDEMNIFICATION OBLIGATIONS SET FORTH IN SECTION 9 WITH REGARD TO CLAIMS BY THIRD PARTIES, IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR CONSEQUENTIAL, INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, PUNITIVE OR ENHANCED DAMAGES, LOST PROFITS OR REVENUES OR DIMINUTION IN VALUE ARISING OUT OF, RELATING TO, OR IN CONNECTION WITH ANY BREACH OF THIS AGREEMENT OR CLAIM HEREUNDER, REGARDLESS OF (A) WHETHER SUCH DAMAGES WERE FORESEEABLE, (B) WHETHER OR NOT IT WAS ADVISED OF THE POSSIBLITY OF SUCH DAMAGES, AND (C) THE LEGAL OR EQUITABLE THEORY (CONTRACT, TORT OR OTHERWISE) UPON WHICH THE CLAIM IS BASED."
        }
      ]
    },
    {
      "query": "\"What is the liability limitation for Ginger-Based Alcohol Beverages between Reed's, Inc. and B C Marketing Concepts Inc.\"?",
      "snippets": [
        {
          "file_path": "cuad/ReedsInc_20191113_10-Q_EX-10.4_11888303_EX-10.4_Development Agreement.txt",
          "span": [
            17591,
            18213
          ],
          "answer": "EXCEPT WITH RESPECT TO THE INDEMNIFICATION OBLIGATIONS SET FORTH IN SECTION 9 WITH REGARD TO CLAIMS BY THIRD PARTIES, IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR CONSEQUENTIAL, INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, PUNITIVE OR ENHANCED DAMAGES, LOST PROFITS OR REVENUES OR DIMINUTION IN VALUE ARISING OUT OF, RELATING TO, OR IN CONNECTION WITH ANY BREACH OF THIS AGREEMENT OR CLAIM HEREUNDER, REGARDLESS OF (A) WHETHER SUCH DAMAGES WERE FORESEEABLE, (B) WHETHER OR NOT IT WAS ADVISED OF THE POSSIBLITY OF SUCH DAMAGES, AND (C) THE LEGAL OR EQUITABLE THEORY (CONTRACT, TORT OR OTHERWISE) UPON WHICH THE CLAIM IS BASED."
        }
      ]
    },
    {
      "query": "\"What is the covenant not to sue clause included in the Recipe Development Agreement between Reed's, Inc. and B C Marketing Concepts Inc. for Ginger-Based Alcohol Beverages?\"",
      "snippets": [
        {
          "file_path": "cuad/ReedsInc_20191113_10-Q_EX-10.4_11888303_EX-10.4_Development Agreement.txt",
          "span": [
            9148,
            9500
          ],
          "answer": "Company agrees that it will not at any time contest the ownership or validity of any Reed's Intellectual Property or Deliverables, nor register or attempt to register any rights with respect to Reed's Intellectual Property, nor do anything that would jeopardize or diminish Reed's rights to or the value of Reed's Intellectual Property or Deliverables."
        },
        {
          "file_path": "cuad/ReedsInc_20191113_10-Q_EX-10.4_11888303_EX-10.4_Development Agreement.txt",
          "span": [
            9692,
            10120
          ],
          "answer": "Reed's shall not at any time acquire any rights, title or interest in Company's Intellectual Property. Reed's agrees that it will not at any time contest the ownership or validity of any Company Intellectual Property, nor register or attempt to register any rights with respect to Company Intellectual Property, nor do anything that would jeopardize or diminish Company's rights to or the value of Company Intellectual Property."
        }
      ]
    },
    {
      "query": "\"What is the current expiration date of the Distributorship Agreement between Signature Orthopaedics Pty Ltd and CPM Medical Consultants LLC for Medical Products?",
      "snippets": [
        {
          "file_path": "cuad/FuseMedicalInc_20190321_10-K_EX-10.43_11575454_EX-10.43_Distributor Agreement.txt",
          "span": [
            17984,
            18303
          ],
          "answer": "This agreement begins on the Commencement Date and, subject to clause 11.2, shall continue for an initial term of one (1) years (Initial Term) and indefinitely after that until terminated by either party giving at least twelve (12) months' prior written notice to expire on or after the expiry date of the initial term."
        }
      ]
    },
    {
      "query": "\"What is the renewal term for the manufacturer contract between Signature Orthopaedics Pty Ltd and CPM Medical Consultants LLC for Medical Products?\"",
      "snippets": [
        {
          "file_path": "cuad/FuseMedicalInc_20190321_10-K_EX-10.43_11575454_EX-10.43_Distributor Agreement.txt",
          "span": [
            17984,
            18303
          ],
          "answer": "This agreement begins on the Commencement Date and, subject to clause 11.2, shall continue for an initial term of one (1) years (Initial Term) and indefinitely after that until terminated by either party giving at least twelve (12) months' prior written notice to expire on or after the expiry date of the initial term."
        }
      ]
    },
    {
      "query": "\"What is the notice period required to terminate the Distributorship Agreement between Signature Orthopaedics Pty Ltd and CPM Medical Consultants LLC for Medical Products?\"",
      "snippets": [
        {
          "file_path": "cuad/FuseMedicalInc_20190321_10-K_EX-10.43_11575454_EX-10.43_Distributor Agreement.txt",
          "span": [
            17984,
            18303
          ],
          "answer": "This agreement begins on the Commencement Date and, subject to clause 11.2, shall continue for an initial term of one (1) years (Initial Term) and indefinitely after that until terminated by either party giving at least twelve (12) months' prior written notice to expire on or after the expiry date of the initial term."
        }
      ]
    },
    {
      "query": "\"Is the Distributorship Agreement between Signature Orthopaedics Pty Ltd and CPM Medical Consultants LLC for Medical Products the governing law of any jurisdiction?",
      "snippets": [
        {
          "file_path": "cuad/FuseMedicalInc_20190321_10-K_EX-10.43_11575454_EX-10.43_Distributor Agreement.txt",
          "span": [
            30821,
            31046
          ],
          "answer": "This agreement and any dispute or claim arising out of or in connection with it or its subject matter or formation (including non-contractual disputes or claims) shall be governed by and construed in accordance with Ohio law."
        }
      ]
    },
    {
      "query": "\"Is the Distributorship Agreement between Signature Orthopaedics Pty Ltd and CPM Medical Consultants LLC for Medical Products an anti-assignment clause?",
      "snippets": [
        {
          "file_path": "cuad/FuseMedicalInc_20190321_10-K_EX-10.43_11575454_EX-10.43_Distributor Agreement.txt",
          "span": [
            12823,
            12960
          ],
          "answer": "The Distributor shall not sub-license, transfer or otherwise deal with the rights of use of the Trade Marks granted under this agreement."
        },
        {
          "file_path": "cuad/FuseMedicalInc_20190321_10-K_EX-10.43_11575454_EX-10.43_Distributor Agreement.txt",
          "span": [
            21828,
            22212
          ],
          "answer": "Without affecting any other rights that it may be entitled to, the Supplier may give notice in writing to the Distributor terminating this agreement immediately if the Distributor purports to assign its rights or obligations under this agreement to an entity that is not (1) affiliated with, (2) related to, or (3) sharing common ownership with the Distributor (a Permitted Assignee)."
        },
        {
          "file_path": "cuad/FuseMedicalInc_20190321_10-K_EX-10.43_11575454_EX-10.43_Distributor Agreement.txt",
          "span": [
            26015,
            26529
          ],
          "answer": "The Distributor shall not assign, transfer, mortgage, charge, declare a trust of or deal in any other manner with this agreement or any of its rights and obligations under or arising out of this agreement, or purport to do any of the same; provided, however, the Distributor may assign or transfer this agreement to a Permitted Assignee without the consent of Supplier. The Distributor shall not sub-contract or delegate in any manner any or all of its obligations under this agreement to any third party or agent."
        }
      ]
    },
    {
      "query": "\"What licenses are granted under the Distributorship Agreement between Signature Orthopaedics Pty Ltd and CPM Medical Consultants LLC for Medical Products?",
      "snippets": [
        {
          "file_path": "cuad/FuseMedicalInc_20190321_10-K_EX-10.43_11575454_EX-10.43_Distributor Agreement.txt",
          "span": [
            11688,
            11910
          ],
          "answer": "The Supplier hereby grants to the Distributor the non-exclusive right, in the Territory, to use the Trade Marks in the promotion, advertisement and sale of the Products, subject to, and for the duration of, this agreement."
        }
      ]
    },
    {
      "query": "\"Do the provisions of the Distributorship Agreement between Signature Orthopaedics Pty Ltd and CPM Medical Consultants LLC for Medical Products remain in effect following termination?\"",
      "snippets": [
        {
          "file_path": "cuad/FuseMedicalInc_20190321_10-K_EX-10.43_11575454_EX-10.43_Distributor Agreement.txt",
          "span": [
            22429,
            23058
          ],
          "answer": "At the Supplier's option, on termination of this agreement:\n\n(a) the Supplier may buy from the Distributor all or any stocks of Products for the current market value for those Products. The Distributor must deliver such Products to the Supplier within 14 days of receiving the Supplier's notice, and the Supplier must pay for the Products in full within 30 days of their delivery. The Supplier shall be responsible for the costs of packaging, insurance and carriage of the Products; or\n\n(b) the Distributor may dispose of the balance of the Products in its possession and account to the Supplier for the Price for those Products;"
        }
      ]
    },
    {
      "query": "\"What are the insurance requirements in this Distributorship Agreement between Signature Orthopaedics Pty Ltd and CPM Medical Consultants LLC for Medical Products?\"",
      "snippets": [
        {
          "file_path": "cuad/FuseMedicalInc_20190321_10-K_EX-10.43_11575454_EX-10.43_Distributor Agreement.txt",
          "span": [
            16264,
            16342
          ],
          "answer": "The Supplier shall add the distributor to their current insurance certificate."
        },
        {
          "file_path": "cuad/FuseMedicalInc_20190321_10-K_EX-10.43_11575454_EX-10.43_Distributor Agreement.txt",
          "span": [
            16978,
            17227
          ],
          "answer": "During the Term, the Supplier shall maintain product liability insurance with a reputable insurer of no less than AU$10 million for any one occurrence for any and all liability (however arising) for a claim that the Products are faulty or defective."
        }
      ]
    },
    {
      "query": "\"Once the Distributorship Agreement is in effect, is there a covenant not to sue clause and if so, does this clause extend to Signature Orthopaedics Pty Ltd and CPM Medical Consultants LLC?\"",
      "snippets": [
        {
          "file_path": "cuad/FuseMedicalInc_20190321_10-K_EX-10.43_11575454_EX-10.43_Distributor Agreement.txt",
          "span": [
            12966,
            13125
          ],
          "answer": "The Distributor shall not do, or omit to do, anything in its use of the Trade Marks that could adversely affect their validity or the goodwill of the Supplier."
        }
      ]
    },
    {
      "query": "What is the expiration date of the Distributor Agreement between B & C General Warehouse Corporation LLC and Distributor for Coffee Products?",
      "snippets": [
        {
          "file_path": "cuad/GentechHoldingsInc_20190808_1-A_EX1A-6 MAT CTRCT_11776814_EX1A-6 MAT CTRCT_Distributor Agreement.txt",
          "span": [
            14759,
            14890
          ],
          "answer": "This Agreement shall become effective on the date first written above and shall continue in effect for a period of Three (3) years."
        }
      ]
    },
    {
      "query": "\"What is the renewal term for the Distributor Agreement between B & C General Warehouse Corporation LLC and Distributor for Coffee Products?\"",
      "snippets": [
        {
          "file_path": "cuad/GentechHoldingsInc_20190808_1-A_EX1A-6 MAT CTRCT_11776814_EX1A-6 MAT CTRCT_Distributor Agreement.txt",
          "span": [
            14924,
            15142
          ],
          "answer": "Distributor shall have the option to renew this Agreement for an additional Three (3) year period by providing prior written notice to Company within Ninety (90) days of the end of the initial period of this Agreement."
        }
      ]
    },
    {
      "query": "\"Considering the Distributor Agreement between B & C General Warehouse Corporation LLC and Distributor for Coffee Products, what is the governing law of the contract?\"",
      "snippets": [
        {
          "file_path": "cuad/GentechHoldingsInc_20190808_1-A_EX1A-6 MAT CTRCT_11776814_EX1A-6 MAT CTRCT_Distributor Agreement.txt",
          "span": [
            20473,
            20727
          ],
          "answer": "This Agreement is a contract under the laws of the State of Florida and for all purposes shall be governed by and construed in accordance with the substantive laws of the State of Florida, without regard to its principles of conflicts of laws provisions."
        }
      ]
    },
    {
      "query": "\"What is the Distributor Agreement between B & C General Warehouse Corporation LLC and Distributor for Coffee Products? Is there a most favored nation clause there?",
      "snippets": [
        {
          "file_path": "cuad/GentechHoldingsInc_20190808_1-A_EX1A-6 MAT CTRCT_11776814_EX1A-6 MAT CTRCT_Distributor Agreement.txt",
          "span": [
            5674,
            6133
          ],
          "answer": "Such Prices and Volume Discount Prices shall only be subject to increase once per year on each anniversary date of this Agreement, provided (i) Company provides Distributor with at least Ninety (90) days prior written notice of any such increase, and (ii) such increase does not exceed 5% of the preceding year's Prices, except for reasons of force majeure, (Chapter 10), and Volume Discount Prices nor the lowest price charged to others for the same Product."
        }
      ]
    },
    {
      "query": "\"What is the Distributor Agreement between B & C General Warehouse Corporation LLC and Distributor for Coffee Products?",
      "snippets": [
        {
          "file_path": "cuad/GentechHoldingsInc_20190808_1-A_EX1A-6 MAT CTRCT_11776814_EX1A-6 MAT CTRCT_Distributor Agreement.txt",
          "span": [
            1721,
            2086
          ],
          "answer": "Subject to the terms and conditions of this Distributor Agreement, Company hereby appoints and grants Distributor the exclusive right to sell and distribute the Products to customers that Distributor introduce and confirmed by Company, (in all territory of United State of America (USA) and to render other services as a distributor for Company as set forth herein."
        },
        {
          "file_path": "cuad/GentechHoldingsInc_20190808_1-A_EX1A-6 MAT CTRCT_11776814_EX1A-6 MAT CTRCT_Distributor Agreement.txt",
          "span": [
            2371,
            2524
          ],
          "answer": "Company shall not sell or otherwise supply, directly or indirectly, the Products to any Distributor's Customer's, except by sale through the Distributor."
        }
      ]
    },
    {
      "query": "\"In the Distributor Agreement between B & C General Warehouse Corporation LLC and Distributor for Coffee Products, Is there a clause preventing the solicitation of clients in this contract?\"",
      "snippets": [
        {
          "file_path": "cuad/GentechHoldingsInc_20190808_1-A_EX1A-6 MAT CTRCT_11776814_EX1A-6 MAT CTRCT_Distributor Agreement.txt",
          "span": [
            2525,
            2653
          ],
          "answer": "The Company shall not contact any of Distributor's Customer's for any reason, without the prior written approval of Distributor."
        }
      ]
    },
    {
      "query": "\"How does the Distributor Agreement in the B & C General Warehouse Corporation LLC and Distributor for Coffee Products relate to anti-assignment clauses?\"",
      "snippets": [
        {
          "file_path": "cuad/GentechHoldingsInc_20190808_1-A_EX1A-6 MAT CTRCT_11776814_EX1A-6 MAT CTRCT_Distributor Agreement.txt",
          "span": [
            22142,
            22356
          ],
          "answer": "Neither Party shall assign, pledge or otherwise transfer any of its rights, interest or obligations hereunder, whether by operation of law or otherwise, without the prior express written consent of the other Party."
        }
      ]
    },
    {
      "query": "\"Is there any restriction in the Distributor Agreement between B & C General Warehouse Corporation LLC and Distributor for Coffee Products?\"",
      "snippets": [
        {
          "file_path": "cuad/GentechHoldingsInc_20190808_1-A_EX1A-6 MAT CTRCT_11776814_EX1A-6 MAT CTRCT_Distributor Agreement.txt",
          "span": [
            5674,
            6133
          ],
          "answer": "Such Prices and Volume Discount Prices shall only be subject to increase once per year on each anniversary date of this Agreement, provided (i) Company provides Distributor with at least Ninety (90) days prior written notice of any such increase, and (ii) such increase does not exceed 5% of the preceding year's Prices, except for reasons of force majeure, (Chapter 10), and Volume Discount Prices nor the lowest price charged to others for the same Product."
        },
        {
          "file_path": "cuad/GentechHoldingsInc_20190808_1-A_EX1A-6 MAT CTRCT_11776814_EX1A-6 MAT CTRCT_Distributor Agreement.txt",
          "span": [
            26135,
            26433
          ],
          "answer": "Subject to Company's right to increase the price only once per year per the terms and restrictions contained in the Agreement, and Company's right to decrease the price at any time upon notice, the Products shall be sold by Company to Distributor at the following Prices and Volume Discount Prices."
        }
      ]
    },
    {
      "query": "\"How many volumes are allowed from the Distributor Agreement between B & C General Warehouse Corporation LLC and Distributor for Coffee Products?",
      "snippets": [
        {
          "file_path": "cuad/GentechHoldingsInc_20190808_1-A_EX1A-6 MAT CTRCT_11776814_EX1A-6 MAT CTRCT_Distributor Agreement.txt",
          "span": [
            10024,
            10395
          ],
          "answer": "In addition to any other responsibilities stated in this Agreement, Company will: (a) Provide, at Distributor's reasonable request and without charge, up to 10 hours of training with regard to any characteristics of the Products that Distributor deems reasonably necessary for Distributor and its employees and agents to fulfill the purposes of Distributor's appointment,"
        }
      ]
    },
    {
      "query": "\"What is the meaning of the Distributor Agreement between B & C General Warehouse Corporation LLC and Distributor for Coffee Products?\"",
      "snippets": [
        {
          "file_path": "cuad/GentechHoldingsInc_20190808_1-A_EX1A-6 MAT CTRCT_11776814_EX1A-6 MAT CTRCT_Distributor Agreement.txt",
          "span": [
            19937,
            20115
          ],
          "answer": "Distributor shall assign to Company, without charge, any rights in the trademarks of Company that may inure to the benefit of Distributor pursuant to this Agreement or otherwise."
        }
      ]
    },
    {
      "query": "\"What are the services that are to be provided after the termination of the Distributor Agreement between B & C General Warehouse Corporation LLC and Distributor for Coffee Products?\"",
      "snippets": [
        {
          "file_path": "cuad/GentechHoldingsInc_20190808_1-A_EX1A-6 MAT CTRCT_11776814_EX1A-6 MAT CTRCT_Distributor Agreement.txt",
          "span": [
            16158,
            16569
          ],
          "answer": "In the event that this Agreement is terminated or expires on its own terms, Company shall have no further responsibilities to Distributor except that in the event the Agreement terminates for any reason other than a breach hereof by Distributor, Company shall be obligated to process orders accepted by Company prior to the effective date of such termination or expiration or within Ninety (90) days thereafter."
        }
      ]
    },
    {
      "query": "\"Do the B & C General Warehouse Corporation LLC and Distributor for Coffee Products have a limitation of liability in their Distributor Agreement?\"",
      "snippets": [
        {
          "file_path": "cuad/GentechHoldingsInc_20190808_1-A_EX1A-6 MAT CTRCT_11776814_EX1A-6 MAT CTRCT_Distributor Agreement.txt",
          "span": [
            18177,
            18358
          ],
          "answer": "IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY SPECIAL, INDIRECT, EXEMPLARY OR CONSEQUENTIAL DAMAGES ARISING OUT OF THIS AGREEMENT OR PURCHASE OR USE OF THE PRODUCTS."
        }
      ]
    },
    {
      "query": "\"Is the Distributor Agreement between B & C General Warehouse Corporation and Distributor for Coffee Products a written contract or an implied contract? What is the duration of any warranties on the agreement?",
      "snippets": [
        {
          "file_path": "cuad/GentechHoldingsInc_20190808_1-A_EX1A-6 MAT CTRCT_11776814_EX1A-6 MAT CTRCT_Distributor Agreement.txt",
          "span": [
            6837,
            7027
          ],
          "answer": "Within Seven (7) days of receipt of such Products, Distributor will notify Company of any shortages, defects, non-conformance, and Company will promptly replace such Products free of charge."
        }
      ]
    },
    {
      "query": "\"Is there a covenant not to sue clause in the Distributor Agreement between B & C General Warehouse Corporation LLC and Distributor for Coffee Products?\"",
      "snippets": [
        {
          "file_path": "cuad/GentechHoldingsInc_20190808_1-A_EX1A-6 MAT CTRCT_11776814_EX1A-6 MAT CTRCT_Distributor Agreement.txt",
          "span": [
            19316,
            19742
          ],
          "answer": "Distributor shall not dispute or contest for any reason whatsoever, directly or indirectly, during the term of this Agreement and thereafter, the validity, ownership or enforceability of any of the trademarks of Company, nor directly or indirectly attempt to acquire or damage the value of the goodwill associated with any of the trademarks of Company, nor counsel, procure or assist any third Party to do any of the foregoing"
        },
        {
          "file_path": "cuad/GentechHoldingsInc_20190808_1-A_EX1A-6 MAT CTRCT_11776814_EX1A-6 MAT CTRCT_Distributor Agreement.txt",
          "span": [
            19744,
            19936
          ],
          "answer": "Distributor will not institute any proceedings with respect to the trademarks of Company either in Distributor's own name or on behalf of Company without express written permission of Company."
        }
      ]
    },
    {
      "query": "\"What is the expiration date for the non-exclusive distributor agreement between iMine Corporation and Sunwai Technology for Cryptocurrency Mining Rigs?\"",
      "snippets": [
        {
          "file_path": "cuad/ImineCorp_20180725_S-1_EX-10.5_11275970_EX-10.5_Distributor Agreement.txt",
          "span": [
            22480,
            22696
          ],
          "answer": "This Agreement shall become effective upon the date first written above and shall remain in full force and effect for a period of two years (2), unless earlier terminated pursuant to the provisions in this Agreement."
        }
      ]
    },
    {
      "query": "\"What is the governing law for the Non-Exclusive Distributor Agreement between iMine Corporation and Sunwai Technology for Cryptocurrency Mining Rigs?\"",
      "snippets": [
        {
          "file_path": "cuad/ImineCorp_20180725_S-1_EX-10.5_11275970_EX-10.5_Distributor Agreement.txt",
          "span": [
            32817,
            32974
          ],
          "answer": "This Agreement shall be governed by and construed pursuant to the laws of the State of Indiana, U.S.A., without reference to principals of conflicts of laws."
        }
      ]
    }
  ]
}